Myeloperoxidase	B-ENZY
concentrations	O
were	O
measured	O
as	O
an	O
index	O
of	O
neutrophil	O
activation	O
.	O

Myeloperoxidase	B-ENZY
activity	O
reached	O
micromolar	O
levels	O
in	O
the	O
lavage	O
fluid	O
when	O
corrected	O
for	O
dilution	O
,	O
and	O
was	O
significantly	O
higher	O
in	O
the	O
plasma	O
of	O
the	O
sepsis	O
patients	O
who	O
subsequently	O
died	O
.	O

The	O
third	O
construct	O
contained	O
the	O
D	O
epitope	O
-	O
coding	O
region	O
of	O
the	O
S	O
gene	O
,	O
from	O
nucleotide	O
1201	O
to	O
1591	O
,	O
which	O
was	O
fused	O
to	O
the	O
alfalfa	O
beta	B-ENZY
-	I-ENZY
amylase	I-ENZY
gene	O
.	O

We	O
conducted	O
the	O
current	O
study	O
to	O
assess	O
the	O
effects	O
of	O
pretreatment	O
with	O
lidocaine	O
on	O
acute	O
lung	O
injury	O
induced	O
by	O
a	O
combination	O
of	O
PLA2	O
and	O
trypsin	B-ENZY
.	O

Allantoic	O
fluids	O
from	O
inoculated	O
embryos	O
were	O
harvested	O
and	O
treated	O
with	O
commercially	O
available	O
neuraminidase	B-ENZY
enzyme	O
.	O

IBV	O
in	O
neuraminidase	B-ENZY
-	O
treated	O
allantoic	O
fluid	O
was	O
identified	O
by	O
clear	O
and	O
consistent	O
HA	O
of	O
chicken	O
red	O
blood	O
cells	O
within	O
1	O
min	O
of	O
incubation	O
.	O

Cache	O
Valley	O
virus	O
N	O
expressed	O
with	O
a	O
histidine	O
tag	O
,	O
bovine	O
serum	O
albumin	O
,	O
and	O
the	O
basic	O
lysozyme	B-ENZY
protein	O
did	O
not	O
shift	O
the	O
IBV	O
RNA	O
.	O

Our	O
laboratory	O
demonstrated	O
in	O
vitro	O
that	O
pancreatic	B-ENZY
elastase	I-ENZY
is	O
a	O
pancreatic	O
enzyme	O
that	O
can	O
induce	O
inflammatory	O
cell	O
cytokine	O
production	O
.	O

Vaporisation	O
of	O
perfluorohexane	O
in	O
a	O
concentration	O
of	O
18	O
Vol	O
.%	O
of	O
inspired	O
gas	B-ENZY
improved	O
significantly	O
oxygenation	O
and	O
lung	O
compliance	O
.	O

ABSTRACT	O
:	O
Coronavirus	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
encodes	O
a	O
trypsin	B-ENZY
-	O
like	O
proteinase	O
(	O
3C	O
-	O
like	O
proteinase	O
)	O
by	O
ORF	O
1a	O
,	O
which	O
has	O
been	O
demonstrated	O
to	O
play	O
a	O
pivotal	O
role	O
in	O
proteolytic	O
processing	O
of	O
gene	O
1	O
-	O
encoded	O
polyproteins	O
.	O

Degenerate	O
primers	O
CK4	O
and	O
CK2	O
,	O
utilized	O
previously	O
in	O
our	O
laboratory	O
,	O
were	O
selected	O
for	O
DACS	B-ENZY
because	O
they	O
successfully	O
amplify	O
a	O
wide	O
range	O
of	O
serotypes	O
represented	O
by	O
various	O
reference	O
strains	O
and	O
field	O
isolates	O
and	O
the	O
resulting	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
product	O
contains	O
diagnostically	O
relevant	O
S	O
-	O
1	O
sequences	O
that	O
can	O
be	O
used	O
to	O
identify	O
the	O
serotype	O
of	O
IBV	O
.	O

Lung	O
recruitment	O
strategies	O
,	O
such	O
as	O
high	O
-	O
frequency	O
oscillatory	O
ventilation	O
(	O
HFOV	O
)	O
and	O
partial	O
liquid	O
ventilation	O
(	O
PLV	O
),	O
improve	O
gas	B-ENZY
exchange	O
and	O
attenuate	O
lung	O
inflammation	O
when	O
instituted	O
immediately	O
after	O
birth	O
.	O

TITLE	O
:	O
Pancreatic	B-ENZY
elastase	I-ENZY
activates	O
pulmonary	O
nuclear	O
factor	O
kappa	O
B	O
and	O
inhibitory	O
kappa	O
B	O
,	O
mimicking	O
pancreatitis	O
-	O
associated	O
adult	O
respiratory	O
distress	O
syndrome	O
.	O

RESULTS	O
:	O
Pancreatic	B-ENZY
elastase	I-ENZY
induced	O
pulmonary	O
IkappaBalpha	O
/	O
IkappaBbeta	O
degradation	O
(	O
30	O
minutes	O
),	O
NF	O
-	O
kappaB	O
activation	O
(	O
60	O
minutes	O
),	O
and	O
TNF	O
gene	O
expression	O
(	O
60	O
minutes	O
)	O
with	O
subsequent	O
neutrophilic	O
inflammation	O
(	O
4	O
hours	O
)	O
and	O
microvascular	O
leakage	O
(	O
24	O
hours	O
),	O
whereas	O
amylase	O
,	O
lipase	B-ENZY
,	O
and	O
trypsin	B-ENZY
did	O
not	O
.	O

The	O
concentrations	O
of	O
adenosine	B-ENZY
deaminase	I-ENZY
and	O
gamma	O
-	O
interferon	O
in	O
pleural	O
fluid	O
are	O
useful	O
in	O
the	O
diagnosis	O
of	O
pleural	O
tuberculosis	O
.	O

To	O
date	O
,	O
two	O
of	O
the	O
MHV	O
replicase	O
-	O
encoded	O
proteinases	O
,	O
papain	B-ENZY
-	O
like	O
proteinase	O
1	O
(	O
PLP1	O
)	O
and	O
the	O
poliovirus	O
3C	O
-	O
like	O
proteinase	O
(	O
3CLpro	O
),	O
have	O
been	O
shown	O
to	O
process	O
the	O
replicase	O
polyprotein	O
.	O

ABSTRACT	O
:	O
Respiratory	O
tract	O
infections	O
with	O
viruses	O
and	O
Pasteurella	O
spp	B-ENZY
.	O
were	O
determined	O
sequentially	O
among	O
26	O
cattle	O
that	O
died	O
during	O
two	O
severe	O
epizootics	O
of	O
shipping	O
fever	O
pneumonia	O
.	O

In	O
certain	O
combination	O
of	O
cells	O
and	O
viruses	O
,	O
pretreatment	O
of	O
virus	O
-	O
infected	O
cells	O
with	O
interferon	O
activates	O
a	O
cellular	O
endoribonuclease	O
,	O
RNase	B-ENZY
L	O
,	O
that	O
causes	O
rRNA	O
degradation	O
.	O

Furthermore	O
,	O
MHV	O
-	O
induced	O
28S	O
rRNA	O
cleavage	O
occurred	O
in	O
MHV	O
-	O
infected	O
DBT	O
cells	O
that	O
do	O
not	O
show	O
apoptotic	O
signs	O
,	O
including	O
activation	O
of	O
caspase	B-ENZY
-	I-ENZY
3	I-ENZY
and	O
DNA	O
fragmentation	O
.	O

As	O
chitin	O
is	O
a	O
basic	O
component	O
of	O
the	O
microsporidian	O
infective	O
stage	O
,	O
the	O
spore	O
,	O
we	O
evaluated	O
in	O
vitro	O
the	O
susceptibility	O
of	O
a	O
human	O
-	O
derived	O
strain	O
of	O
Encephalitozoon	O
hellem	O
to	O
nikkomycin	O
Z	O
,	O
a	O
peptide	O
-	O
nucleoside	O
antibiotic	O
known	O
as	O
a	O
competitive	O
inhibitor	O
of	O
chitin	B-ENZY
synthase	I-ENZY
enzymes	O
.	O

An	O
rFPV	O
-	O
derived	O
D	O
-	O
RNA	O
containing	O
the	O
luciferase	B-ENZY
gene	O
under	O
the	O
control	O
of	O
an	O
IBV	O
transcription	O
-	O
associated	O
sequence	O
was	O
also	O
rescued	O
and	O
expressed	O
luciferase	B-ENZY
on	O
serial	O
passage	O
.	O

The	O
RBCV	O
strains	O
had	O
a	O
receptor	O
-	O
destroying	O
enzyme	O
function	O
mediated	O
by	O
acetylesterase	B-ENZY
(	O
AE	O
)	O
activity	O
of	O
the	O
haemagglutinin	O
-	O
esterase	O
(	O
HE	O
)	O
glycoprotein	O
.	O

Neuraminidase	B-ENZY
treatment	O
of	O
purified	O
virions	O
resulted	O
in	O
a	O
shift	O
of	O
the	O
sedimentation	O
value	O
from	O
the	O
higher	O
to	O
the	O
lower	O
density	O
.	O

Blood	O
gas	B-ENZY
,	O
gas	B-ENZY
exchange	O
,	O
and	O
hemodynamic	O
measurements	O
were	O
performed	O
at	O
the	O
following	O
time	O
points	O
:	O
a	O
)	O
baseline	O
;	O
b	O
)	O
during	O
the	O
optimal	O
or	O
maximum	O
dose	O
of	O
PGI2	O
;	O
and	O
c	O
)	O
1	O
hr	O
after	O
withdrawal	O
of	O
the	O
drug	O
.	O

These	O
four	O
isolates	O
were	O
further	O
characterized	O
by	O
the	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
and	O
restriction	O
fragment	O
length	O
polymorphism	O
techniques	O
.	O

ABSTRACT	O
:	O
Structure	O
activity	O
relationships	O
(	O
SARs	O
)	O
of	O
product	O
-	O
based	O
inhibitors	O
of	O
hepatitis	O
C	O
virus	O
NS3	O
protease	O
were	O
evaluated	O
using	O
an	O
in	O
vitro	O
assay	O
system	O
comprising	O
the	O
native	O
bifunctional	O
full	O
-	O
length	O
NS3	O
(	O
protease	O
-	O
helicase	O
/	O
NTPase	B-ENZY
).	O

CONCLUSIONS	O
:	O
APRV	O
and	O
maintenance	O
of	O
patients	O
'	O
spontaneous	O
ventilation	O
is	O
feasible	O
during	O
prone	O
positioning	O
,	O
and	O
this	O
approach	O
may	O
have	O
beneficial	O
synergistic	O
effects	O
on	O
gas	B-ENZY
exhange	O
in	O
patients	O
with	O
severe	O
acute	O
lung	O
injury	O
.	O

Increasing	O
the	O
intracellular	O
level	O
of	O
mitochondrial	O
aconitase	B-ENZY
by	O
iron	O
supplementation	O
resulted	O
in	O
increased	O
RNA	O
-	O
binding	O
activity	O
in	O
cell	O
extracts	O
and	O
increased	O
virus	O
production	O
as	O
well	O
as	O
viral	O
protein	O
synthesis	O
at	O
early	O
hours	O
of	O
infection	O
.	O

Respiratory	O
function	O
was	O
determined	O
by	O
using	O
whole	O
-	O
body	O
plethysmography	O
and	O
lung	O
gas	B-ENZY
diffusion	O
.	O

ABSTRACT	O
:	O
The	O
nucleocapsid	O
(	O
N	O
)	O
gene	O
of	O
turkey	O
coronavirus	O
(	O
TCV	O
)	O
was	O
amplified	O
by	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
,	O
cloned	O
,	O
and	O
expressed	O
in	O
the	O
baculovirus	O
expression	O
system	O
.	O

In	O
the	O
WT	O
mice	O
there	O
was	O
upregulation	O
of	O
gelatinase	B-ENZY
B	I-ENZY
and	O
stromelysin	B-ENZY
1	I-ENZY
in	O
the	O
injured	O
lungs	O
which	O
,	O
as	O
expected	O
,	O
was	O
absent	O
in	O
the	O
genetically	O
deficient	O
gelatinase	B-ENZY
B	I-ENZY
-	O
and	O
stromelysin	B-ENZY
1	I-ENZY
-	O
deficient	O
mice	O
,	O
respectively	O
.	O

Further	O
,	O
the	O
mechanism	O
of	O
their	O
involvement	O
in	O
the	O
lung	O
injury	O
appears	O
to	O
be	O
different	O
,	O
with	O
the	O
stromelysin	B-ENZY
1	I-ENZY
-	O
deficient	O
mice	O
having	O
a	O
reduction	O
in	O
the	O
numbers	O
of	O
neutrophils	O
recruited	O
into	O
the	O
lung	O
whereas	O
the	O
gelatinase	B-ENZY
B	I-ENZY
-	O
deficient	O
mice	O
had	O
the	O
same	O
numbers	O
of	O
lung	O
neutrophils	O
as	O
did	O
the	O
injured	O
WT	O
controls	O
.	O

Gas	B-ENZY
exchange	O
,	O
pulmonary	O
mechanic	O
,	O
and	O
haemodynamic	O
parameters	O
were	O
obtained	O
at	O
regular	O
intervals	O
.	O

TITLE	O
:	O
The	O
autocatalytic	O
release	O
of	O
a	O
putative	O
RNA	O
virus	O
transcription	O
factor	O
from	O
its	O
polyprotein	O
precursor	O
involves	O
two	O
paralogous	O
papain	B-ENZY
-	O
like	O
proteases	O
that	O
cleave	O
the	O
same	O
peptide	O
bond	O
.	O

Results	O
indicated	O
a	O
100	O
%	O
homology	O
of	O
sequence	O
between	O
the	O
protein	O
recognized	O
by	O
the	O
autoAb	O
and	O
liver	O
fumarylacetoacetate	B-ENZY
hydrolase	I-ENZY
(	O
FAH	O
),	O
the	O
enzyme	O
that	O
mediates	O
the	O
last	O
step	O
of	O
tyrosine	O
catabolism	O
.	O

Systemic	O
and	O
pulmonary	O
hemodynamics	O
as	O
well	O
as	O
gas	B-ENZY
exchange	O
measurements	O
were	O
recorded	O
via	O
respective	O
indwelling	O
catheters	O
.	O

In	O
ARDS	O
but	O
not	O
in	O
sepsis	O
patients	O
clear	O
of	O
pulmonary	O
organ	O
failure	O
,	O
a	O
changing	O
balance	O
of	O
prostaglandin	O
I2	O
and	O
thromboxane	O
A2	O
may	O
modulate	O
gas	B-ENZY
exchange	O
,	O
presumably	O
via	O
interference	O
with	O
hypoxic	O
pulmonary	O
vasoconstriction	O
.	O

ABSTRACT	O
:	O
To	O
examine	O
whether	O
measurement	O
of	O
procalcitonin	O
(	O
PCT	O
)	O
in	O
comparison	O
with	O
interleukin	O
-	O
6	O
is	O
a	O
reliable	O
marker	O
to	O
score	O
the	O
extent	O
of	O
lung	O
contusion	O
in	O
bronchoalveolar	O
lavage	O
(	O
BAL	B-ENZY
)	O
fluids	O
in	O
polytrauma	O
patients	O
.	O

TITLE	O
:	O
Molecular	O
determinants	O
of	O
species	O
specificity	O
in	O
the	O
coronavirus	O
receptor	O
aminopeptidase	B-ENZY
N	I-ENZY
(	O
CD13	O
):	O
influence	O
of	O
N	O
-	O
linked	O
glycosylation	O
.	O

TGI	O
consisted	O
in	O
insufflating	O
fresh	O
gas	B-ENZY
via	O
a	O
small	O
catheter	O
placed	O
in	O
the	O
trachea	O
(	O
0	O
(	O
2	O
)	O
at	O
6	O
L	O
*	O
min	O
(-	O
1	O
)	O
in	O
the	O
first	O
patient	O
and	O
4	O
L	O
*	O
min	O
(-	O
1	O
)	O
in	O
the	O
second	O
case	O
).	O

Endotoxin	O
induced	O
a	O
severe	O
lung	O
injury	O
characterised	O
by	O
a	O
decrease	O
in	O
mean	O
systemic	O
blood	O
pressure	O
and	O
an	O
increase	O
in	O
pulmonary	O
artery	O
pressure	O
,	O
hypoxia	O
,	O
and	O
an	O
increase	O
in	O
pulmonary	O
myeloperoxidase	B-ENZY
activity	O
.	O

This	O
case	O
is	O
characteristic	O
for	O
acute	O
intoxications	O
with	O
irreversible	O
acetylcholinesterase	B-ENZY
inhibitors	O
,	O
such	O
as	O
organophosphate	O
compounds	O
.	O

Intracellular	O
double	O
-	O
stranded	O
(	O
ds	O
)	O
RNAs	O
equivalent	O
in	O
size	O
to	O
the	O
26	O
.	O
2	O
kb	O
genomic	O
RNA	O
and	O
two	O
sgRNAs	O
were	O
also	O
identified	O
by	O
RNase	B-ENZY
/	O
DNase	B-ENZY
digestion	O
of	O
total	O
RNA	O
from	O
GAV	O
-	O
infected	O
prawn	O
tissue	O
.	O

Reverse	B-ENZY
transcriptase	I-ENZY
polymerase	O
chain	O
reaction	O
was	O
positive	O
for	O
a	O
respiratory	O
virus	O
in	O
56	O
(	O
65	O
%)	O
of	O
the	O
86	O
illnesses	O
.	O

Reconstituted	O
fgl2	O
catalyzed	O
the	O
cleavage	O
of	O
human	O
prothrombin	O
to	O
thrombin	B-ENZY
with	O
kinetics	O
consistent	O
with	O
a	O
first	O
order	O
reaction	O
,	O
with	O
an	O
apparent	O
V	O
(	O
max	O
)	O
value	O
of	O
6	O
mol	O
/	O
min	O
/	O
mol	O
fgl2	O
and	O
an	O
apparent	O
K	O
(	O
m	O
)	O
value	O
for	O
prothrombin	O
of	O
8	O
.	O
3	O
microM	O
.	O
The	O
catalytic	O
activity	O
was	O
totally	O
dependent	O
on	O
calcium	O
,	O
and	O
factor	O
Va	O
(	O
500	O
nM	O
)	O
enhanced	O
the	O
catalytic	O
efficiency	O
of	O
fgl2	O
by	O
increasing	O
the	O
apparent	O
V	O
(	O
max	O
)	O
value	O
to	O
3670	O
mol	O
/	O
min	O
/	O
mol	O
fgl2	O
and	O
decreasing	O
the	O
apparent	O
K	O
(	O
m	O
)	O
value	O
for	O
prothrombin	O
to	O
7	O
.	O
2	O
microM	O
.	O
By	O
a	O
combination	O
of	O
site	O
-	O
directed	O
mutagenesis	O
and	O
production	O
of	O
truncated	O
proteins	O
,	O
it	O
was	O
clearly	O
shown	O
that	O
residue	O
Ser	O
(	O
89	O
)	O
was	O
critical	O
for	O
the	O
prothrombinase	B-ENZY
activity	O
of	O
fgl2	O
.	O

Our	O
data	O
suggested	O
that	O
host	O
cells	O
,	O
in	O
response	O
to	O
MHV	O
replication	O
,	O
activated	O
p38	O
MAPK	B-ENZY
,	O
which	O
subsequently	O
phosphorylated	O
eIF4E	O
to	O
efficiently	O
translate	O
certain	O
host	O
proteins	O
,	O
including	O
IL	O
-	O
6	O
,	O
during	O
virus	O
-	O
induced	O
severe	O
host	O
protein	O
synthesis	O
inhibition	O
.	O

After	O
90	O
min	O
PaO	B-ENZY
(	O
2	O
)/	O
FIO	O
(	O
2	O
)	O
had	O
increased	O
from	O
111	O
+/-	O
44	O
to	O
254	O
+/-	O
69	O
in	O
the	O
bolus	O
group	O
and	O
from	O
86	O
+/-	O
40	O
to	O
238	O
+/-	O
102	O
in	O
the	O
infusion	O
group	O
,	O
but	O
early	O
FIO	O
(	O
2	O
)	O
reduction	O
and	O
increase	O
in	O
PaO	B-ENZY
(	O
2	O
)/	O
FIO	O
(	O
2	O
)	O
seemed	O
delayed	O
in	O
the	O
infusion	O
group	O
.	O

Trauma	O
,	O
emergency	O
vascular	O
,	O
and	O
general	O
surgical	O
patients	O
with	O
PaO	B-ENZY
(	O
2	O
)/	O
FiO	O
)(	O
2	O
)	O
(	O
PF	O
)	O
ratio	O
<	O
200	O
were	O
entered	O
into	O
a	O
protocol	O
designed	O
to	O
maintain	O
mixed	O
venous	O
saturation	O
(	O
SVO	O
(	O
2	O
))	O
>	O
70	O
%	O
with	O
FiO	O
(	O
2	O
)	O
<	O
0	O
.	O
50	O
.	O

In	O
this	O
series	O
of	O
3	O
patients	O
,	O
etanercept	O
(	O
Enbrel	O
;	O
Immunex	O
,	O
Seattle	O
,	O
WA	O
),	O
a	O
soluble	O
,	O
dimeric	O
tumor	O
necrosis	O
factor	O
alpha	O
-	O
binding	O
protein	O
,	O
was	O
administered	O
to	O
3	O
consecutive	O
pediatric	O
allogeneic	O
BMT	B-ENZY
recipients	O
with	O
IPS	O
.	O

The	O
ratio	O
of	O
arterial	O
blood	O
PaO	B-ENZY
(	O
2	O
)	O
and	O
the	O
fraction	O
of	O
oxygen	O
in	O
the	O
ventilator	O
was	O
8	O
.	O
5	O
+/-	O
2	O
.	O
7	O
kPa	O
(	O
64	O
+/-	O
20	O
mmHg	O
)	O
before	O
transfer	O
and	O
9	O
.	O
7	O
+/-	O
3	O
.	O
6	O
kPa	O
(	O
73	O
+/-	O
27	O
mmHg	O
)	O
after	O
transfer	O
.	O

Lung	O
tissues	O
were	O
analyzed	O
for	O
activation	O
of	O
NF	O
-	O
kappaB	O
,	O
myeloperoxidase	B-ENZY
activity	O
,	O
and	O
wet	O
/	O
dry	O
weight	O
ratio	O
.	O

At	O
baseline	O
the	O
patients	O
had	O
severe	O
ARDS	O
as	O
noted	O
by	O
a	O
mean	O
lung	O
injury	O
score	O
(	O
LIS	B-ENZY
)	O
of	O
3	O
.	O
2	O
(	O
SD	O
0	O
.	O
3	O
)	O
and	O
Pao2	O
/	O
FIo2	O
ratio	O
12	O
.	O
2	O
(	O
SD	O
3	O
.	O
2	O
)	O
kPa	O
.	O

ABSTRACT	O
:	O
The	O
observation	O
that	O
mice	O
infected	O
with	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
develop	O
autoantibodies	O
directed	O
mainly	O
to	O
liver	O
fumarylacetoacetate	B-ENZY
hydrolase	I-ENZY
(	O
FAH	O
)	O
enabled	O
the	O
development	O
of	O
an	O
ELISA	O
applicable	O
to	O
the	O
detection	O
of	O
MHV	O
-	O
infection	O
.	O

Children	O
with	O
severe	O
ACS	B-ENZY
should	O
have	O
a	O
magnetic	O
resonance	O
image	O
of	O
the	O
brain	O
,	O
neurologic	O
examination	O
by	O
a	O
neurologist	O
,	O
and	O
cognitive	O
testing	O
to	O
detect	O
the	O
presence	O
of	O
neurologic	O
morbidity	O
.	O

An	O
ELISA	O
was	O
used	O
to	O
test	O
for	O
the	O
presence	O
of	O
MHV	O
-	O
specific	O
antibody	O
,	O
and	O
TaqMan	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
analysis	O
was	O
used	O
to	O
detect	O
MHV	O
in	O
the	O
feces	O
.	O

We	O
speculate	O
that	O
the	O
enhanced	O
lung	O
recruitment	O
by	O
HFOV	O
enhances	O
the	O
effects	O
of	O
low	O
dose	O
iNO	O
on	O
gas	B-ENZY
exchange	O
.	O

Their	O
PaO	B-ENZY
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
ratio	O
dropped	O
from	O
109	O
+/-	O
37	O
to	O
94	O
+/-	O
36	O
,	O
P	O
=	O
0	O
.	O
011	O
,	O
when	O
changed	O
from	O
the	O
prone	O
to	O
supine	O
position	O
.	O

On	O
virions	O
,	O
the	O
180	O
-	O
kDa	O
S	O
glycoprotein	O
of	O
the	O
MHV	O
-	O
A59	O
strain	O
can	O
be	O
cleaved	O
by	O
trypsin	B-ENZY
to	O
form	O
the	O
90	O
-	O
kDa	O
N	O
-	O
terminal	O
receptor	O
-	O
binding	O
subunit	O
(	O
S1	O
)	O
and	O
the	O
90	O
-	O
kDa	O
membrane	O
-	O
anchored	O
fusion	O
subunit	O
(	O
S2	O
).	O

ABSTRACT	O
:	O
Human	O
coronavirus	O
HCoV	O
-	O
229E	O
uses	O
human	O
aminopeptidase	B-ENZY
N	I-ENZY
(	O
hAPN	O
)	O
as	O
its	O
receptor	O
(	O
C	O
.	O
L	O
.	O
Yeager	O
et	O
al	O
.,	O
Nature	O
357	O
:	O
420	O
-	O
422	O
,	O
1992	O
).	O

Primary	O
endpoint	O
PaO	B-ENZY
(	O
2	O
)/	O
FIO	O
(	O
2	O
)	O
at	O
48	O
h	O
,	O
secondary	O
endpoints	O
:	O
PaO	B-ENZY
(	O
2	O
)/	O
FIO	O
(	O
2	O
)	O
at	O
2	O
,	O
4	O
,	O
12	O
,	O
and	O
24	O
h	O
,	O
survival	O
,	O
survival	O
without	O
rescue	O
,	O
days	O
on	O
ventilator	O
,	O
subgroups	O
analyzed	O
by	O
analysis	O
of	O
variance	O
to	O
identify	O
patients	O
who	O
might	O
benefit	O
from	O
surfactant	O
.	O

A	O
significant	O
difference	O
in	O
PaO	B-ENZY
(	O
2	O
)/	O
FIO	O
(	O
2	O
)	O
in	O
favor	O
of	O
surfactant	O
at	O
48	O
h	O
was	O
found	O
in	O
the	O
subgroup	O
with	O
an	O
initial	O
PaO	B-ENZY
(	O
2	O
)/	O
FIO	O
(	O
2	O
)	O
ratio	O
higher	O
than	O
65	O
and	O
in	O
patients	O
without	O
pneumonia	O
.	O

ABSTRACT	O
:	O
A	O
novel	O
series	O
of	O
potent	O
,	O
selective	O
HIV	O
-	O
1	O
N	O
-	O
acylthiocarbamate	O
(	O
ATC	O
)	O
nonnucleoside	O
reverse	B-ENZY
transcriptase	I-ENZY
inhibitors	O
(	O
NNRTIs	O
)	O
is	O
described	O
.	O

Heparin	O
,	O
despite	O
effectively	O
inhibiting	O
thrombin	B-ENZY
formation	O
,	O
has	O
not	O
shown	O
consistent	O
benefits	O
in	O
reducing	O
lung	O
injury	O
,	O
and	O
its	O
efficacy	O
has	O
not	O
yet	O
been	O
evaluated	O
in	O
a	O
controlled	O
study	O
.	O

ABSTRACT	O
:	O
This	O
article	O
describes	O
a	O
rare	O
case	O
of	O
bone	O
marrow	O
transplantation	O
(	O
BMT	B-ENZY
)	O
from	O
an	O
unrelated	O
donor	O
(	O
URD	O
)	O
in	O
an	O
adult	O
Japanese	O
male	O
with	O
Down	O
syndrome	O
(	O
DS	O
)	O
diagnosed	O
as	O
having	O
acute	O
mixed	O
lineage	O
leukemia	O
.	O

On	O
day	O
205	O
post	O
-	O
BMT	B-ENZY
,	O
however	O
,	O
bronchiolitis	O
obliterans	O
(	O
BO	O
)	O
occurred	O
as	O
a	O
chronic	O
GVHD	O
disorder	O
.	O

From	O
November	O
1999	O
to	O
May	O
2001	O
,	O
259	O
specimens	O
from	O
53	O
calves	O
(<	O
or	O
=	O
6	O
months	O
old	O
),	O
27	O
young	O
adults	O
(	O
52	O
years	O
),	O
125	O
adults	O
(>	O
or	O
=	O
2	O
years	O
),	O
and	O
54	O
animals	O
of	O
unknown	O
age	O
were	O
examined	O
by	O
an	O
antigen	O
-	O
capture	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
and	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
assay	O
developed	O
to	O
detect	O
BoTV	O
.	O

Other	O
enteric	O
organisms	O
detected	O
alone	O
or	O
in	O
combination	O
with	O
BoTV	O
in	O
calf	O
samples	O
were	O
rotavirus	O
,	O
coronavirus	O
,	O
Salmonella	O
spp	B-ENZY
.,	O
Cryptosporidium	O
spp	B-ENZY
.,	O
and	O
Giardia	O
spp	B-ENZY
.;	O
but	O
no	O
consistent	O
association	O
between	O
BoTV	O
and	O
these	O
organisms	O
was	O
observed	O
.	O

TITLE	O
:	O
Detection	O
of	O
sendai	O
virus	O
and	O
pneumonia	O
virus	O
of	O
mice	O
by	O
use	O
of	O
fluorogenic	O
nuclease	O
reverse	B-ENZY
transcriptase	I-ENZY
polymerase	O
chain	O
reaction	O
analysis	O
.	O

Reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
assays	O
have	O
proven	O
useful	O
for	O
detection	O
of	O
Sendai	O
virus	O
and	O
PVM	O
immunodeficient	O
animals	O
and	O
contaminated	O
biomaterials	O
.	O

The	O
pathogenesis	O
of	O
these	O
lung	O
diseases	O
is	O
characterized	O
by	O
a	O
neutrophil	O
-	O
predominant	O
inflammation	O
associated	O
with	O
excessive	O
release	O
of	O
neutrophil	O
proteases	O
,	O
including	O
neutrophil	B-ENZY
elastase	I-ENZY
(	O
NE	O
),	O
a	O
terminal	O
pulmonary	O
tissue	O
destroyer	O
.	O

The	O
changes	O
mainly	O
existed	O
in	O
the	O
mild	O
to	O
moderate	O
elevation	O
of	O
alanine	B-ENZY
aminotransferase	I-ENZY
and	O
aspartate	B-ENZY
aminotransferase	I-ENZY
.	O

During	O
CVVH	O
,	O
the	O
patients	O
'	O
conditions	O
and	O
pancreatic	O
enzymes	O
(	O
amylase	O
and	O
lipase	B-ENZY
)	O
were	O
observed	O
,	O
serum	O
concentration	O
of	O
endotoxin	O
was	O
measured	O
as	O
well	O
.	O

When	O
being	O
admitted	O
to	O
hospital	O
,	O
serum	O
ALT	O
and	O
(	O
or	O
)	O
AST	B-ENZY
levels	O
were	O
elevated	O
in	O
37	O
.	O
7	O
%	O
SARS	O
patients	O
.	O

Creatine	B-ENZY
kinase	I-ENZY
(	O
CK	B-ENZY
)	O
and	O
(	O
or	O
)	O
creatine	B-ENZY
kinase	I-ENZY
MB	O
(	O
CK	B-ENZY
-	O
MB	O
)	O
levels	O
elevated	O
in	O
72	O
.	O
7	O
%	O
patients	O
when	O
they	O
hospitalized	O
.	O

Infiltration	O
of	O
pancreatic	O
and	O
lung	O
tissue	O
with	O
neutrophils	O
(	O
measured	O
as	O
increase	O
in	O
myeloperoxidase	B-ENZY
activity	O
)	O
was	O
associated	O
with	O
enhanced	O
lipid	O
peroxidation	O
(	O
increased	O
tissue	O
levels	O
of	O
malondialdehyde	O
).	O

We	O
have	O
constructed	O
a	O
prototype	O
RNA	O
vector	O
containing	O
the	O
5	O
'	O
and	O
3	O
'	O
ends	O
of	O
the	O
human	O
coronavirus	O
genome	O
,	O
the	O
entire	O
human	O
coronavirus	O
replicase	O
gene	O
,	O
and	O
three	O
reporter	O
genes	O
(	O
i	O
.	O
e	O
.,	O
the	O
chloramphenicol	O
acetyltransferase	O
[	O
CAT	O
]	O
gene	O
,	O
the	O
firefly	B-ENZY
luciferase	I-ENZY
[	O
LUC	O
]	O
gene	O
,	O
and	O
the	O
green	O
fluorescent	O
protein	O
[	O
GFP	O
]	O
gene	O
).	O

Diagnosis	O
was	O
made	O
on	O
the	O
basis	O
of	O
viral	O
culture	O
and	O
electron	O
microscopy	O
findings	O
that	O
exhibited	O
typical	O
crown	O
-	O
like	O
particles	O
and	O
through	O
amplification	O
of	O
the	O
viral	O
genome	O
by	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
.	O

A	O
systematic	O
search	O
for	O
perinatal	O
transmission	O
of	O
the	O
SARS	O
-	O
associated	O
coronavirus	O
,	O
including	O
serial	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
assays	O
,	O
viral	O
cultures	O
,	O
and	O
paired	O
serologic	O
titers	O
,	O
failed	O
to	O
detect	O
the	O
virus	O
in	O
any	O
of	O
the	O
infants	O
.	O

Treatment	O
delay	O
was	O
associated	O
with	O
AST	B-ENZY
level	O
at	O
maximal	O
radiographic	O
score	O
(	O
r	O
=	O
0	O
.	O
53	O
,	O
P	O
=.	O
001	O
),	O
treatment	O
radiographic	O
score	O
(	O
r	O
=	O
0	O
.	O
60	O
,	O
P	O
<.	O
001	O
),	O
and	O
time	O
to	O
maximal	O
radiographic	O
score	O
(	O
r	O
=	O
-	O
0	O
.	O
36	O
,	O
P	O
=.	O
02	O
).	O

Furthermore	O
,	O
theoretical	O
and	O
structural	O
considerations	O
propose	O
that	O
BN	O
is	O
converted	O
into	O
bananin	O
5	O
'-	O
monophosphate	O
(	O
BNP	O
)	O
by	O
the	O
cell	O
type	O
-	O
ubiquitous	O
human	O
enzyme	O
pyridoxal	B-ENZY
kinase	I-ENZY
(	O
EC	O
2	O
.	O
7	O
.	O
1	O
.	O
35	O
).	O

Although	O
NIPPV	O
administered	O
via	O
full	O
-	O
face	O
masks	O
might	O
be	O
an	O
effective	O
treatment	O
for	O
rapidly	O
improving	O
vital	O
signs	O
and	O
gas	B-ENZY
exchange	O
and	O
sense	O
of	O
dyspnea	O
in	O
both	O
groups	O
during	O
the	O
initial	O
24	O
hours	O
of	O
ventilatory	O
support	O
,	O
the	O
patients	O
in	O
non	O
-	O
survivor	O
group	O
had	O
higher	O
APACHEII	O
score	O
,	O
respiratory	O
rates	O
and	O
lower	O
SpO	O
(	O
2	O
),	O
MRI	O
than	O
the	O
patients	O
in	O
survivor	O
group	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
at	O
the	O
same	O
intervals	O
after	O
initiation	O
of	O
support	O
.	O

RESULTS	O
:	O
Although	O
NIPPV	O
administered	O
via	O
full	O
-	O
face	O
masks	O
might	O
be	O
an	O
effective	O
treatment	O
for	O
rapidly	O
improving	O
vital	O
signs	O
and	O
gas	B-ENZY
exchange	O
and	O
sense	O
of	O
dyspnea	O
in	O
both	O
groups	O
during	O
the	O
initial	O
24	O
hours	O
of	O
ventilatory	O
support	O
,	O
the	O
patients	O
in	O
non	O
-	O
survivor	O
group	O
had	O
higher	O
APACHEII	O
score	O
,	O
respiratory	O
rates	O
and	O
lower	O
SpO	O
(	O
2	O
),	O
MRI	O
than	O
the	O
patients	O
in	O
survivor	O
group	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
at	O
the	O
same	O
intervals	O
after	O
initiation	O
of	O
support	O
.	O

Expression	O
levels	O
increased	O
when	O
the	O
luciferase	B-ENZY
gene	O
was	O
inserted	O
closer	O
to	O
the	O
3	O
'	O
end	O
of	O
the	O
genome	O
.	O

ABSTRACT	O
:	O
In	O
this	O
report	O
,	O
we	O
describe	O
a	O
real	O
-	O
time	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
(	O
RRT	O
-	O
PCR	O
)	O
diagnostic	O
test	O
for	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
with	O
the	O
use	O
of	O
fluorescence	O
resonance	O
energy	O
transfer	O
(	O
FRET	O
)	O
technology	O
.	O

Common	O
laboratory	O
abnormalities	O
included	O
mild	O
leukopenia	O
,	O
lymphopenia	O
,	O
and	O
increased	O
aspartate	B-ENZY
transaminase	I-ENZY
,	O
alanine	B-ENZY
transaminase	I-ENZY
,	O
lactic	O
dehydrogenase	O
,	O
and	O
creatine	B-ENZY
kinase	I-ENZY
.	O

ABSTRACT	O
:	O
This	O
study	O
reports	O
on	O
the	O
development	O
of	O
a	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
for	O
the	O
specific	O
detection	O
of	O
turkey	O
coronavirus	O
(	O
TCoV	O
).	O

Common	O
laboratory	O
features	O
included	O
lymphopenia	O
(	O
72	O
.	O
4	O
%),	O
thrombocytopenia	O
(	O
34	O
.	O
5	O
%)	O
and	O
elevated	O
C	O
-	O
reactive	O
protein	O
(	O
CRP	O
),	O
lactate	O
dehydrogenase	O
(	O
LDH	O
),	O
and	O
aspartate	B-ENZY
aminotransferase	I-ENZY
(	O
AST	B-ENZY
)	O
(	O
93	O
.	O
1	O
,	O
62	O
.	O
1	O
,	O
44	O
.	O
8	O
%,	O
respectively	O
).	O

Fecal	O
samples	O
were	O
evaluated	O
for	O
Eimeria	O
spp	B-ENZY
,	O
Giardia	O
spp	B-ENZY
,	O
Cryptosporidium	O
spp	B-ENZY
,	O
enteric	O
viruses	O
,	O
and	O
Salmonella	O
spp	B-ENZY
.	O

The	O
ACE2	O
sequence	O
is	O
similar	O
(	O
sequence	O
identities	O
43	O
%	O
and	O
35	O
%,	O
and	O
similarities	O
61	O
%	O
and	O
55	O
%,	O
respectively	O
)	O
to	O
those	O
of	O
the	O
testis	O
-	O
specific	O
form	O
of	O
ACE	B-ENZY
(	O
tACE	B-ENZY
)	O
and	O
the	O
Drosophila	O
homolog	O
of	O
ACE	B-ENZY
(	O
AnCE	O
).	O

Metachromatic	O
scores	O
yielded	O
significantly	O
different	O
results	O
between	O
controls	O
and	O
principals	O
(	O
P	O
<	O
0	O
.	O
01	O
),	O
demonstrating	O
a	O
significant	O
disappearance	O
of	O
metachromatic	O
granules	O
from	O
lung	O
MCs	B-ENZY
in	O
principals	O
.	O

The	O
rats	O
were	O
killed	O
24	O
hours	O
after	O
injury	O
and	O
some	O
parameters	O
of	O
lung	O
injury	O
were	O
evaluated	O
--	O
i	O
.	O
e	O
.,	O
bronchoalveolar	O
lavage	O
(	O
BAL	B-ENZY
),	O
lung	O
tissue	O
myeloperoxidase	B-ENZY
levels	O
(	O
MPO	O
)	O
and	O
wet	O
/	O
dry	O
ratios	O
of	O
lung	O
tissue	O
.	O

The	O
protective	O
effects	O
of	O
pioglitazone	O
treatment	O
were	O
correlated	O
with	O
the	O
reduction	O
by	O
79	O
%	O
of	O
the	O
increase	O
of	O
thiobarbituric	O
acid	O
reactive	O
substances	O
(	O
P	O
=	O
0	O
.	O
045	O
)	O
and	O
the	O
reduction	O
by	O
58	O
%	O
of	O
myeloperoxidase	B-ENZY
activity	O
increase	O
(	O
P	O
<	O
0	O
.	O
001	O
).	O

Secretory	O
phospholipase	B-ENZY
A2	I-ENZY
(	O
sPLA2	O
),	O
a	O
potent	O
inflammatory	O
mediator	O
,	O
is	O
elevated	O
in	O
ACS	B-ENZY
,	O
and	O
sPLA2	O
levels	O
in	O
serum	O
or	O
plasma	O
predict	O
impending	O
ACS	B-ENZY
.	O

In	O
addition	O
sPLA2	O
may	O
play	O
a	O
major	O
role	O
in	O
the	O
actual	O
damage	O
to	O
the	O
lung	O
resulting	O
in	O
a	O
new	O
pulmonary	O
infiltrate	O
on	O
chest	O
radiography	O
,	O
respiratory	O
symptoms	O
,	O
and	O
ultimately	O
alveolar	O
collapse	O
and	O
the	O
impairment	O
of	O
gas	B-ENZY
exchange	O
.	O

TITLE	O
:	O
NAT	B-ENZY
screening	O
of	O
blood	O
donors	O
for	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
can	O
potentially	O
prevent	O
transfusion	O
associated	O
transmissions	O
.	O

Patients	O
were	O
randomly	O
assigned	O
to	O
placebo	O
(	O
nitrogen	O
gas	B-ENZY
)	O
or	O
inhaled	O
nitric	O
oxide	O
at	O
5	O
ppm	O
until	O
28	O
days	O
,	O
discontinuation	O
of	O
assisted	O
breathing	O
,	O
or	O
death	O
.	O

There	O
are	O
several	O
other	O
neuraminidase	B-ENZY
inhibitors	O
in	O
development	O
.	O

It	O
is	O
used	O
in	O
the	O
treatment	O
of	O
patients	O
with	O
extremely	O
severe	O
,	O
acute	O
respiratory	O
distress	O
in	O
order	O
to	O
provide	O
gas	B-ENZY
exchange	O
through	O
an	O
extracorporeal	O
artificial	O
oxygenator	O
.	O

ABSTRACT	O
:	O
A	O
36	O
-	O
year	O
-	O
old	O
male	O
with	O
a	O
known	O
history	O
of	O
sickle	O
cell	O
disease	O
(	O
SCD	O
)	O
and	O
acute	O
chest	O
syndrome	O
(	O
ACS	B-ENZY
)	O
was	O
treated	O
in	O
our	O
hospital	O
.	O

ACS	B-ENZY
evolving	O
to	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
is	O
a	O
rare	O
but	O
severe	O
complication	O
.	O

In	O
ACS	B-ENZY
iNO	O
should	O
be	O
considered	O
a	O
beneficial	O
therapeutic	O
option	O
.	O

RESULTS	O
:	O
Alanine	B-ENZY
aminotransferase	I-ENZY
(	O
ALT	O
),	O
aspartate	B-ENZY
aminotransferase	I-ENZY
(	O
AST	B-ENZY
),	O
lactate	O
dehydrogenase	O
(	O
LDH	O
),	O
total	O
bilirubin	O
(	O
TBil	O
)	O
of	O
patients	O
with	O
SARS	O
were	O
higher	O
than	O
those	O
of	O
controls	O
,	O
they	O
were	O
(	O
91	O
.	O
61	O
+/-	O
50	O
.	O
53	O
)	O
U	O
/	O
L	O
vs	O
.	O
(	O
32	O
.	O
91	O
+/-	O
10	O
.	O
56	O
)	O
U	O
/	O
L	O
,	O
(	O
78	O
.	O
68	O
+/-	O
33	O
.	O
32	O
)	O
U	O
/	O
L	O
vs	O
.	O
(	O
29	O
.	O
43	O
+/-	O
8	O
.	O
89	O
)	O
U	O
/	O
L	O
,	O
(	O
429	O
.	O
95	O
+/-	O
188	O
.	O
94	O
)	O
U	O
/	O
L	O
vs	O
.	O
(	O
200	O
.	O
83	O
+/-	O
44	O
.	O
86	O
)	O
U	O
/	O
L	O
,	O
(	O
11	O
.	O
67	O
+/-	O
4	O
.	O
26	O
)	O
micromol	O
/	O
L	O
vs	O
.	O
(	O
8	O
.	O
44	O
+/-	O
3	O
.	O
86	O
)	O
micromol	O
/	O
L	O
,	O
all	O
P	O
<	O
0	O
.	O
001	O
.	O

TITLE	O
:	O
Development	O
of	O
reverse	B-ENZY
transcriptase	I-ENZY
PCR	O
and	O
nested	O
PCR	O
to	O
detect	O
porcine	O
hemagglutinating	O
encephalomyelitis	O
virus	O
.	O

Furthermore	O
,	O
we	O
established	O
an	O
RNA	O
5	O
'-	O
triphosphatase	B-ENZY
activity	O
for	O
the	O
SARS	O
-	O
CoV	O
nsp13	O
helicase	O
which	O
may	O
be	O
involved	O
in	O
the	O
formation	O
of	O
the	O
5	O
'	O
cap	O
structure	O
of	O
viral	O
RNAs	O
.	O

ABSTRACT	O
:	O
Cleavage	O
of	O
the	O
mouse	O
hepatitis	O
coronavirus	O
strain	O
A59	O
spike	O
protein	O
was	O
blocked	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
by	O
a	O
peptide	O
furin	B-ENZY
inhibitor	O
,	O
indicating	O
that	O
furin	B-ENZY
or	O
a	O
furin	B-ENZY
-	O
like	O
enzyme	O
is	O
responsible	O
for	O
this	O
process	O
.	O

TITLE	O
:	O
Phosphorylation	O
of	O
p38	O
MAPK	B-ENZY
and	O
its	O
downstream	O
targets	O
in	O
SARS	O
coronavirus	O
-	O
infected	O
cells	O
.	O

S	O
protein	O
could	O
be	O
cleaved	O
by	O
exogenous	O
trypsin	B-ENZY
but	O
not	O
by	O
coexpressed	O
furin	B-ENZY
,	O
suggesting	O
that	O
the	O
protein	O
is	O
not	O
normally	O
processed	O
during	O
infection	O
.	O

Other	O
common	O
abnormal	O
laboratory	O
findings	O
included	O
leukopenia	O
,	O
thrombocytopenia	O
,	O
and	O
elevated	O
levels	O
of	O
aminotransferase	O
,	O
lactate	O
dehydrogenase	O
,	O
and	O
creatine	B-ENZY
kinase	I-ENZY
.	O

Using	O
the	O
NTPase	B-ENZY
active	O
site	O
,	O
HCoV	O
-	O
229E	O
nsp13	O
also	O
mediates	O
RNA	O
5	O
'-	O
triphosphatase	B-ENZY
activity	O
,	O
which	O
may	O
be	O
involved	O
in	O
the	O
capping	O
of	O
viral	O
RNAs	O
.	O

TITLE	O
:	O
Microwave	O
or	O
autoclave	O
treatments	O
destroy	O
the	O
infectivity	O
of	O
infectious	O
bronchitis	O
virus	O
and	O
avian	O
pneumovirus	O
but	O
allow	O
detection	O
by	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
.	O

TITLE	O
:	O
Identification	O
of	O
six	O
new	O
polymorphisms	O
in	O
the	O
human	O
coronavirus	O
229E	O
receptor	O
gene	O
(	O
aminopeptidase	B-ENZY
N	I-ENZY
/	O
CD13	O
).	O

Regarding	O
the	O
current	O
literature	O
,	O
recruitment	O
maneuvers	O
may	O
be	O
considered	O
as	O
a	O
rescue	O
therapy	O
in	O
the	O
early	O
stage	O
of	O
severe	O
hypoxemic	O
lung	O
failure	O
,	O
if	O
a	O
lung	O
protective	O
ventilation	O
strategy	O
and	O
other	O
additive	O
adjuncts	O
like	O
prone	O
positioning	O
or	O
the	O
application	O
of	O
inhaled	O
vasodilators	O
failed	O
to	O
induce	O
adequate	O
gas	B-ENZY
exchange	O
.	O

The	O
damage	O
of	O
several	O
organs	O
was	O
common	O
,	O
including	O
the	O
elevated	O
ALT	O
or	O
AST	B-ENZY
in	O
20	O
patients	O
(	O
37	O
.	O
7	O
%),	O
elevated	O
BUN	O
or	O
SCR	O
in	O
6	O
patients	O
(	O
11	O
.	O
3	O
%)	O
and	O
elevated	O
LDH	O
or	O
CK	O
or	O
HBDH	O
in	O
23	O
patients	O
(	O
43	O
.	O
4	O
%).	O

The	O
damage	O
of	O
several	O
organs	O
was	O
common	O
,	O
including	O
the	O
elevated	O
ALT	O
or	O
AST	B-ENZY
in	O
20	O
patients	O
(	O
37	O
.	O
7	O
%),	O
elevated	O
BUN	O
or	O
SCR	O
in	O
6	O
patients	O
(	O
11	O
.	O
3	O
%)	O
and	O
elevated	O
LDH	O
or	O
CK	O
or	O
HBDH	O
in	O
23	O
patients	O
(	O
43	O
.	O
4	O
%).	O

Inflammatory	O
cytokines	O
(	O
TNF	O
-	O
alpha	O
,	O
IL	O
-	O
6	O
),	O
protein	O
concentration	O
in	O
bronchoalveolar	O
lavage	O
(	O
BAL	B-ENZY
)	O
fluid	O
,	O
lung	O
wet	O
-	O
to	O
-	O
dry	O
weight	O
ratio	O
,	O
histology	O
,	O
immunohistochemistry	O
,	O
and	O
AQP1	O
Western	O
blot	O
were	O
performed	O
.	O

ABSTRACT	O
:	O
This	O
study	O
analyzed	O
the	O
effect	O
of	O
phasic	O
tracheal	O
gas	B-ENZY
insufflation	O
at	O
mid	O
-	O
to	O
end	O
-	O
expiration	O
in	O
patients	O
with	O
severe	O
head	O
trauma	O
and	O
acute	O
lung	O
injury	O
(	O
ALI	O
)/	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

The	O
ACE	B-ENZY
gene	O
underwent	O
duplication	O
at	O
the	O
origin	O
of	O
Chordata	O
,	O
just	O
before	O
the	O
""""	O
Cambrian	O
Explosion	O
""""	O
in	O
the	O
number	O
of	O
species	O
.	O

The	O
crystal	O
structure	O
of	O
testicular	O
ACE	B-ENZY
(	O
tACE	B-ENZY
)	O
was	O
recently	O
published	O
.	O

One	O
hour	O
of	O
NPPV	O
therapy	O
led	O
to	O
significant	O
increases	O
in	O
PaO	B-ENZY
(	O
2	O
),	O
SpO	O
(	O
2	O
)	O
and	O
PaO	B-ENZY
(	O
2	O
)/	O
FiO	O
(	O
2	O
),	O
and	O
decrease	O
in	O
respiratory	O
rate	O
(	O
all	O
P	O
<	O
0	O
.	O
01	O
).	O

The	O
virus	O
was	O
first	O
identified	O
by	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
and	O
showed	O
a	O
distinct	O
restriction	O
fragment	O
length	O
polymorphism	O
pattern	O
from	O
previously	O
described	O
Israeli	O
isolates	O
.	O

This	O
paper	O
reviews	O
the	O
biochemistry	O
of	O
ACE2	O
and	O
discusses	O
key	O
findings	O
such	O
as	O
the	O
elucidation	O
of	O
crystal	O
structures	O
for	O
ACE2	O
and	O
testicular	O
ACE	B-ENZY
and	O
the	O
development	O
of	O
ACE2	O
inhibitors	O
that	O
have	O
now	O
provided	O
a	O
basis	O
for	O
future	O
research	O
on	O
this	O
enzyme	O
.	O

Upon	O
infection	O
of	O
Escherichia	O
coli	O
cells	O
containing	O
the	O
two	O
plasmids	O
encoding	O
the	O
cI	O
.	O
SCoV	O
P1	O
/	O
P2	O
-	O
cro	O
and	O
the	O
beta	B-ENZY
-	I-ENZY
galactosidase	I-ENZY
-	O
SCoV	O
3C	O
-	O
like	O
protease	O
constructs	O
,	O
lambda	O
phage	O
replicated	O
up	O
to	O
2	O
,	O
000	O
-	O
fold	O
more	O
efficiently	O
than	O
in	O
cells	O
that	O
did	O
not	O
express	O
the	O
SCoV	O
3C	O
-	O
like	O
protease	O
.	O

By	O
allowing	O
patients	O
with	O
the	O
acute	O
respiratory	O
distress	O
syndrome	O
to	O
breathe	O
spontaneously	O
,	O
one	O
can	O
expect	O
improvements	O
in	O
gas	B-ENZY
exchange	O
and	O
systemic	O
blood	O
flow	O
,	O
based	O
on	O
findings	O
from	O
both	O
experimental	O
and	O
clinical	O
trials	O
.	O

ABSTRACT	O
:	O
The	O
ubiquitin	O
-	O
proteasome	B-ENZY
system	O
is	O
involved	O
in	O
cellular	O
endocytosis	O
and	O
maturation	O
of	O
some	O
viruses	O
.	O

Arginase	B-ENZY
was	O
not	O
induced	O
in	O
BMMphi	O
from	O
both	O
strains	O
by	O
IL	O
-	O
12	O
/	O
IL	O
-	O
18	O
or	O
IFNgamma	O
but	O
only	O
by	O
IL	O
-	O
4	O
/	O
IL	O
-	O
10	O
.	O

TITLE	O
:	O
Rapid	O
differentiation	O
of	O
avian	O
infectious	O
bronchitis	O
virus	O
isolates	O
by	O
sample	O
to	O
residual	O
ratio	O
quantitation	O
using	O
real	O
-	O
time	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
.	O

The	O
protein	O
sequence	O
of	O
the	O
chymotrypsin	B-ENZY
-	O
like	O
cysteine	O
proteinase	O
(	O
CCP	O
)	O
responsible	O
for	O
SARS	O
viral	O
replication	O
has	O
been	O
identified	O
as	O
a	O
target	O
for	O
developing	O
anti	O
-	O
SARS	O
drugs	O
.	O

Helicobacter	O
spp	B-ENZY
.	O

This	O
Q	O
-	O
RT	O
-	O
PCR	O
assay	O
can	O
be	O
used	O
to	O
detect	O
SARS	O
-	O
CoV	O
.	O
Moreover	O
,	O
GAPDH	B-ENZY
mRNA	O
may	O
be	O
useful	O
to	O
rule	O
out	O
false	O
negative	O
results	O
in	O
SARS	O
-	O
CoV	O
detection	O
,	O
and	O
the	O
current	O
extraction	O
method	O
for	O
urine	O
may	O
not	O
be	O
sensitive	O
enough	O
to	O
detect	O
low	O
titres	O
of	O
SARS	O
-	O
CoV	O
.	O
RESULTS	O
:	O
Varying	O
amounts	O
of	O
SARS	O
-	O
CoV	O
were	O
found	O
in	O
the	O
26	O
SARS	O
-	O
CoV	O
positive	O
specimens	O
and	O
SARS	O
-	O
CoV	O
was	O
not	O
detected	O
in	O
the	O
40	O
follow	O
up	O
specimens	O
and	O
controls	O
.	O

CONCLUSIONS	O
:	O
The	O
ACE	B-ENZY
I	O
/	O
D	O
polymorphism	O
is	O
not	O
directly	O
related	O
to	O
increased	O
susceptibility	O
to	O
SARS	O
-	O
coronavirus	O
infection	O
and	O
is	O
not	O
associated	O
with	O
poor	O
outcomes	O
after	O
SARS	O
-	O
coronavirus	O
infection	O
.	O

A	O
virus	O
with	O
only	O
the	O
F115	O
change	O
,	O
which	O
was	O
previously	O
thought	O
to	O
be	O
the	O
only	O
change	O
important	O
for	O
plaque	O
formation	O
of	O
F	O
1	O
-	O
R	O
F	O
,	O
did	O
not	O
confer	O
upon	O
the	O
virus	O
the	O
ability	O
to	O
form	O
plaques	O
without	O
the	O
addition	O
of	O
trypsin	B-ENZY
.	O

ABSTRACT	O
:	O
Aminopeptidase	B-ENZY
N	I-ENZY
,	O
or	O
CD13	O
,	O
is	O
a	O
receptor	O
for	O
serologically	O
related	O
coronaviruses	O
of	O
humans	O
,	O
pigs	O
,	O
and	O
cats	O
.	O

An	O
analysis	O
of	O
receptor	O
engagement	O
revealed	O
that	O
NL63	O
-	O
S	O
binds	O
angiotensin	O
-	O
converting	O
enzyme	O
(	O
ACE	B-ENZY
)	O
2	O
,	O
the	O
receptor	O
for	O
SARS	O
-	O
CoV	O
,	O
and	O
HCoV	O
-	O
NL63	O
uses	O
ACE2	O
as	O
a	O
receptor	O
for	O
infection	O
of	O
target	O
cells	O
.	O

In	O
all	O
these	O
16	O
cases	O
,	O
it	O
was	O
regarded	O
retrospectively	O
as	O
ethically	O
justifiable	O
not	O
to	O
start	O
CPR	B-ENZY
.	O

In	O
patients	O
who	O
died	O
at	O
a	O
Swedish	O
University	O
Hospital	O
,	O
we	O
did	O
not	O
find	O
a	O
single	O
case	O
in	O
which	O
it	O
was	O
regarded	O
as	O
unethical	O
not	O
to	O
start	O
CPR	B-ENZY
.	O

Tracer	O
gas	B-ENZY
(	O
perfume	O
of	O
plant	O
oil	O
)	O
was	O
emitted	O
to	O
the	O
bathroom	O
of	O
wards	O
when	O
SARS	O
index	O
patient	O
lived	O
.	O

The	O
distribution	O
of	O
tracer	O
gas	B-ENZY
in	O
the	O
wards	O
was	O
associated	O
with	O
SARS	O
patients	O
in	O
this	O
building	O
.	O

The	O
interaction	O
between	O
SARS	O
coronavirus	O
3C	O
-	O
like	O
(	O
3CL	O
)	O
proteinase	O
and	O
an	O
octapeptide	O
interface	O
inhibitor	O
was	O
studied	O
by	O
affinity	O
capillary	O
electrophoresis	O
(	O
ACE	B-ENZY
).	O

Two	O
hours	O
after	O
blunt	O
chest	O
trauma	O
,	O
plasma	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
and	O
interleukin	O
-	O
6	O
were	O
markedly	O
increased	O
,	O
as	O
was	O
peripheral	O
blood	O
mononuclear	O
cell	O
cytokine	O
production	O
,	O
lung	O
myeloperoxidase	B-ENZY
activity	O
,	O
and	O
lung	O
chemokine	O
concentrations	O
.	O

TITLE	O
:	O
[	O
RNase	B-ENZY
III	I-ENZY
-	O
prepared	O
short	O
interfering	O
RNAs	O
induce	O
degradation	O
of	O
SARS	O
-	O
coronavirus	O
mRNAs	O
in	O
human	O
cells	O
].	O

Alanine	B-ENZY
aminotransferase	I-ENZY
(	O
ALT	O
)	O
and	O
aspartate	B-ENZY
transaminase	I-ENZY
(	O
AST	B-ENZY
)	O
levels	O
increased	O
slightly	O
in	O
3	O
patients	O
.	O

ABSTRACT	O
:	O
Gas	B-ENZY
exchange	O
alterations	O
have	O
been	O
described	O
in	O
cirrhotic	O
patients	O
;	O
but	O
by	O
the	O
moment	O
,	O
a	O
few	O
prospective	O
studies	O
have	O
focused	O
in	O
them	O
.	O

HPS	B-ENZY
was	O
confirmed	O
in	O
8	O
patients	O
(	O
16	O
%).	O

The	O
difference	O
in	O
chloride	O
sensitivity	O
between	O
ACE2	O
and	O
ACE	B-ENZY
was	O
investigated	O
,	O
and	O
the	O
absence	O
of	O
a	O
second	O
chloride	O
-	O
binding	O
site	O
(	O
CL2	O
)	O
in	O
ACE2	O
confirmed	O
.	O

After	O
successful	O
CPR	B-ENZY
,	O
reversible	O
myocardial	O
dysfunction	O
,	O
consisting	O
of	O
systolic	O
myocardial	O
dysfunction	O
and	O
disturbances	O
of	O
segmental	O
contractility	O
,	O
may	O
occur	O
.	O

ABSTRACT	O
:	O
In	O
contrast	O
to	O
the	O
relatively	O
ubiquitous	O
angiotensin	O
-	O
converting	O
enzyme	O
(	O
ACE	B-ENZY
),	O
expression	O
of	O
the	O
mammalian	O
ACE	B-ENZY
homologue	O
,	O
ACE2	O
,	O
was	O
initially	O
described	O
in	O
the	O
heart	O
,	O
kidney	O
and	O
testis	O
.	O

The	O
selective	O
neutrophil	B-ENZY
elastase	I-ENZY
inhibitor	O
sivelestat	O
reduces	O
neutrophil	B-ENZY
elastase	I-ENZY
activity	O
and	O
attenuates	O
acute	O
changes	O
in	O
the	O
pulmonary	O
microcirculation	O
.	O

The	O
selection	O
of	O
25	O
test	O
materials	O
includes	O
eleven	O
trioxa	O
-	O
adamantane	O
-	O
triols	O
(	O
TATs	O
)	O
[	O
BN	O
,	O
IBNCA	O
,	O
ABNCA	O
,	O
VANBA	O
,	O
ethylVANBA	O
,	O
euBN	O
,	O
euVANBA	O
,	O
ansaBN	O
,	O
Ehrlich	O
BN	O
,	O
[	O
6	O
]	O
prismaneBN	O
,	O
nitrodiBN	O
],	O
trivially	O
termed	O
bananins	O
,	O
one	O
trioxa	O
-	O
adamantan	O
-	O
ol	O
(	O
TAO	O
)	O
THYMOBA	O
,	O
one	O
bis	B-ENZY
-	O
bananin	O
pi	O
-	O
bananin	O
(	O
piBN	O
),	O
one	O
triazaadamantane	O
delta	O
-	O
bananin	O
(	O
deltaBN	O
),	O
seven	O
potential	O
nucleic	O
acid	O
-	O
binding	O
drugs	O
(	O
XBQC	O
,	O
INDO	O
,	O
PivINDO	O
,	O
AZTRION	O
,	O
AZADO	O
,	O
AZOCYS	O
,	O
AZOGALL	O
),	O
one	O
potential	O
antiviral	O
interferon	O
-	O
inducer	O
and	O
distant	O
nucleoside	O
analog	O
diazon	O
,	O
one	O
potential	O
HIV	O
protein	O
Vif	O
antagonist	O
AZODIAZON	O
,	O
one	O
folic	O
acid	O
-	O
diazon	O
condensate	O
DIAZONOFOL	O
,	O
and	O
one	O
special	O
nucleoside	O
analog	O
(	O
fructoinosine	O
/	O
fructovir	O
).	O

Sequence	O
alignments	O
and	O
protein	O
secondary	O
structure	O
prediction	O
data	O
suggest	O
the	O
presence	O
of	O
a	O
3C	B-ENZY
-	I-ENZY
like	I-ENZY
serine	I-ENZY
protease	I-ENZY
domain	O
with	O
similarity	O
to	O
the	O
arterivirus	O
3C	B-ENZY
-	I-ENZY
like	I-ENZY
serine	I-ENZY
protease	I-ENZY
and	O
a	O
single	O
papain	B-ENZY
-	O
like	O
cysteine	O
protease	O
domain	O
with	O
similarity	O
to	O
the	O
picornavirus	O
leader	O
protease	O
.	O

Sequencing	O
and	O
analysis	O
of	O
three	O
bat	B-ENZY
-	O
SARS	O
-	O
CoV	O
genomes	O
from	O
samples	O
collected	O
at	O
different	O
dates	O
showed	O
that	O
bat	B-ENZY
-	O
SARS	O
-	O
CoV	O
is	O
closely	O
related	O
to	O
SARS	O
-	O
CoV	O
from	O
humans	O
and	O
civets	O
.	O

Our	O
results	O
showed	O
that	O
STR2	O
protein	O
expression	O
with	O
the	O
use	O
of	O
an	O
138	O
base	O
-	O
pair	O
intron	O
addition	O
increased	O
by	O
1	O
.	O
9	O
-,	O
2	O
.	O
5	O
-,	O
and	O
4	O
.	O
1	O
-	O
fold	O
in	O
Vero	O
E6	O
,	O
QBI	O
-	O
293A	O
cells	O
,	O
and	O
CHO	O
/	O
dhFr	O
-	O
cells	O
(	O
dihydrofolate	B-ENZY
reductase	I-ENZY
[	O
dhfr	O
]	O
gene	O
deficient	O
CHO	O
cells	O
),	O
respectively	O
.	O

In	O
the	O
ethanol	O
group	O
,	O
serum	O
and	O
tissue	O
MDA	O
levels	O
and	O
MPO	O
activities	O
were	O
increased	O
(	O
p	O
=	O
0	O
.	O
007	O
,	O
p	O
=	O
0	O
.	O
001	O
and	O
p	O
=	O
0	O
.	O
000	O
),	O
and	O
lung	O
tissue	O
Na	O
(+)-	O
K	O
(+)	O
ATPase	B-ENZY
activities	O
and	O
erythrocyte	O
GSH	O
were	O
decreased	O
(	O
p	O
=	O
0	O
.	O
001	O
and	O
p	O
=	O
0	O
.	O
000	O
)	O
compared	O
to	O
the	O
controls	O
.	O

RESULTS	O
:	O
In	O
the	O
ethanol	O
group	O
,	O
serum	O
and	O
tissue	O
MDA	O
levels	O
and	O
MPO	O
activities	O
were	O
increased	O
(	O
p	O
=	O
0	O
.	O
007	O
,	O
p	O
=	O
0	O
.	O
001	O
and	O
p	O
=	O
0	O
.	O
000	O
),	O
and	O
lung	O
tissue	O
Na	O
(+)-	O
K	O
(+)	O
ATPase	B-ENZY
activities	O
and	O
erythrocyte	O
GSH	O
were	O
decreased	O
(	O
p	O
=	O
0	O
.	O
001	O
and	O
p	O
=	O
0	O
.	O
000	O
)	O
compared	O
to	O
the	O
controls	O
.	O

After	O
induction	O
of	O
severe	O
lung	O
injury	O
by	O
repeated	O
saline	O
lung	O
lavage	O
,	O
19	O
adult	O
white	O
Japanese	O
rabbits	O
were	O
randomized	O
into	O
two	O
groups	O
that	O
received	O
PLV	O
with	O
HFO	O
(	O
n	O
=	O
9	O
)	O
or	O
HFO	O
gas	B-ENZY
ventilation	O
(	O
n	O
=	O
10	O
).	O

The	O
HFO	O
-	O
PLV	O
group	O
showed	O
improved	O
total	O
lung	O
compliance	O
with	O
maintenance	O
of	O
significantly	O
lower	O
mean	O
airway	O
pressure	O
as	O
compared	O
with	O
the	O
HFO	O
-	O
GAS	B-ENZY
group	O
so	O
as	O
to	O
keep	O
SpO2	O
>	O
90	O
%.	O

STAR	O
demonstrated	O
similar	O
or	O
better	O
sensitivity	O
and	O
precision	O
compared	O
to	O
two	O
commonly	O
used	O
methods	O
,	O
SYBR	O
Green	O
-	O
based	O
and	O
TaqMan	O
probe	O
-	O
based	O
real	O
-	O
time	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
.	O

In	O
this	O
study	O
,	O
a	O
detailed	O
in	O
silico	O
analysis	O
of	O
the	O
ORF1ab	O
,	O
encoding	O
the	O
7	O
,	O
182	O
-	O
amino	O
acid	O
replicase	O
polyprotein	O
in	O
the	O
CoV	O
-	O
HKU1	O
genome	O
showed	O
that	O
the	O
replicase	O
polyprotein	O
of	O
CoV	O
-	O
HKU1	O
is	O
cleaved	O
by	O
its	O
papain	B-ENZY
-	O
like	O
proteases	O
and	O
3C	O
-	O
like	O
protease	O
(	O
3CL	O
(	O
pro	O
))	O
into	O
16	O
polypeptides	O
homologous	O
to	O
the	O
corresponding	O
polypeptides	O
in	O
other	O
coronaviruses	O
.	O

ABSTRACT	O
:	O
Design	O
,	O
synthesis	O
,	O
and	O
biological	O
evaluation	O
of	O
peptidomimetic	O
severe	O
acute	O
respiratory	O
syndrome	O
chymotrypsin	B-ENZY
-	O
like	O
protease	O
(	O
SARS	O
-	O
3CLpro	O
)	O
inhibitors	O
for	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
are	O
described	O
.	O

TITLE	O
:	O
[	O
Cloning	O
of	O
ACE	B-ENZY
-	O
2	O
gene	O
encoding	O
the	O
functional	O
receptor	O
for	O
the	O
SARS	O
coronavirus	O
and	O
its	O
expression	O
in	O
eukaryotic	O
cells	O
].	O

ABSTRACT	O
:	O
Angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE	B-ENZY
-	O
2	O
)	O
has	O
been	O
identified	O
as	O
a	O
functional	O
receptor	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
),	O
so	O
its	O
gene	O
was	O
cloned	O
and	O
eukaryotic	O
expressed	O
for	O
further	O
insight	O
into	O
mechanisms	O
in	O
SARS	O
-	O
CoV	O
entry	O
and	O
pathogenesis	O
,	O
as	O
well	O
as	O
development	O
of	O
a	O
safe	O
and	O
reliable	O
neutralization	O
assay	O
for	O
SARS	O
-	O
CoV	O
.	O
Total	O
RNA	O
was	O
extracted	O
from	O
right	O
atrial	O
tissue	O
of	O
a	O
patient	O
with	O
right	O
heart	O
failure	O
resected	O
during	O
a	O
valvular	O
replacement	O
surgery	O
by	O
Trizol	O
one	O
-	O
step	O
method	O
,	O
and	O
the	O
full	O
-	O
length	O
ACE	B-ENZY
-	O
2	O
encoding	O
gene	O
was	O
acquired	O
by	O
RT	O
-	O
nested	O
-	O
PCR	O
.	O

In	O
this	O
study	O
,	O
we	O
present	O
a	O
very	O
sensitive	O
and	O
specific	O
TaqMan	O
-	O
based	O
,	O
real	O
-	O
time	O
quantitative	O
reverse	B-ENZY
transcriptase	I-ENZY
PCR	O
(	O
qRT	O
-	O
PCR	O
)	O
for	O
the	O
rapid	O
detection	O
and	O
quantitation	O
of	O
human	O
coronaviruses	O
(	O
HCoVs	O
)	O
OC43	O
and	O
229E	O
.	O

Endothelial	O
injury	O
bio	O
-	O
markers	O
tPA	B-ENZY
and	O
sTM	O
were	O
detected	O
by	O
commercial	O
ELISA	O
-	O
methods	O
.	O

Increased	O
plasma	O
concentrations	O
of	O
tPA	B-ENZY
and	O
sTM	O
in	O
patients	O
with	O
SARS	O
suggest	O
the	O
possibility	O
of	O
endothelial	O
injury	O
.	O

Sera	O
were	O
collected	O
in	O
large	O
amounts	O
at	O
the	O
peak	O
,	O
where	O
IgG	O
was	O
precipitated	O
using	O
ammonium	O
sulphate	O
and	O
subsequently	O
digested	O
with	O
pepsin	B-ENZY
.	O

A	O
proteasome	B-ENZY
inhibitor	O
stabilized	O
IBV	O
3b	O
in	O
mammalian	O
cells	O
,	O
but	O
had	O
little	O
effect	O
on	O
IBV	O
3b	O
in	O
avian	O
cells	O
,	O
suggesting	O
that	O
rapid	O
turnover	O
of	O
IBV	O
3b	O
in	O
mammalian	O
cells	O
is	O
proteasome	B-ENZY
-	O
dependent	O
while	O
turnover	O
in	O
avian	O
cells	O
may	O
be	O
proteasome	B-ENZY
-	O
independent	O
.	O

Using	O
reciprocal	O
bone	O
marrow	O
transplantation	O
(	O
BMT	B-ENZY
)	O
to	O
generate	O
HO	O
-	O
1	O
-	O
chimeric	O
mice	O
,	O
we	O
found	O
that	O
absence	O
of	O
HO	O
-	O
1	O
in	O
the	O
lung	O
parenchyma	O
,	O
not	O
in	O
bone	O
marrow	O
-	O
derived	O
inflammatory	O
cells	O
,	O
was	O
responsible	O
for	O
enhanced	O
SP	O
-	O
B	O
downregulation	O
and	O
severe	O
physiologic	O
lung	O
dysfunction	O
.	O

An	O
animal	O
model	O
of	O
human	O
coronavirus	O
infectious	O
disease	O
has	O
been	O
generated	O
by	O
gene	O
transfer	O
of	O
the	O
human	O
receptor	O
for	O
virus	O
-	O
cell	O
interaction	O
(	O
aminopeptidase	B-ENZY
N	I-ENZY
,	O
APN	O
,	O
CD13	O
)	O
into	O
mice	O
.	O

In	O
contrast	O
to	O
the	O
previous	O
suggestion	O
that	O
only	O
small	O
residues	O
in	O
substrate	O
could	O
be	O
accommodated	O
to	O
the	O
S1	O
'	O
subsite	O
,	O
we	O
have	O
found	O
that	O
bulky	O
residues	O
such	O
as	O
Tyr	O
and	O
Trp	B-ENZY
were	O
also	O
acceptable	O
.	O

TITLE	O
:	O
SARS	O
coronavirus	O
,	O
but	O
not	O
human	O
coronavirus	O
NL63	O
,	O
utilizes	O
cathepsin	B-ENZY
L	I-ENZY
to	O
infect	O
ACE2	O
-	O
expressing	O
cells	O
.	O

Compared	O
with	O
cells	O
heterozygous	O
for	O
L	O
-	O
SIGN	O
,	O
cells	O
homozygous	O
for	O
L	O
-	O
SIGN	O
show	O
higher	O
binding	O
capacity	O
for	O
SARS	O
-	O
CoV	O
,	O
higher	O
proteasome	B-ENZY
-	O
dependent	O
viral	O
degradation	O
and	O
a	O
lower	O
capacity	O
for	O
trans	O
infection	O
.	O

TITLE	O
:	O
The	O
nucleocapsid	O
protein	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
coronavirus	O
inhibits	O
the	O
activity	O
of	O
cyclin	O
-	O
cyclin	B-ENZY
-	I-ENZY
dependent	I-ENZY
kinase	I-ENZY
complex	O
and	O
blocks	O
S	O
phase	O
progression	O
in	O
mammalian	O
cells	O
.	O

TITLE	O
:	O
Changes	O
in	O
respiratory	O
mechanics	O
and	O
gas	B-ENZY
exchange	O
during	O
the	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

Ser380	O
,	O
which	O
has	O
been	O
reported	O
to	O
be	O
involved	O
in	O
autophosphorylation	O
by	O
activation	O
of	O
the	O
C	O
-	O
terminal	O
kinase	O
domain	O
,	O
was	O
phosphorylated	O
in	O
confluent	O
SARS	O
-	O
CoV	O
-	O
infected	O
cells	O
,	O
and	O
this	O
phosphorylation	O
was	O
inhibited	O
by	O
,	O
which	O
is	O
an	O
inhibitor	O
of	O
p38	O
mitogen	O
-	O
activated	O
protein	O
kinases	O
(	O
MAPK	B-ENZY
).	O

ABSTRACT	O
:	O
Serum	O
samples	O
collected	O
from	O
178	O
shot	O
wild	O
boars	O
(	O
Sus	O
scrofa	O
)	O
were	O
tested	O
for	O
the	O
presence	O
of	O
antibodies	O
against	O
classical	O
swine	O
fever	O
virus	O
,	O
Aujeszky	O
'	O
s	O
disease	O
virus	O
(	O
ADV	O
),	O
porcine	O
reproductive	O
and	O
respiratory	O
syndrome	O
virus	O
,	O
porcine	O
respiratory	O
coronavirus	O
(	O
PRCV	O
),	O
transmissible	O
gastroenteritis	O
virus	O
,	O
swine	O
influenza	O
virus	O
,	O
porcine	O
parvovirus	O
(	O
PPV	O
),	O
swine	O
vesicular	O
disease	O
virus	O
,	O
Actinobacillus	O
pleuropneumoniae	O
(	O
APP	O
),	O
Mycoplasma	O
hyopneumoniae	O
,	O
Salmonella	O
spp	B-ENZY
.,	O
Brucella	O
spp	B-ENZY
.	O

in	O
85	O
sera	O
(	O
47	O
%)	O
and	O
HPS	B-ENZY
in	O
33	O
sera	O
(	O
18	O
%).	O

FIC	O
reduced	O
significantly	O
at	O
6	O
months	O
while	O
the	O
SF	O
-	O
36	O
PCS	O
and	O
MCS	B-ENZY
did	O
not	O
show	O
any	O
change	O
.	O

TITLE	O
:	O
Furin	B-ENZY
cleavage	O
of	O
the	O
SARS	O
coronavirus	O
spike	O
glycoprotein	O
enhances	O
cell	O
-	O
cell	O
fusion	O
but	O
does	O
not	O
affect	O
virion	O
entry	O
.	O

The	O
lack	O
of	O
effect	O
of	O
furin	B-ENZY
cleavage	O
on	O
virion	O
infectivity	O
mirrors	O
that	O
observed	O
in	O
the	O
normally	O
cleaved	O
S	O
glycoprotein	O
of	O
the	O
murine	O
coronavirus	O
and	O
highlights	O
an	O
additional	O
level	O
of	O
complexity	O
in	O
coronavirus	O
entry	O
.	O

Growth	O
arrest	O
and	O
apoptosis	O
via	O
caspase	B-ENZY
-	I-ENZY
3	I-ENZY
and	O
caspase	B-ENZY
-	I-ENZY
9	I-ENZY
activities	O
were	O
demonstrated	O
in	O
SARS	O
-	O
CoV	O
3CLpro	O
-	O
expressing	O
human	O
promonocyte	O
cells	O
.	O

The	O
inhibitor	O
was	O
identified	O
through	O
high	O
-	O
throughput	O
screening	O
of	O
a	O
compound	O
library	O
using	O
a	O
luciferase	B-ENZY
-	O
expressing	O
West	O
Nile	O
(	O
WN	O
)	O
virus	O
infection	O
assay	O
.	O

We	O
discuss	O
that	O
the	O
BCoV	O
group	O
of	O
viruses	O
may	O
have	O
evolved	O
from	O
a	O
TGEV	O
-	O
like	O
ancestor	O
by	O
acquiring	O
an	O
acetylesterase	B-ENZY
gene	O
through	O
heterologous	O
recombination	O
.	O

Angiotensin	O
-	O
converting	O
enzyme	O
(	O
ACE	B-ENZY
)	O
plays	O
a	O
central	O
role	O
in	O
generating	O
angiotensin	O
II	O
from	O
angiotensin	O
I	O
,	O
and	O
capillary	O
blood	O
vessels	O
in	O
the	O
lung	O
are	O
one	O
of	O
the	O
major	O
sites	O
of	O
ACE	B-ENZY
expression	O
and	O
angiotensin	O
II	O
production	O
in	O
the	O
human	O
body	O
.	O

Torovirus	O
-	O
specific	O
nucleic	O
acid	O
confirmed	O
by	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
was	O
found	O
in	O
12	O
of	O
230	O
calves	O
(	O
5	O
.	O
2	O
%).	O

Phylogenetic	O
analysis	O
of	O
RNA	O
-	O
dependent	O
-	O
RNA	O
-	O
polymerase	O
(	O
pol	O
)	O
and	O
helicase	O
genes	O
revealed	O
six	O
novel	O
coronaviruses	O
from	O
six	O
different	O
bat	B-ENZY
species	O
,	O
in	O
addition	O
to	O
the	O
two	O
previously	O
described	O
coronaviruses	O
.	O

Animals	O
had	O
severe	O
acute	O
pancreatitis	O
(	O
SAP	O
)	O
induced	O
by	O
intraductal	O
injection	O
of	O
sodium	O
taurocholate	O
and	O
trypsin	B-ENZY
and	O
were	O
randomly	O
assigned	O
to	O
three	O
groups	O
:	O
1	O
)	O
Controls	O
,	O
2	O
)	O
Low	O
-	O
volume	O
(	O
LV	O
)	O
(	O
20	O
ml	O
/	O
kg	O
/	O
h	O
)	O
continuous	O
venovenous	O
hemofiltration	O
(	O
CVVH	O
)	O
and	O
3	O
)	O
High	O
-	O
volume	O
(	O
HV	O
)	O
(	O
100	O
ml	O
/	O
kg	O
/	O
h	O
)	O
CVVH	O
at	O
the	O
onset	O
of	O
the	O
induction	O
of	O
SAP	O
.	O

In	O
phase	O
2	O
(	O
n	O
=	O
17	O
),	O
doses	O
were	O
0	O
ppm	O
(	O
Group	O
5	O
,	O
n	O
=	O
5	O
);	O
60	O
ppm	O
(	O
Group	O
6	O
,	O
n	O
=	O
5	O
);	O
and	O
90	O
ppm	O
(	O
Group	O
7	O
,	O
n	O
=	O
7	O
),	O
and	O
the	O
multiple	O
inert	O
gas	B-ENZY
elimination	O
technique	O
(	O
MIGET	O
)	O
was	O
used	O
to	O
characterize	O
the	O
etiology	O
of	O
hypoxemia	O
.	O

In	O
patients	O
with	O
hypoxemia	O
,	O
bronchoscopy	O
and	O
BAL	B-ENZY
may	O
trigger	O
a	O
need	O
for	O
invasive	O
mechanical	O
ventilation	O
,	O
thus	O
considerably	O
decreasing	O
the	O
chances	O
of	O
survival	O
.	O

Except	O
for	O
presence	O
of	O
bilateral	O
infiltrate	O
on	O
chest	O
radiograph	O
and	O
severe	O
hypoxemia	O
on	O
arterial	O
blood	O
gas	B-ENZY
,	O
most	O
diagnostic	O
studies	O
are	O
used	O
to	O
exclude	O
mimics	O
of	O
ARDS	O
and	O
potentially	O
modify	O
treatment	O
.	O

ABSTRACT	O
:	O
Our	O
previous	O
reports	O
,	O
both	O
experimental	O
and	O
human	O
studies	O
,	O
have	O
shown	O
the	O
importance	O
of	O
fibrinogen	O
-	O
like	O
protein	O
-	O
2	O
(	O
fgl2	O
)	O
prothrombinase	B-ENZY
in	O
the	O
development	O
of	O
fulminant	O
viral	O
hepatitis	O
,	O
a	O
disease	O
with	O
a	O
mortality	O
of	O
more	O
than	O
80	O
%	O
in	O
cases	O
lacking	O
immediate	O
organ	O
transplantation	O
.	O

The	O
relative	O
sensitivity	O
and	O
specificity	O
of	O
multiplex	O
RT	O
-	O
PCR	O
were	O
evaluated	O
,	O
with	O
results	O
suggesting	O
that	O
this	O
assay	O
is	O
equal	O
in	O
quality	O
to	O
conventional	O
single	O
-	O
agent	O
RT	O
-	O
PCR	O
assays	O
(	O
sensitivity	O
:	O
100	O
%,	O
92	O
.	O
9	O
%,	O
100	O
%	O
for	O
TGEV	O
,	O
PEDV	O
,	O
GARs	B-ENZY
;	O
specificity	O
:	O
100	O
%	O
for	O
all	O
3	O
viruses	O
).	O

After	O
controlling	O
for	O
age	O
and	O
sex	O
,	O
multiple	O
logistic	O
regression	O
analysis	O
showed	O
that	O
hematological	O
factors	O
significantly	O
associated	O
with	O
fatality	O
included	O
initial	O
neutrophil	O
count	O
>	O
7000	O
/	O
microL	O
(	O
odds	O
ratio	O
[	O
OR	O
]	O
=	O
6	O
.	O
4	O
),	O
initial	O
CRP	O
concentration	O
>	O
47	O
.	O
5	O
mg	O
/	O
L	O
(	O
OR	O
=	O
5	O
.	O
8	O
)	O
and	O
lactic	B-ENZY
acid	I-ENZY
dehydrogenase	I-ENZY
(	O
LDH	O
)	O
>	O
593	O
.	O
5	O
IU	O
/	O
L	O
(	O
OR	O
=	O
4	O
.	O
2	O
).	O

Among	O
the	O
signaling	O
pathways	O
in	O
persistently	O
infected	O
cells	O
,	O
Akt	O
and	O
JNK	B-ENZY
were	O
phosphorylated	O
in	O
SARS	O
-	O
CoV	O
-	O
nucleocapsid	O
(	O
N	O
)	O
protein	O
-	O
expressing	O
Vero	O
E6	O
cells	O
using	O
vaccinia	O
viral	O
vector	O
(	O
DIs	O
),	O
strongly	O
suggesting	O
that	O
N	O
protein	O
-	O
induced	O
phosphorylation	O
of	O
Akt	O
and	O
JNK	B-ENZY
are	O
necessary	O
to	O
establish	O
persistence	O
.	O

Oxygenation	O
parameters	O
(	O
oxygenation	O
index	O
,	O
OI	O
;	O
Pao	B-ENZY
(	O
2	O
)/	O
Fio	O
(	O
2	O
)	O
ratio	O
,	O
P	O
/	O
F	O
)	O
and	O
mean	O
airway	O
pressures	O
(	O
mPaw	O
)	O
were	O
recorded	O
at	O
baseline	O
and	O
at	O
1	O
to	O
4	O
,	O
8	O
to	O
12	O
,	O
and	O
12	O
to	O
24	O
hours	O
after	O
initiation	O
of	O
HFPV	O
.	O

This	O
result	O
suggests	O
a	O
mechanism	O
of	O
inactivation	O
of	O
3C	O
peptidases	O
by	O
methyl	O
ketone	O
inhibitors	O
that	O
is	O
distinct	O
from	O
that	O
occurring	O
in	O
the	O
structurally	O
related	O
serine	O
proteinases	O
or	O
in	O
the	O
papain	B-ENZY
-	O
like	O
cysteine	O
peptidases	O
.	O

When	O
given	O
as	O
a	O
single	O
serotype	O
vaccine	O
,	O
the	O
Mass	O
strain	O
was	O
detected	O
by	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)-	O
restriction	O
fragment	O
length	O
polymorphism	O
(	O
RFLP	O
)	O
only	O
in	O
the	O
tracheas	O
,	O
whereas	O
the	O
Ark	O
strain	O
was	O
detected	O
in	O
both	O
the	O
tracheas	O
and	O
cecal	O
tonsils	O
.	O

TITLE	O
:	O
Treatment	O
of	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
:	O
role	O
of	O
extracorporeal	O
gas	B-ENZY
exchange	O
.	O

Bat	B-ENZY
-	O
CoV	O
1A	O
and	O
1B	O
were	O
detected	O
in	O
apparently	O
healthy	O
Miniopterus	O
magnater	O
and	O
Miniopterus	O
pusillus	O
,	O
respectively	O
,	O
on	O
repeated	O
sampling	O
occasions	O
at	O
a	O
single	O
habitat	O
,	O
suggesting	O
that	O
these	O
viruses	O
have	O
established	O
a	O
persistent	O
infection	O
in	O
these	O
populations	O
.	O

TITLE	O
:	O
Detection	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
in	O
stool	O
specimens	O
by	O
commercially	O
available	O
real	O
-	O
time	O
reverse	B-ENZY
transcriptase	I-ENZY
PCR	O
assays	O
.	O

Cost	O
-	O
effectiveness	O
analyses	O
(	O
CEAs	B-ENZY
)	O
have	O
become	O
increasingly	O
common	O
to	O
aid	O
decisions	O
about	O
the	O
allocation	O
of	O
scarce	O
healthcare	O
resources	O
.	O

TITLE	O
:	O
Replication	O
of	O
murine	O
hepatitis	O
virus	O
is	O
regulated	O
by	O
papain	B-ENZY
-	O
like	O
proteinase	O
1	O
processing	O
of	O
nonstructural	O
proteins	O
1	O
,	O
2	O
,	O
and	O
3	O
.	O

Particularly	O
noteworthy	O
,	O
the	O
serine	O
to	O
alanine	O
mutation	O
resides	O
in	O
the	O
region	O
of	O
the	O
major	O
antigenic	O
site	O
A	O
/	O
B	O
(	O
aa	O
506	O
-	O
706	O
)	O
that	O
elicits	O
neutralizing	O
antibodies	O
and	O
within	O
the	O
domain	O
mediating	O
the	O
cell	O
surface	O
receptor	O
aminopeptidase	B-ENZY
N	I-ENZY
binding	O
(	O
aa	O
522	O
-	O
744	O
).	O

Cross	O
-	O
infection	O
between	O
the	O
huge	O
number	O
of	O
bat	B-ENZY
species	O
may	O
generate	O
new	O
viruses	O
which	O
are	O
able	O
to	O
jump	O
the	O
trans	O
-	O
mammalian	O
species	O
barrier	O
more	O
efficiently	O
.	O

RM	O
was	O
effective	O
in	O
17	O
patients	O
except	O
one	O
case	O
of	O
severe	O
pulmonary	O
infection	O
,	O
whose	O
PaO	B-ENZY
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
was	O
only	O
improved	O
by	O
40	O
%.	O

PaO	B-ENZY
(	O
2	O
),	O
SaO	O
(	O
2	O
)	O
and	O
PaO	B-ENZY
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
were	O
increased	O
by	O
68	O
mm	O
Hg	O
,	O
9	O
.	O
5	O
%,	O
and	O
104	O
.	O
7	O
%	O
respectively	O
.	O

ABSTRACT	O
:	O
We	O
previously	O
demonstrated	O
that	O
infection	O
of	O
cultured	O
cells	O
with	O
murine	O
coronavirus	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
resulted	O
in	O
activation	O
of	O
the	O
mitogen	B-ENZY
-	I-ENZY
activated	I-ENZY
protein	I-ENZY
kinase	I-ENZY
(	O
Raf	O
/	O
MEK	B-ENZY
/	O
ERK	B-ENZY
)	O
signal	O
transduction	O
pathway	O
(	O
Y	O
.	O
Cai	O
et	O
al	O
.,	O
Virology	O
355	O
:	O
152	O
-	O
163	O
,	O
2006	O
).	O

Here	O
we	O
show	O
that	O
inhibition	O
of	O
the	O
Raf	O
/	O
MEK	B-ENZY
/	O
ERK	B-ENZY
signaling	O
pathway	O
by	O
the	O
MEK	B-ENZY
inhibitor	O
UO126	O
significantly	O
impaired	O
MHV	O
progeny	O
production	O
(	O
a	O
reduction	O
of	O
95	O
to	O
99	O
%	O
in	O
virus	O
titer	O
),	O
which	O
correlated	O
with	O
the	O
phosphorylation	O
status	O
of	O
ERK1	O
/	O
2	O
.	O

We	O
commenced	O
treatment	O
with	O
high	O
-	O
dose	O
pulse	O
methylprednisolone	O
and	O
neutrophil	B-ENZY
elastase	I-ENZY
inhibitor	O
under	O
mechanical	O
ventilation	O
.	O

The	O
cardiac	O
output	O
(	O
CO	O
),	O
systemic	O
vascular	O
resistance	O
(	O
SVR	O
),	O
pulmonary	O
vascular	O
resistance	O
(	O
PVR	O
),	O
mean	O
pulmonary	O
arterial	O
pressure	O
(	O
MPAP	O
),	O
pulmonary	O
artery	O
wedge	O
pressure	O
(	O
PAWP	O
),	O
arterial	O
oxygen	O
content	O
(	O
CaO	B-ENZY
(	O
2	O
)),	O
O	O
(	O
2	O
)	O
content	O
of	O
mixed	O
venous	O
blood	O
(	O
CvO	O
(	O
2	O
)),	O
oxygen	O
consumption	O
(	O
VO	O
(	O
2	O
)),	O
oxygen	O
delivery	O
(	O
DO	O
(	O
2	O
))	O
and	O
oxygen	O
extraction	O
rate	O
(	O
O	O
(	O
2	O
)	O
ER	O
)	O
were	O
measured	O
with	O
the	O
aid	O
of	O
a	O
Swan	O
-	O
Ganz	O
catheter	O
,	O
the	O
thoracic	O
fluid	O
content	O
(	O
TFC	O
)	O
were	O
measured	O
with	O
BioZ	O
(	O
r	O
)	O
Cardio	O
Dynamics	O
.	O

DO	O
(	O
2	O
),	O
VO	O
(	O
2	O
)	O
and	O
O	O
(	O
2	O
)	O
ER	O
were	O
stabilized	O
at	O
72	O
hours	O
with	O
amelioration	O
of	O
partial	O
pressure	O
of	O
oxygen	O
in	O
artery	O
(	O
PaO	B-ENZY
(	O
2	O
)),	O
PaO	B-ENZY
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
and	O
peak	O
airway	O
pressure	O
(	O
Ppeak	O
)	O
(	O
P	O
<	O
0	O
.	O
05	O
or	O
P	O
<	O
0	O
.	O
01	O
).	O

The	O
high	O
Ka	O
/	O
Ks	O
ratio	O
of	O
NS7a	O
and	O
NS7b	O
in	O
bat	B-ENZY
-	O
CoV	O
HKU9	O
implies	O
that	O
these	O
two	O
group	O
2d	O
-	O
specific	O
genes	O
are	O
under	O
high	O
selective	O
pressure	O
and	O
hence	O
are	O
rapidly	O
evolving	O
.	O

ABSTRACT	O
:	O
Angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
)	O
is	O
a	O
regulator	O
of	O
the	O
renin	B-ENZY
angiotensin	O
system	O
involved	O
in	O
acute	O
lung	O
failure	O
,	O
cardiovascular	O
functions	O
and	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
infections	O
in	O
mammals	O
.	O

New	O
zoonotic	O
viruses	O
may	O
emerge	O
from	O
bat	B-ENZY
reservoirs	O
and	O
known	O
ones	O
may	O
spread	O
to	O
a	O
wider	O
geographical	O
range	O
.	O

Analyses	O
of	O
data	O
from	O
surveillance	O
studies	O
can	O
shed	O
more	O
light	O
on	O
the	O
dynamics	O
of	O
bat	B-ENZY
viruses	O
,	O
(	O
i	O
.	O
e	O
.,	O
population	O
persistence	O
of	O
viruses	O
in	O
bats	O
).	O

This	O
must	O
be	O
avoided	O
or	O
given	O
with	O
caution	O
under	O
expert	O
supervision	O
in	O
patients	O
with	O
glucose	B-ENZY
-	I-ENZY
6	I-ENZY
-	I-ENZY
phosphate	I-ENZY
dehydrogenase	I-ENZY
deficiency	O
(	O
G6PD	B-ENZY
),	O
in	O
whom	O
it	O
may	O
cause	O
severe	O
haemolysis	O
.	O

Furthermore	O
,	O
the	O
most	O
closely	O
related	O
bat	B-ENZY
and	O
SARS	O
coronaviruses	O
diverged	O
in	O
1986	O
,	O
an	O
estimated	O
divergence	O
time	O
of	O
17	O
years	O
prior	O
to	O
the	O
outbreak	O
,	O
suggesting	O
that	O
there	O
may	O
have	O
been	O
transmission	O
via	O
an	O
unknown	O
intermediate	O
host	O
.	O

These	O
results	O
indicate	O
that	O
diverse	O
coronaviruses	O
are	O
endemic	O
in	O
different	O
bat	B-ENZY
species	O
,	O
with	O
repeated	O
introductions	O
to	O
other	O
animals	O
and	O
occasional	O
establishment	O
in	O
other	O
species	O
.	O

The	O
expression	O
of	O
IL	O
-	O
1beta	O
and	O
IL	O
-	O
18	O
mRNA	O
were	O
decreased	O
significantly	O
in	O
the	O
SAP	O
-	O
ICE	O
-	O
I	O
group	O
(	O
P	O
<	O
0	O
.	O
01	O
,	O
vs	O
SAP	O
-	O
S	O
),	O
whereas	O
Caspase	B-ENZY
-	I-ENZY
1	I-ENZY
mRNA	O
expression	O
had	O
no	O
significant	O
difference	O
(	O
P	O
>	O
0	O
.	O
05	O
).	O

Recently	O
,	O
we	O
and	O
another	O
group	O
independently	O
identified	O
several	O
horseshoe	O
bat	B-ENZY
species	O
(	O
genus	O
Rhinolophus	O
)	O
as	O
the	O
reservoir	O
host	O
for	O
a	O
large	O
number	O
of	O
viruses	O
that	O
have	O
a	O
close	O
genetic	O
relationship	O
with	O
the	O
coronavirus	O
associated	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
).	O

Functional	O
classification	O
of	O
identified	O
up	O
-	O
regulated	O
proteins	O
indicated	O
that	O
protein	O
metabolism	O
and	O
modification	O
,	O
particularly	O
in	O
the	O
ubiquitin	O
proteasome	B-ENZY
pathway	O
,	O
was	O
the	O
main	O
biological	O
process	O
occurring	O
in	O
SARS	O
CoV	O
3CLpro	O
-	O
expressing	O
cells	O
.	O

Thirty	O
-	O
six	O
percent	O
of	O
identified	O
up	O
-	O
regulated	O
proteins	O
were	O
located	O
in	O
the	O
mitochondria	O
,	O
including	O
apoptosis	O
-	O
inducing	O
factor	O
,	O
ATP	B-ENZY
synthase	I-ENZY
beta	O
chain	O
and	O
cytochrome	O
c	O
oxidase	O
.	O

Mutation	O
analysis	O
of	O
3a	O
revealed	O
that	O
C	O
-	O
terminal	O
region	O
(	O
176	O
aa	O
approximately	O
274	O
aa	O
),	O
including	O
a	O
potential	O
calcium	O
ATPase	B-ENZY
motif	O
,	O
was	O
essential	O
for	O
induction	O
of	O
cell	O
cycle	O
arrest	O
.	O

CONCLUSIONS	O
:	O
The	O
combination	O
of	O
two	O
innovative	O
treatment	O
modalities	O
resulted	O
in	O
rapid	O
stabilization	O
and	O
improvement	O
of	O
gas	B-ENZY
exchange	O
during	O
severe	O
ARDS	O
refractory	O
to	O
conventional	O
lung	O
protective	O
ventilation	O
.	O

Gas	B-ENZY
exchange	O
and	O
hemodynamics	O
were	O
determined	O
before	O
,	O
during	O
,	O
and	O
after	O
HFO	O
sessions	O
.	O

Likewise	O
,	O
the	O
frequency	O
of	O
the	O
D	O
allele	O
was	O
significantly	O
less	O
in	O
patients	O
with	O
higher	O
LIS	B-ENZY
(	O
50	O
%	O
D	O
)	O
than	O
lower	O
LIS	B-ENZY
(	O
21	O
%	O
D	O
).	O

Using	O
intramolecularly	O
quenched	O
fluorogenic	O
(	O
IQF	O
)	O
peptides	O
based	O
on	O
hSARS	O
-	O
CoV	O
spike	O
protein	O
(	O
Abz	O
-(	O
755	O
)	O
Glu	O
-	O
Gln	O
-	O
Asp	O
-	O
Arg	O
-	O
Asn	O
-	O
Thr	O
-	O
Arg	O
-	O
Glu	O
-	O
Val	O
-	O
Phe	O
-	O
Ala	O
-	O
Gln	O
(	O
766	O
)-	O
Tyx	O
-	O
NH	O
(	O
2	O
))	O
and	O
in	O
vitro	O
studies	O
,	O
we	O
show	O
that	O
besides	O
furin	B-ENZY
,	O
other	O
PCs	O
,	O
like	O
PC5	O
and	O
PC7	O
,	O
might	O
also	O
be	O
involved	O
in	O
this	O
cleavage	O
event	O
.	O

Through	O
kinetic	O
measurements	O
with	O
recombinant	O
PCs	O
,	O
we	O
observed	O
that	O
the	O
peptide	O
was	O
cleaved	O
efficiently	O
by	O
both	O
furin	B-ENZY
and	O
PC5	O
,	O
but	O
very	O
poorly	O
by	O
PC7	O
.	O

Following	O
cleavage	O
by	O
furin	B-ENZY
,	O
the	O
sheet	O
content	O
increased	O
,	O
possibly	O
at	O
the	O
expense	O
of	O
turn	O
and	O
random	O
structures	O
.	O

The	O
system	O
is	O
characterized	O
by	O
a	O
new	O
low	O
-	O
resistance	O
gas	B-ENZY
exchange	O
membrane	O
that	O
is	O
integrated	O
in	O
an	O
arterial	O
-	O
venous	O
bypass	O
established	O
by	O
cannulation	O
of	O
the	O
femoral	O
artery	O
and	O
vein	O
.	O

Intravascular	O
PLY	O
,	O
but	O
not	O
the	O
pneumolysoid	O
Pd	O
-	O
B	O
(	O
PLY	O
with	O
a	O
Trp	B-ENZY
-	O
Phe	O
substitution	O
at	O
position	O
433	O
),	O
caused	O
an	O
impressive	O
dose	O
-	O
dependent	O
increase	O
in	O
pulmonary	O
vascular	O
resistance	O
and	O
increased	O
PAF	O
in	O
lung	O
homogenates	O
,	O
as	O
detected	O
by	O
reversed	O
-	O
phase	O
high	O
-	O
performance	O
liquid	O
chromatography	O
coupled	O
to	O
tandem	O
mass	O
spectrometry	O
.	O

14	O
s	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
and	O
thrombin	B-ENZY
time	O
from	O
18	O
+/-	O

TITLE	O
:	O
Proteinase	O
dysbalance	O
in	O
pathology	O
:	O
the	O
neprilysin	B-ENZY
(	O
NEP	O
)	O
and	O
angiotensin	O
-	O
converting	O
enzyme	O
(	O
ACE	B-ENZY
)	O
families	O
.	O

The	O
role	O
and	O
regulation	O
of	O
the	O
neprilysin	B-ENZY
(	O
NEP	O
)	O
family	O
of	O
metalloproteinases	O
is	O
highlighted	O
in	O
particular	O
in	O
the	O
context	O
of	O
proteolytic	O
events	O
underlying	O
the	O
pathology	O
of	O
Alzheimer	O
'	O
s	O
disease	O
.	O

This	O
system	O
was	O
applied	O
to	O
develop	O
a	O
quantitative	O
measurement	O
of	O
cell	O
-	O
cell	O
fusion	O
using	O
hepatitis	O
C	O
virus	O
(	O
HCV	O
)	O
NS3	O
/	O
4A	O
protease	O
and	O
a	O
secretion	O
-	O
blocked	O
EGFP	O
-	O
4A	O
/	O
4B	O
-	O
SEAP	O
(	O
EGFP	O
:	O
enhanced	O
green	O
fluorescent	O
protein	O
;	O
4A	O
/	O
4B	O
:	O
a	O
decapeptide	O
substrate	O
of	O
NS3	O
/	O
4A	O
protease	O
;	O
SEAP	O
:	O
secreted	O
alkaline	B-ENZY
phosphatase	I-ENZY
)	O
fusion	O
gene	O
.	O

Early	O
testing	O
for	O
anti	O
-	O
synthetase	O
antibodies	O
,	O
particularly	O
anti	O
-	O
Jo	O
-	O
1	O
,	O
and	O
creatine	B-ENZY
kinase	I-ENZY
determination	O
are	O
useful	O
procedures	O
in	O
patients	O
presenting	O
with	O
ILD	O
.	O

ABSTRACT	O
:	O
Angiotensin	O
-	O
converting	O
enzyme	O
(	O
ACE	B-ENZY
)	O
and	O
ACE2	O
are	O
highly	O
homologous	O
metalloproteases	O
that	O
provide	O
essential	O
catalytic	O
functions	O
in	O
the	O
renin	B-ENZY
-	O
angiotensin	O
system	O
(	O
RAS	O
).	O

Three	O
antiviral	O
tests	O
were	O
compared	O
based	O
on	O
different	O
evaluation	O
principles	O
:	O
cell	O
viability	O
(	O
MTT	O
-	O
based	O
colorimetric	O
assay	O
),	O
number	O
of	O
infected	O
cells	O
(	O
immunoperoxidase	O
assay	O
)	O
and	O
amount	O
of	O
viral	O
protein	O
expression	O
(	O
luciferase	B-ENZY
-	O
based	O
assay	O
).	O

RESULTS	O
:	O
Cerulein	O
injection	O
caused	O
severe	O
AP	O
,	O
confirmed	O
by	O
an	O
increase	O
in	O
serum	O
amylase	O
and	O
lipase	B-ENZY
levels	O
,	O
histopathological	O
findings	O
of	O
severe	O
AP	O
,	O
and	O
pancreatic	O
MPO	O
activity	O
,	O
compared	O
to	O
the	O
values	O
obtained	O
in	O
the	O
sham	O
group	O
.	O

Quantitation	O
of	O
a	O
house	O
-	O
keeping	O
gene	O
,	O
glyceraldehyde	O
-	O
3	O
-	O
phosphate	O
dehydrogenase	O
(	O
GAPDH	B-ENZY
)	O
was	O
undertaken	O
to	O
standardize	O
the	O
amount	O
of	O
tissue	O
tested	O
.	O

Since	O
it	O
has	O
been	O
suggested	O
that	O
the	O
receptor	O
-	O
binding	O
motif	O
(	O
RBM	O
)	O
of	O
SARS	O
-	O
CoV	O
may	O
have	O
been	O
acquired	O
from	O
a	O
group	O
1	O
coronavirus	O
,	O
we	O
conducted	O
a	O
surveillance	O
study	O
and	O
identified	O
bat	B-ENZY
-	O
SARS	O
-	O
CoV	O
and	O
bat	B-ENZY
-	O
CoV	O
HKU2	O
in	O
8	O
.	O
7	O
%	O
and	O
7	O
.	O
5	O
%	O
respectively	O
of	O
R	O
.	O
sinicus	O
in	O
Hong	O
Kong	O
and	O
Guangdong	O
.	O

However	O
,	O
viruses	O
with	O
gene	O
7	O
disruptions	O
were	O
not	O
as	O
efficient	O
as	O
wild	O
-	O
type	O
virus	O
in	O
inducing	O
DNA	O
fragmentation	O
,	O
as	O
judged	O
by	O
terminal	B-ENZY
deoxynucleotidyltransferase	I-ENZY
-	O
mediated	O
dUTP	O
-	O
biotin	O
nick	O
end	O
labeling	O
(	O
TUNEL	O
)	O
staining	O
,	O
indicating	O
that	O
the	O
gene	O
7	O
products	O
do	O
contribute	O
to	O
virus	O
-	O
induced	O
apoptosis	O
.	O

ABSTRACT	O
:	O
The	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
papain	B-ENZY
-	O
like	O
protease	O
(	O
SARS	O
-	O
CoV	O
PLpro	O
)	O
carries	O
out	O
N	O
-	O
terminal	O
processing	O
of	O
the	O
viral	O
replicase	O
polyprotein	O
,	O
and	O
also	O
exhibits	O
Lys48	O
-	O
linked	O
polyubiquitin	O
chain	O
debranching	O
and	O
ISG15	O
precursor	O
processing	O
activities	O
in	O
vitro	O
.	O

ABSTRACT	O
:	O
To	O
describe	O
the	O
epidemiology	O
and	O
clinical	O
profile	O
of	O
acute	O
chest	O
syndrome	O
(	O
ACS	B-ENZY
)	O
in	O
Omani	O
Arab	O
children	O
.	O

There	O
were	O
31	O
(	O
59	O
.	O
6	O
%)	O
males	O
and	O
ages	O
ranged	O
between	O
14	O
months	O
and	O
12	O
years	O
[	O
median	O
(	O
SD	O
)	O
6	O
.	O
5	O
(	O
2	O
.	O
49	O
)	O
years	O
];	O
ACS	B-ENZY
occurred	O
fairly	O
evenly	O
in	O
those	O
aged	O
between	O
2	O
and	O
10	O
years	O
.	O

Furthermore	O
,	O
administration	O
of	O
MSCs	O
transfected	O
with	O
pANGPT1	O
resulted	O
in	O
nearly	O
complete	O
reversal	O
of	O
LPS	O
-	O
induced	O
increases	O
in	O
lung	O
permeability	O
as	O
assessed	O
by	O
reductions	O
in	O
IgM	O
and	O
albumin	O
levels	O
in	O
BAL	B-ENZY
(	O
96	O
%,	O
CI	O
6	O
%-	O
185	O
%;	O
and	O
74	O
%,	O
CI	O
23	O
%-	O
126	O
%,	O
respectively	O
).	O

ABSTRACT	O
:	O
Seven	O
novel	O
gammaherpesviruses	O
(	O
GHV	O
)	O
and	O
one	O
novel	O
betaherpesvirus	O
were	O
discovered	O
in	O
seven	O
different	O
European	O
bat	B-ENZY
species	O
(	O
order	O
Chiroptera	O
,	O
family	O
Vespertilionidae	O
)	O
with	O
a	O
pan	O
-	O
herpesvirus	O
PCR	O
assay	O
,	O
targeting	O
the	O
DNA	O
polymerase	O
(	O
DPOL	O
)	O
gene	O
.	O

High	O
-	O
frequency	O
oscillation	O
(	O
HFO	O
)	O
exerts	O
beneficial	O
effects	O
on	O
gas	B-ENZY
exchange	O
in	O
neonates	O
with	O
acute	O
respiratory	O
failure	O
.	O

The	O
S1	O
glycoprotein	O
genes	O
of	O
these	O
IBV	O
isolates	O
were	O
amplified	O
by	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
(	O
RTPCR	O
)	O
and	O
analyzed	O
by	O
restriction	O
fragment	O
length	O
polymorphism	O
(	O
RFLP	O
)	O
analysis	O
.	O

There	O
were	O
no	O
statistically	O
significant	O
associations	O
between	O
any	O
single	O
urokinase	B-ENZY
polymorphism	O
or	O
haplotype	O
and	O
risk	O
for	O
developing	O
ALI	O
.	O

TITLE	O
:	O
Effect	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
on	O
bystander	O
willingness	O
to	O
perform	O
cardiopulmonary	O
resuscitation	O
(	O
CPR	B-ENZY
)--	O
is	O
compression	O
-	O
only	O
preferred	O
to	O
standard	O
CPR	B-ENZY
?	O

Furthermore	O
,	O
p38	O
MAPK	B-ENZY
inhibitor	O
,	O
SB203580	O
,	O
inhibits	O
CPE	O
induced	O
by	O
HCoV	O
-	O
229E	O
infection	O
and	O
viral	O
replication	O
.	O

TITLE	O
:	O
Evidence	O
of	O
the	O
recombinant	O
origin	O
of	O
a	O
bat	B-ENZY
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)-	O
like	O
coronavirus	O
and	O
its	O
implications	O
on	O
the	O
direct	O
ancestor	O
of	O
SARS	O
coronavirus	O
.	O

This	O
clone	O
served	O
as	O
basis	O
for	O
the	O
generation	O
of	O
recombinant	O
FCoV	O
(	O
recFCoV	O
)	O
that	O
was	O
shown	O
to	O
bear	O
the	O
same	O
features	O
in	O
vitro	O
as	O
the	O
parental	O
FCoV	O
.	O
Using	O
this	O
system	O
,	O
accessory	O
3abc	O
genes	O
in	O
the	O
FCoV	O
genome	O
were	O
replaced	O
by	O
green	O
fluorescent	O
protein	O
(	O
recFCoV	O
-	O
GFP	O
)	O
and	O
Renilla	O
luciferase	B-ENZY
genes	O
(	O
recFCoV	O
-	O
RL	O
).	O

Prevention	O
includes	O
epidemiological	O
control	O
of	O
donor	O
populations	O
;	O
checks	O
on	O
each	O
donor	O
'	O
s	O
health	O
condition	O
;	O
analysis	O
of	O
each	O
donation	O
for	O
the	O
main	O
pathogens	O
using	O
serological	O
methods	O
;	O
additional	O
analysis	O
of	O
all	O
plasma	O
for	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
),	O
hepatitis	O
B	O
virus	O
(	O
HBV	O
),	O
hepatitis	O
C	O
virus	O
(	O
HCV	O
),	O
hepatitis	O
A	O
virus	O
(	O
HAV	O
)	O
and	O
the	O
B19	O
virus	O
,	O
using	O
nucleic	O
acid	O
amplification	O
techniques	O
(	O
NAT	B-ENZY
).	O

Caco	O
-	O
2	O
and	O
N2a	O
cells	O
served	O
as	O
models	O
for	O
persistent	O
SARS	O
-	O
CoV	O
infection	O
,	O
whereas	O
Vero	O
E6	O
and	O
A549	O
cells	O
did	O
as	O
prototype	O
cell	O
lines	O
lytically	O
infected	O
by	O
SARS	O
-	O
CoV	O
.	O
The	O
experiments	O
revealed	O
that	O
N	O
induces	O
the	O
intrinsic	O
apoptotic	O
pathway	O
,	O
resulting	O
in	O
processing	O
of	O
N	O
at	O
residues	O
400	O
and	O
403	O
by	O
caspase	B-ENZY
-	I-ENZY
6	I-ENZY
and	O
/	O
or	O
caspase	B-ENZY
-	I-ENZY
3	I-ENZY
.	O

In	O
addition	O
,	O
our	O
studies	O
indicate	O
that	O
the	O
nuclear	O
localization	O
of	O
N	O
is	O
essential	O
for	O
its	O
caspase	B-ENZY
-	I-ENZY
6	I-ENZY
-	O
mediated	O
cleavage	O
.	O

ABSTRACT	O
:	O
Only	O
recently	O
has	O
the	O
important	O
role	O
of	O
abdominal	O
compartment	O
syndrome	O
(	O
ACS	B-ENZY
)	O
been	O
recognized	O
as	O
a	O
contributing	O
factor	O
to	O
the	O
multiple	O
organ	O
failure	O
commonly	O
seen	O
in	O
severe	O
acute	O
pancreatitis	O
(	O
SAP	O
).	O

Decompressive	O
laparostomy	O
for	O
ACS	B-ENZY
is	O
a	O
life	O
-	O
saving	O
procedure	O
usually	O
performed	O
through	O
a	O
midline	O
incision	O
followed	O
by	O
a	O
negative	O
pressure	O
wound	O
dressing	O
.	O

Sequence	O
analysis	O
of	O
a	O
440	O
-	O
bp	O
amplicon	O
in	O
gene	O
1b	O
showed	O
that	O
these	O
Rocky	O
Mountain	O
bat	B-ENZY
coronaviruses	O
formed	O
3	O
clusters	O
in	O
phylogenetic	O
group	O
1	O
that	O
were	O
distinct	O
from	O
group	O
1	O
coronaviruses	O
of	O
Asian	O
bats	O
.	O

We	O
detected	O
antibody	O
reactive	O
with	O
SARS	O
-	O
CoV	O
antigen	O
in	O
47	O
(	O
6	O
.	O
7	O
%)	O
of	O
705	O
bat	B-ENZY
serum	O
specimens	O
comprising	O
26	O
species	O
collected	O
in	O
Africa	O
;	O
thus	O
,	O
African	O
bats	O
may	O
harbor	O
agents	O
related	O
to	O
putative	O
group	O
4	O
CoV	O
.	O

We	O
examined	O
the	O
evolutionary	O
relationships	O
between	O
bat	B-ENZY
CoVs	O
and	O
their	O
hosts	O
by	O
using	O
sequence	O
data	O
of	O
the	O
virus	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
gene	O
and	O
the	O
bat	B-ENZY
cytochrome	O
b	O
gene	O
.	O

ABSTRACT	O
:	O
RNase	B-ENZY
-	O
resistant	O
,	O
noninfectious	O
virus	O
-	O
like	O
particles	O
containing	O
exogenous	O
RNA	O
sequences	O
(	O
armored	O
RNA	O
)	O
are	O
good	O
candidates	O
as	O
RNA	O
controls	O
and	O
standards	O
in	O
RNA	O
virus	O
detection	O
.	O

The	O
identification	O
of	O
:	O
the	O
renin	B-ENZY
/	O
prorenin	O
receptor	O
;	O
the	O
angiotensin	O
-	O
converting	O
enzyme	O
homologue	O
,	O
ACE2	O
,	O
as	O
an	O
angiotensin	O
peptide	O
-	O
processing	O
enzyme	O
and	O
a	O
virus	O
receptor	O
for	O
severe	O
acute	O
respiratory	O
syndrome	O
,	O
the	O
Mas	O
as	O
a	O
receptor	O
for	O
angiotensin	O
(	O
1	O
-	O
7	O
)	O
[	O
Ang	O
(	O
1	O
-	O
7	O
)],	O
and	O
the	O
possibility	O
of	O
signaling	O
through	O
ACE	B-ENZY
have	O
contributed	O
to	O
switch	O
our	O
understanding	O
of	O
the	O
RAS	O
from	O
the	O
classical	O
limited	O
-	O
proteolysis	O
linear	O
cascade	O
to	O
a	O
cascade	O
with	O
multiple	O
mediators	O
,	O
multiple	O
receptors	O
and	O
multifunctional	O
enzymes	O
.	O

Using	O
a	O
ELISA	O
method	O
,	O
we	O
found	O
an	O
increase	O
in	O
thrombopoietin	O
(	O
TPO	B-ENZY
)	O
levels	O
in	O
the	O
plasma	O
of	O
convalesced	O
SARS	O
patients	O
(	O
290	O
+/-	O
53	O
pg	O
/	O
ml	O
)	O
and	O
active	O
SARS	O
patients	O
(	O
251	O
+/-	O
23	O
pg	O
/	O
ml	O
)	O
comparing	O
to	O
that	O
from	O
normal	O
control	O
patients	O
(	O
228	O
+/-	O
17	O
pg	O
/	O
ml	O
).	O

Our	O
objective	O
was	O
to	O
study	O
amiodarone	O
uptake	O
,	O
clarify	O
the	O
origin	O
of	O
vacuoles	O
,	O
and	O
investigate	O
the	O
effect	O
of	O
amiodarone	O
on	O
the	O
life	O
cycle	O
of	O
the	O
coronavirus	O
responsible	O
for	O
the	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
(	O
SARS	O
),	O
which	O
,	O
to	O
enter	O
cells	O
,	O
relies	O
on	O
the	O
proteolytic	O
cleavage	O
of	O
a	O
viral	O
spike	O
protein	O
by	O
the	O
endosomal	O
proteinase	O
cathepsin	B-ENZY
L	I-ENZY
.	O
Using	O
alveolar	O
macrophages	O
,	O
we	O
studied	O
uptake	O
of	O
(	O
125	O
)	O
I	O
-	O
amiodarone	O
and	O
(	O
125	O
)	O
I	O
-	O
B2	O
,	O
an	O
analog	O
lacking	O
the	O
lateral	O
group	O
diethylamino	O
-	O
beta	O
-	O
ethoxy	O
,	O
and	O
analyzed	O
the	O
effects	O
of	O
amiodarone	O
on	O
the	O
distribution	O
of	O
endosomal	O
markers	O
and	O
on	O
the	O
uptake	O
of	O
an	O
acidotropic	O
dye	O
.	O

RESULTS	O
:	O
Chronic	O
alcohol	O
ingestion	O
significantly	O
increased	O
gene	O
and	O
protein	O
expression	O
of	O
each	O
Na	O
,	O
K	O
-	O
ATPase	B-ENZY
subunit	O
in	O
rat	O
lungs	O
.	O

Mimicyp	O
adopts	O
a	O
typical	O
cyclophilin	B-ENZY
-	O
fold	O
,	O
yet	O
it	O
also	O
forms	O
trimers	O
unlike	O
any	O
previously	O
characterized	O
homologue	O
.	O

During	O
HFO	O
,	O
25	O
of	O
30	O
patients	O
maintained	O
acceptable	O
gas	B-ENZY
exchange	O
at	O
frequencies	O
>	O
6	O
Hz	O
;	O
12	O
reached	O
maximal	O
frequencies	O
of	O
>	O
or	O
=	O
10	O
Hz	O
.	O

In	O
addition	O
,	O
oleic	O
acid	O
significantly	O
increased	O
inflammatory	O
mediators	O
and	O
neutrophil	O
-	O
derived	O
factors	O
but	O
depressed	O
Na	O
+-	O
K	O
+-	O
ATPase	B-ENZY
.	O

It	O
depressed	O
the	O
Na	O
+-	O
K	O
+-	O
ATPase	B-ENZY
activity	O
but	O
up	O
-	O
regulated	O
inducible	O
nitric	O
oxide	O
synthase	O
.	O

To	O
investigate	O
whether	O
and	O
which	O
structural	O
protein	O
of	O
SARS	O
-	O
CoV	O
induced	O
transcription	O
of	O
hfgl2	O
prothrombinase	B-ENZY
gene	O
,	O
three	O
eukaryotic	O
expression	O
plasmids	O
expressing	O
nucleocapsid	O
protein	O
(	O
N	O
),	O
membrane	O
protein	O
(	O
M	O
)	O
and	O
spike	O
protein	O
2	O
(	O
S2	O
)	O
of	O
SARS	O
-	O
CoV	O
were	O
co	O
-	O
transfected	O
with	O
hfgl2	O
promoter	O
luciferase	B-ENZY
-	O
reporter	O
plasmids	O
and	O
beta	B-ENZY
-	I-ENZY
galactosidase	I-ENZY
plasmid	O
in	O
CHO	O
cells	O
,	O
respectively	O
.	O

Desialylation	O
induced	O
by	O
neuraminidase	B-ENZY
treatment	O
of	O
tracheal	O
organ	O
cultures	O
prior	O
to	O
infection	O
by	O
IBV	O
delayed	O
the	O
ciliostatic	O
effect	O
or	O
resulted	O
in	O
partial	O
loss	O
of	O
ciliary	O
activity	O
.	O

Inhibition	O
of	O
ciliostasis	O
was	O
also	O
observed	O
when	O
TOCs	O
were	O
pretreated	O
with	O
an	O
alpha2	O
,	O
3	O
-	O
specific	O
neuraminidase	B-ENZY
.	O

Here	O
,	O
we	O
report	O
the	O
full	O
genomic	O
sequences	O
of	O
bat	B-ENZY
CoVs	O
1A	O
,	O
1B	O
and	O
HKU8	O
.	O

Bat	B-ENZY
CoVs	O
1A	O
and	O
1B	O
,	O
which	O
are	O
commonly	O
found	O
in	O
the	O
Miniopterus	O
,	O
are	O
phylogenetically	O
closely	O
related	O
.	O

The	O
biological	O
basis	O
for	O
the	O
host	O
restriction	O
of	O
bat	B-ENZY
coronaviruses	O
,	O
however	O
,	O
is	O
yet	O
to	O
be	O
determined	O
.	O

The	O
results	O
suggest	O
that	O
the	O
Trp	B-ENZY
-	O
rich	O
region	O
of	O
S	O
protein	O
is	O
essential	O
for	O
SARS	O
-	O
CoV	O
infectivity	O
.	O

Multiple	O
-	O
factor	O
Logistic	O
regression	O
analysis	O
indicated	O
that	O
the	O
MODS	O
(	O
OR	O
=	O
67	O
.	O
358	O
,	O
P	O
<	O
0	O
.	O
01	O
),	O
APACHE	O
II	O
score	O
(	O
OR	O
=	O
9	O
.	O
716	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
and	O
ACS	B-ENZY
(	O
OR	O
=	O
5	O
.	O
775	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
were	O
the	O
independent	O
risk	O
factors	O
affecting	O
the	O
prognosis	O
of	O
SAP	O
during	O
its	O
early	O
stage	O
,	O
whereas	O
pancreatic	O
infection	O
(	O
OR	O
=	O
9	O
.	O
652	O
,	O
P	O
<	O
0	O
.	O
01	O
),	O
MODS	O
(	O
OR	O
=	O
5	O
.	O
212	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
and	O
celiac	O
hemorrhage	O
(	O
OR	O
=	O
4	O
.	O
707	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
were	O
the	O
independent	O
risk	O
factors	O
during	O
the	O
advanced	O
stage	O
of	O
SAP	O
.	O

Clinical	O
and	O
general	O
laboratory	O
manifestations	O
included	O
fever	O
,	O
chills	O
,	O
rigor	O
,	O
myalgia	O
,	O
malaise	O
,	O
diarrhoea	O
,	O
cough	O
,	O
dyspnoea	O
,	O
pneumonia	O
,	O
lymphopenia	O
,	O
neutrophilia	O
,	O
thrombocytopenia	O
,	O
and	O
elevated	O
serum	O
lactate	O
dehydrogenase	O
(	O
LD	O
),	O
alanine	B-ENZY
aminotransferase	I-ENZY
(	O
ALT	O
)	O
and	O
creatine	B-ENZY
kinase	I-ENZY
(	O
CK	O
)	O
activities	O
.	O

Finally	O
,	O
using	O
a	O
complete	O
site	O
-	O
saturation	O
mutagenesis	O
methodology	O
focused	O
on	O
the	O
CDR	B-ENZY
(	O
complementarity	O
determining	O
regions	O
),	O
a	O
single	O
point	O
mutation	O
(	O
51E7	O
)	O
was	O
identified	O
that	O
improved	O
the	O
80	O
%	O
plaque	O
reduction	O
neutralization	O
of	O
the	O
virus	O
by	O
greater	O
than	O
8	O
-	O
fold	O
.	O

In	O
contrast	O
to	O
sepsis	O
-	O
induced	O
ALI	O
,	O
BAL	B-ENZY
fluid	O
cell	O
counts	O
remained	O
constant	O
with	O
no	O
infiltration	O
of	O
neutrophils	O
.	O

Intriguingly	O
,	O
viral	O
infection	O
,	O
judged	O
by	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
analysis	O
of	O
SARS	O
-	O
CoV	O
mRNA	O
expression	O
,	O
was	O
significantly	O
attenuated	O
by	O
deletion	O
of	O
the	O
cytoplasmic	O
tail	O
of	O
ACE2	O
or	O
knock	O
-	O
down	O
of	O
TACE	B-ENZY
expression	O
by	O
siRNA	O
.	O

The	O
second	O
antibody	O
in	O
the	O
kit	O
was	O
replaced	O
with	O
horseradish	O
peroxidase	B-ENZY
-	O
conjugated	O
protein	O
-	O
A	O
(	O
HRP	O
-	O
SPA	O
)	O
based	O
on	O
the	O
characteristics	O
of	O
binding	O
between	O
Staphylococcus	O
aureus	O
protein	O
A	O
(	O
SPA	O
)	O
and	O
mammal	O
IgG	O
Fc	O
fragment	O
.	O

After	O
stabilization	O
,	O
pigs	O
belonging	O
to	O
group	O
II	O
were	O
observed	O
only	O
,	O
whereas	O
in	O
those	O
belonging	O
to	O
groups	O
III	O
to	O
V	O
,	O
a	O
surfactant	O
-	O
depletion	O
severe	O
(	O
Pao	B-ENZY
(	O
2	O
)/	O
Fio	O
(	O
2	O
)	O
<	O
100	O
)	O
postpneumonectomy	O
acute	O
respiratory	O
distress	O
syndrome	O
was	O
induced	O
.	O

RESULTS	O
:	O
(	O
1	O
)	O
Contents	O
of	O
caspase	B-ENZY
-	I-ENZY
3	I-ENZY
and	O
p73	O
in	O
lung	O
tissue	O
homogenates	O
in	O
HFOV	O
group	O
and	O
HFOV	O
+	O
PS	O
group	O
were	O
significantly	O
lower	O
than	O
those	O
in	O
CMV	O
group	O
and	O
CMV	O
+	O
PS	O
group	O
(	O
P	O
<	O
0	O
.	O
05	O
or	O
P	O
<	O
0	O
.	O
01	O
),	O
and	O
also	O
contents	O
of	O
caspase	B-ENZY
-	I-ENZY
3	I-ENZY
and	O
p73	O
in	O
lung	O
tissue	O
homogenates	O
in	O
groups	O
with	O
exogenous	O
PS	O
were	O
significantly	O
lower	O
than	O
those	O
of	O
groups	O
without	O
exogenous	O
PS	O
(	O
all	O
P	O
<	O
0	O
.	O
05	O
).	O

Many	O
of	O
the	O
bat	B-ENZY
astroviruses	O
form	O
distinct	O
phylogenetic	O
clusters	O
in	O
the	O
genus	O
Mamastrovirus	O
within	O
the	O
family	O
Astroviridae	O
.	O

Identification	O
of	O
IBV	O
was	O
by	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
of	O
RNA	O
extracted	O
from	O
oropharyngeal	O
swabs	O
taken	O
from	O
poultry	O
flocks	O
exhibiting	O
signs	O
of	O
clinical	O
disease	O
thought	O
to	O
be	O
attributable	O
to	O
IBV	O
.	O

MBL	O
is	O
a	O
serum	O
lectin	O
that	O
mediates	O
phagocytosis	O
and	O
activates	O
the	O
lectin	O
pathway	O
of	O
complement	O
involving	O
MASP	B-ENZY
-	I-ENZY
2	I-ENZY
.	O

Nephrotoxic	O
drugs	O
such	O
as	O
ACE	B-ENZY
inhibitors	O
,	O
NSAIDs	O
,	O
aminoglycosides	O
,	O
cephalosporins	O
should	O
be	O
avoided	O
.	O

These	O
changes	O
were	O
accompanied	O
by	O
increased	O
BAL	B-ENZY
levels	O
of	O
PMN	O
chemoattractants	O
(	O
KC	O
and	O
MIP	O
-	O
2	O
)	O
and	O
modest	O
increases	O
in	O
lung	O
vascular	O
and	O
alveolar	O
permeability	O
.	O

We	O
next	O
explored	O
the	O
potential	O
synergism	O
between	O
rhPBEF	O
challenge	O
(	O
intratracheal	O
)	O
and	O
a	O
model	O
of	O
limited	O
VILI	O
(	O
4	O
h	O
,	O
30	O
ml	O
/	O
kg	O
tidal	O
volume	O
)	O
and	O
observed	O
dramatic	O
increases	O
in	O
BAL	B-ENZY
PMNs	O
,	O
BAL	B-ENZY
protein	O
,	O
and	O
cytokine	O
levels	O
(	O
IL	O
-	O
6	O
,	O
TNF	O
-	O
alpha	O
,	O
KC	O
)	O
compared	O
with	O
either	O
challenge	O
alone	O
.	O

Recent	O
studies	O
have	O
identified	O
three	O
membrane	O
-	O
active	O
regions	O
in	O
the	O
S2	O
domain	O
of	O
SARS	O
-	O
CoV	O
glycoprotein	O
,	O
one	O
situated	O
downstream	O
of	O
the	O
minimum	O
furin	B-ENZY
cleavage	O
,	O
which	O
is	O
considered	O
the	O
fusion	O
peptide	O
(	O
SARSFP	O
),	O
an	O
internal	O
fusion	O
peptide	O
located	O
immediately	O
upstream	O
of	O
the	O
HR1	O
region	O
(	O
SARSIFP	O
)	O
and	O
the	O
pre	O
-	O
transmembrane	O
domain	O
(	O
SARSPTM	O
).	O

ABSTRACT	O
:	O
Many	O
emerging	O
and	O
reemerging	O
viruses	O
,	O
such	O
as	O
rabies	O
,	O
SARS	O
,	O
Marburg	O
,	O
and	O
Ebola	O
have	O
bat	B-ENZY
populations	O
as	O
disease	O
reservoirs	O
.	O

Understanding	O
the	O
spillover	O
from	O
bats	O
to	O
humans	O
and	O
other	O
animals	O
,	O
and	O
the	O
associated	O
health	O
risks	O
requires	O
an	O
analysis	O
of	O
the	O
disease	O
dynamics	O
in	O
bat	B-ENZY
populations	O
.	O

TITLE	O
:	O
Detection	O
of	O
respiratory	O
viruses	O
and	O
Legionella	O
spp	B-ENZY
.	O

Using	O
a	O
SARS	O
-	O
CoV	O
replicon	O
expressing	O
a	O
luciferase	B-ENZY
reporter	O
under	O
the	O
control	O
of	O
a	O
transcription	O
regulating	O
sequence	O
,	O
it	O
has	O
been	O
shown	O
that	O
several	O
viral	O
proteins	O
(	O
N	O
,	O
X	O
and	O
SUD	O
domains	O
of	O
nsp3	O
,	O
and	O
nsp12	O
)	O
provided	O
in	O
trans	O
stimulated	O
the	O
replicon	O
reporter	O
activity	O
,	O
indicating	O
that	O
these	O
proteins	O
may	O
regulate	O
coronavirus	O
replication	O
and	O
transcription	O
.	O

Moreover	O
,	O
the	O
protection	O
seems	O
to	O
be	O
associated	O
with	O
a	O
restricted	O
phospholipase	B-ENZY
A2	I-ENZY
activity	O
.	O

In	O
both	O
assays	O
,	O
we	O
find	O
that	O
the	O
NL63	O
S	O
protein	O
has	O
a	O
weaker	O
interaction	O
with	O
ACE	B-ENZY
-	O
2	O
than	O
the	O
SARS	O
-	O
CoV	O
S	O
protein	O
,	O
particularly	O
in	O
solution	O
binding	O
,	O
but	O
the	O
residues	O
required	O
for	O
contact	O
are	O
similar	O
.	O

A	O
lower	O
-	O
affinity	O
interaction	O
with	O
ACE	B-ENZY
-	O
2	O
might	O
partly	O
explain	O
the	O
different	O
pathological	O
consequences	O
of	O
infection	O
by	O
SARS	O
-	O
CoV	O
and	O
NL63	O
.	O

Here	O
,	O
we	O
provide	O
evidence	O
that	O
Papain	B-ENZY
-	O
like	O
protease	O
domain	O
2	O
(	O
PLP2	O
),	O
a	O
catalytic	O
domain	O
of	O
the	O
nonstructural	O
protein	O
3	O
(	O
nsp3	O
)	O
of	O
MHV	O
-	O
A59	O
,	O
can	O
bind	O
to	O
IRF3	O
,	O
cause	O
its	O
deubiquitination	O
and	O
prevent	O
its	O
nuclear	O
translocation	O
.	O

We	O
found	O
that	O
HeLa	O
cells	O
infected	O
with	O
229E	O
via	O
APN	O
formed	O
syncytia	O
when	O
treated	O
with	O
trypsin	B-ENZY
or	O
other	O
proteases	O
but	O
not	O
in	O
a	O
low	O
-	O
pH	O
environment	O
,	O
a	O
finding	O
consistent	O
with	O
syncytium	O
formation	O
by	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
).	O

Furthermore	O
,	O
229E	O
infection	O
was	O
inhibited	O
in	O
CPL	B-ENZY
knockdown	O
cells	O
by	O
small	O
interfering	O
RNA	O
,	O
compared	O
with	O
what	O
was	O
seen	O
for	O
a	O
normal	O
counterpart	O
producing	O
CPL	B-ENZY
.	O

We	O
also	O
found	O
229E	O
virion	O
S	O
protein	O
to	O
be	O
cleaved	O
by	O
CPL	B-ENZY
.	O

ABSTRACT	O
:	O
Bioline	O
-	O
coated	O
polymethylpentene	O
(	O
PMP	O
)	O
membrane	O
oxygenators	O
(	O
MO	O
)	O
are	O
used	O
for	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
to	O
improve	O
gas	B-ENZY
exchange	O
in	O
patients	O
with	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

ABSTRACT	O
:	O
Neutrophil	B-ENZY
elastase	I-ENZY
is	O
believed	O
to	O
play	O
an	O
important	O
role	O
in	O
acute	O
lung	O
injury	O
(	O
ALI	O
).	O

Compared	O
with	O
those	O
from	O
paradigm	O
1	O
,	O
litters	O
from	O
paradigm	O
2	O
were	O
less	O
likely	O
to	O
be	O
positive	O
for	O
MHV	O
and	O
Helicobacter	O
spp	B-ENZY
.	O

TITLE	O
:	O
Activation	O
of	O
p38	O
MAPK	B-ENZY
by	O
feline	O
infectious	O
peritonitis	O
virus	O
regulates	O
pro	O
-	O
inflammatory	O
cytokine	O
production	O
in	O
primary	O
blood	O
-	O
derived	O
feline	O
mononuclear	O
cells	O
.	O

FIPV	O
-	O
induced	O
p38	O
MAPK	B-ENZY
activation	O
and	O
pro	O
-	O
inflammatory	O
cytokine	O
production	O
was	O
inhibited	O
by	O
the	O
pyridinyl	O
imidazole	O
inhibitors	O
SB	O
203580	O
and	O
SC	O
409	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

The	O
effect	O
of	O
GSK	B-ENZY
-	O
3	O
inhibitor	O
was	O
reproduced	O
in	O
another	O
coronavirus	O
,	O
the	O
neurotropic	O
JHM	O
strain	O
of	O
mouse	O
hepatitis	O
virus	O
.	O

At	O
presentation	O
,	O
all	O
patients	O
but	O
two	O
had	O
a	O
PaO	B-ENZY
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
<	O
300	O
,	O
while	O
ARDS	O
was	O
present	O
in	O
17	O
and	O
acute	O
lung	O
injury	O
in	O
15	O
cases	O
.	O

ABSTRACT	O
:	O
Angiotensin	O
-	O
converting	O
enzyme	O
(	O
ACE	B-ENZY
)-	O
2	O
is	O
a	O
homolog	O
of	O
the	O
well	O
-	O
characterized	O
plasma	O
membrane	O
-	O
bound	O
angiotensin	O
-	O
converting	O
enzyme	O
.	O

TITLE	O
:	O
Extracorporeal	O
gas	B-ENZY
exchange	O
.	O

Two	O
hundred	O
and	O
ninety	O
-	O
seven	O
nasopharyngeal	O
secretions	O
were	O
collected	O
and	O
multiplex	O
reverse	B-ENZY
transcriptase	I-ENZY
polymerase	O
chain	O
reactions	O
(	O
RT	O
-	O
PCR	O
)/	O
polymerase	O
chain	O
reactions	O
(	O
PCR	O
)	O
were	O
performed	O
to	O
detect	O
respiratory	O
viruses	O
.	O

Multivariate	O
analysis	O
showed	O
that	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
pulmonary	O
artery	O
catheter	O
placement	O
,	O
comorbidities	O
,	O
hospital	O
-	O
acquired	O
infection	O
,	O
APACHE	O
II	O
score	O
and	O
maximum	O
LOD	B-ENZY
score	O
,	O
were	O
independent	O
risk	O
factors	O
for	O
hospital	O
mortality	O
.	O

To	O
differentiate	O
the	O
genotypes	O
without	O
sequencing	O
,	O
a	O
simple	O
technique	O
-	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
/	O
restriction	O
fragment	O
length	O
polymorphism	O
analysis	O
(	O
RT	O
-	O
PCR	O
/	O
RFLP	O
)-	O
was	O
developed	O
.	O

Bronchoalveolar	O
lavage	O
(	O
BAL	B-ENZY
)	O
samples	O
of	O
128	O
patients	O
with	O
atypical	O
pneumonia	O
(	O
HIV	O
-	O
infected	O
n	O
=	O
50	O
,	O
hematological	O
malignancy	O
n	O
=	O
51	O
,	O
immunosuppressive	O
treatment	O
n	O
=	O
27	O
)	O
were	O
prospectively	O
evaluated	O
for	O
P	O
.	O
jirovecii	O
and	O
retrospectively	O
for	O
new	O
respiratory	O
viruses	O
(	O
HMPV	O
,	O
HBoV	O
,	O
HCoV	O
-	O
NL63	O
/	O
SARS	O
/	O
HKU1	O
).	O

ABSTRACT	O
:	O
As	O
anti	O
-	O
HCV	O
aryl	O
diketoacids	O
(	O
ADK	O
)	O
are	O
good	O
metal	O
chelators	O
,	O
we	O
anticipated	O
that	O
ADKs	O
might	O
serve	O
as	O
potential	O
inhibitors	O
of	O
SARS	O
CoV	O
(	O
SCV	O
)	O
NTPase	B-ENZY
/	O
helicase	O
(	O
Hel	O
)	O
by	O
mimicking	O
the	O
binding	O
modes	O
of	O
the	O
bismuth	O
complexes	O
which	O
effectively	O
competes	O
for	O
the	O
Zn	O
(	O
2	O
+)	O
ion	O
binding	O
sites	O
in	O
SCV	O
Hel	O
thereby	O
disrupting	O
and	O
inhibiting	O
both	O
the	O
NTPase	B-ENZY
and	O
helicase	O
activities	O
.	O

Using	O
current	O
definitions	O
,	O
the	O
incidence	O
of	O
the	O
clinical	O
manifestation	O
,	O
abdominal	O
compartment	O
syndrome	O
(	O
ACS	B-ENZY
),	O
has	O
been	O
reported	O
as	O
27	O
%	O
in	O
the	O
largest	O
study	O
so	O
far	O
.	O

We	O
also	O
screened	O
bat	B-ENZY
tissues	O
by	O
PCR	O
using	O
primers	O
designed	O
to	O
amplify	O
nucleic	O
acids	O
from	O
members	O
of	O
certain	O
families	O
of	O
viruses	O
.	O

TITLE	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
M	O
protein	O
inhibits	O
type	O
I	O
interferon	O
production	O
by	O
impeding	O
the	O
formation	O
of	O
TRAF3	O
.	O
TANK	O
.	O
TBK1	B-ENZY
/	O
IKKepsilon	O
complex	O
.	O

TITLE	O
:	O
Lack	O
of	O
association	O
between	O
polymorphisms	O
of	O
MASP2	B-ENZY
and	O
susceptibility	O
to	O
SARS	O
coronavirus	O
infection	O
.	O

The	O
aims	O
of	O
this	O
study	O
were	O
to	O
validate	O
a	O
colorimetric	O
method	O
to	O
measure	O
total	O
sialic	O
acid	O
(	O
TSA	B-ENZY
)	O
in	O
feline	O
serum	O
and	O
to	O
investigate	O
the	O
serum	O
concentration	O
of	O
TSA	B-ENZY
in	O
clinically	O
healthy	O
cats	O
seronegative	O
(	O
n	O
=	O
9	O
)	O
and	O
seropositive	O
(	O
n	O
=	O
48	O
)	O
for	O
feline	O
coronavirus	O
(	O
FCoV	O
),	O
and	O
in	O
cats	O
affected	O
by	O
feline	O
infectious	O
peritonitis	O
(	O
FIP	O
,	O
n	O
=	O
28	O
),	O
tumors	O
(	O
n	O
=	O
20	O
),	O
or	O
inflammation	O
(	O
n	O
=	O
16	O
).	O

The	O
correlation	O
between	O
TSA	B-ENZY
and	O
alpha	O
(	O
1	O
)-	O
acid	O
glycoprotein	O
(	O
AGP	O
)	O
was	O
also	O
investigated	O
.	O

The	O
method	O
employed	O
in	O
this	O
study	O
is	O
precise	O
and	O
accurate	O
at	O
TSA	B-ENZY
levels	O
(	O
in	O
mg	O
/	O
L	O
)	O
commonly	O
encountered	O
in	O
feline	O
serum	O
.	O

TITLE	O
:	O
Sivelestat	O
(	O
selective	O
neutrophil	B-ENZY
elastase	I-ENZY
inhibitor	O
)	O
improves	O
the	O
mortality	O
rate	O
of	O
sepsis	O
associated	O
with	O
both	O
acute	O
respiratory	O
distress	O
syndrome	O
and	O
disseminated	O
intravascular	O
coagulation	O
patients	O
.	O

The	O
complications	O
in	O
P	O
.	O
vivax	O
were	O
thrombocytopenia	O
,	O
biochemical	O
evidence	O
of	O
hepatic	O
dysfunction	O
,	O
renal	O
damage	O
,	O
positive	O
DCT	B-ENZY
and	O
death	O
due	O
to	O
ARDS	O
.	O

The	O
present	O
evidence	O
supports	O
that	O
bat	B-ENZY
coronaviruses	O
are	O
the	O
gene	O
pools	O
of	O
group	O
1	O
and	O
2	O
coronaviruses	O
,	O
whereas	O
bird	O
coronaviruses	O
are	O
the	O
gene	O
pools	O
of	O
group	O
3	O
coronaviruses	O
.	O

In	O
contrast	O
,	O
the	O
second	O
site	O
is	O
involved	O
in	O
the	O
furin	B-ENZY
dependence	O
of	O
viral	O
entry	O
and	O
syncytium	O
formation	O
.	O

Pretreatment	O
of	O
Penn	O
-	O
98	O
-	O
1	O
with	O
trypsin	B-ENZY
reversed	O
its	O
properties	O
in	O
syncytium	O
formation	O
,	O
virus	O
production	O
,	O
and	O
genome	O
transport	O
to	O
the	O
ER	O
.	O

Studies	O
using	O
wild	O
bat	B-ENZY
sera	O
revealed	O
that	O
it	O
is	O
highly	O
likely	O
that	O
the	O
immunodominant	O
epitopes	O
overlap	O
with	O
the	O
major	O
neutralizing	O
sites	O
of	O
the	O
SL	O
-	O
CoV	O
S	O
protein	O
.	O

ABSTRACT	O
:	O
To	O
determine	O
the	O
coverage	O
of	O
infectious	O
bronchitis	O
virus	O
(	O
IBV	O
)	O
vaccine	O
field	O
boost	O
in	O
commercial	O
broilers	O
,	O
estimate	O
the	O
relative	O
amount	O
of	O
vaccine	O
virus	O
in	O
the	O
trachea	O
,	O
and	O
follow	O
the	O
clearance	O
of	O
the	O
vaccine	O
,	O
we	O
collected	O
approximately	O
100	O
tracheal	O
swabs	O
at	O
various	O
times	O
postvaccination	O
from	O
10	O
different	O
flocks	O
and	O
used	O
real	O
-	O
time	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
PCR	O
(	O
RT	O
-	O
PCR	O
)	O
to	O
detect	O
the	O
virus	O
.	O

TITLE	O
:	O
[	O
Porcine	O
aminopeptidase	B-ENZY
N	I-ENZY
is	O
a	O
functional	O
receptor	O
for	O
the	O
PEDV	O
coronavirus	O
].	O

Sixty	O
-	O
two	O
percent	O
of	O
the	O
patients	O
had	O
at	O
least	O
one	O
previous	O
episode	O
of	O
ACS	B-ENZY
.	O

One	O
-	O
third	O
of	O
patients	O
who	O
received	O
RCE	O
for	O
ACS	B-ENZY
had	O
no	O
respiratory	O
symptoms	O
on	O
admission	O
.	O

At	O
each	O
VT	O
,	O
gas	B-ENZY
exchange	O
and	O
hemodynamic	O
measurements	O
were	O
obtained	O
with	O
the	O
av	O
-	O
ECLA	O
circuit	O
clamped	O
and	O
declamped	O
.	O

Following	O
PRCV	O
infection	O
,	O
more	O
severe	O
PRRSV	O
-	O
related	O
pulmonary	O
alveolar	O
macrophage	O
(	O
PAM	B-ENZY
)	O
apoptosis	O
occurred	O
,	O
as	O
determined	O
by	O
an	O
in	O
situ	O
terminal	O
deoxynucleotidyl	O
transferase	O
-	O
mediated	O
dUTP	O
nick	O
end	O
labelling	O
assay	O
,	O
suggesting	O
increased	O
PRRSV	O
replication	O
in	O
PAMs	O
.	O

This	O
trypsin	B-ENZY
-	O
or	O
CPL	B-ENZY
-	O
mediated	O
conversion	O
to	O
6HB	O
can	O
be	O
blocked	O
by	O
a	O
heptad	O
repeat	O
peptide	O
known	O
to	O
block	O
the	O
formation	O
of	O
6HB	O
.	O

These	O
results	O
suggest	O
that	O
trypsin	B-ENZY
suffices	O
for	O
the	O
induction	O
of	O
membrane	O
fusion	O
of	O
receptor	O
-	O
primed	O
S	O
protein	O
,	O
but	O
an	O
additional	O
unidentified	O
cellular	O
factor	O
is	O
required	O
to	O
trigger	O
membrane	O
fusion	O
by	O
CPL	B-ENZY
.	O

On	O
the	O
other	O
hand	O
,	O
rabies	O
control	O
in	O
bat	B-ENZY
still	O
remains	O
non	O
realistic	O
,	O
particularly	O
as	O
the	O
pathogenicity	O
of	O
bat	B-ENZY
Lyssavirus	O
for	O
bats	O
is	O
still	O
under	O
debate	O
,	O
suggesting	O
that	O
a	O
""""	O
diplomatic	O
relationship	O
""""	O
between	O
partners	O
would	O
have	O
arisen	O
from	O
a	O
long	O
term	O
cohabitation	O
.	O

TITLE	O
:	O
RNase	B-ENZY
L	O
mediated	O
protection	O
from	O
virus	O
induced	O
demyelination	O
.	O

Patients	O
who	O
died	O
had	O
greater	O
initial	O
severity	O
of	O
illness	O
,	O
worse	O
hypoxemia	O
,	O
higher	O
creatine	B-ENZY
kinase	I-ENZY
levels	O
,	O
higher	O
creatinine	O
levels	O
,	O
and	O
ongoing	O
organ	O
dysfunction	O
.	O

After	O
adjusting	O
for	O
a	O
reduced	O
opportunity	O
of	O
patients	O
dying	O
early	O
to	O
receive	O
neuraminidase	B-ENZY
inhibitors	O
,	O
neuraminidase	B-ENZY
inhibitor	O
treatment	O
(	O
vs	O
no	O
treatment	O
)	O
was	O
associated	O
with	O
improved	O
survival	O
(	O
odds	O
ratio	O
,	O
8	O
.	O
5	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1	O
.	O
2	O
-	O
62	O
.	O
8	O
).	O

Neuraminidase	B-ENZY
inhibitors	O
were	O
administered	O
to	O
152	O
patients	O
(	O
90	O
.	O
5	O
%).	O

In	O
this	O
article	O
,	O
we	O
discuss	O
the	O
mechanical	O
and	O
chemical	O
effects	O
of	O
meconium	O
on	O
a	O
newborn	O
'	O
s	O
airway	O
,	O
meconium	O
-	O
induced	O
inflammation	O
,	O
mediated	O
by	O
proinflammatory	O
cytokines	O
and	O
chemokines	O
,	O
the	O
complement	O
system	O
and	O
the	O
proinflammatory	O
enzyme	O
phospholipase	B-ENZY
A2	I-ENZY
.	O

There	O
was	O
a	O
major	O
contribution	O
of	O
the	O
IRE1	O
/	O
XBP1	O
pathway	O
,	O
followed	O
by	O
caspase	B-ENZY
-	I-ENZY
3	I-ENZY
activation	O
and	O
nuclear	O
fragmentation	O
,	O
with	O
no	O
significant	O
role	O
of	O
the	O
ATF6	O
and	O
eIF2	O
-	O
alpha	O
/	O
ATF4	O
pathways	O
.	O

While	O
mAb	O
341C	O
binds	O
to	O
a	O
mostly	O
linear	O
epitope	O
composed	O
of	O
residues	O
(	O
507	O
)	O
PAT	B-ENZY
(	O
509	O
)	O
and	O
V	O
(	O
349	O
),	O
mAb	O
240C	O
binds	O
to	O
an	O
epitope	O
that	O
partially	O
overlaps	O
the	O
former	O
by	O
at	O
least	O
two	O
residues	O
(	O
P	O
(	O
507	O
)	O
and	O
A	O
(	O
508	O
)).	O

Since	O
treatment	O
of	O
ARDS	O
,	O
IPF	O
and	O
plastic	O
bronchitis	O
will	O
require	O
repeated	O
administration	O
of	O
pf	O
-	O
tPA	B-ENZY
,	O
the	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
safety	O
of	O
prolonged	O
,	O
repeated	O
administration	O
of	O
pf	O
-	O
mouse	O
tPA	B-ENZY
(	O
pf	O
-	O
mtPA	O
)	O
to	O
the	O
lungs	O
of	O
healthy	O
mice	O
.	O

He	O
had	O
been	O
exposed	O
to	O
irritant	O
gas	B-ENZY
when	O
polishing	O
the	O
inside	O
of	O
a	O
stainless	O
tank	O
using	O
a	O
chemical	O
cleaner	O
containing	O
hydrofluoric	O
acid	O
and	O
nitric	O
acid	O
.	O

Specific	O
parameters	O
assessed	O
in	O
the	O
innate	O
pulmonary	O
inflammatory	O
response	O
were	O
leukocytes	O
,	O
macrophages	O
,	O
and	O
polymorphonuclear	O
neutrophils	O
(	O
PMNs	O
)	O
in	O
BAL	B-ENZY
;	O
whole	O
lung	O
myeloperoxidase	B-ENZY
activity	O
;	O
and	O
a	O
series	O
of	O
cytokines	O
or	O
chemokines	O
present	O
in	O
BAL	B-ENZY
at	O
5	O
or	O
24	O
hours	O
after	O
injury	O
:	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
,	O
interleukin	O
(	O
IL	O
)-	O
1beta	O
,	O
IL	O
-	O
6	O
,	O
interferon	O
-	O
gamma	O
,	O
IL	O
-	O
10	O
,	O
macrophage	O
inflammatory	O
protein	O
-	O
2	O
,	O
cytokine	O
-	O
induced	O
neutrophil	O
chemoattractant	O
-	O
1	O
,	O
and	O
monocyte	O
chemoattractant	O
protein	O
-	O
1	O
.	O

RESULTS	O
:	O
Rats	O
with	O
LC	O
,	O
CASP	O
,	O
LC	O
+	O
CASP	O
all	O
had	O
severe	O
lung	O
injury	O
compared	O
with	O
uninjured	O
controls	O
based	O
on	O
decreased	O
arterial	O
oxygenation	O
or	O
increased	O
BAL	B-ENZY
albumin	O
at	O
5	O
or	O
24	O
hours	O
postinsult	O
.	O

Cell	O
immortalisation	O
can	O
occur	O
spontaneously	O
,	O
however	O
we	O
used	O
a	O
retroviral	O
system	O
to	O
immortalise	O
cells	O
via	O
the	O
transfer	O
and	O
stable	O
production	O
of	O
the	O
Simian	O
virus	O
40	O
Large	O
T	O
antigen	O
and	O
the	O
human	O
telomerase	O
reverse	B-ENZY
transcriptase	I-ENZY
protein	O
.	O

Veno	O
-	O
venous	O
extracorporeal	O
membrane	O
oxygenation	O
with	O
a	O
new	O
miniaturized	O
device	O
supports	O
gas	B-ENZY
transfer	O
effectively	O
,	O
allows	O
for	O
highly	O
protective	O
ventilation	O
and	O
is	O
very	O
reliable	O
.	O

TITLE	O
:	O
Circulation	O
of	O
group	O
2	O
coronaviruses	O
in	O
a	O
bat	B-ENZY
species	O
common	O
to	O
urban	O
areas	O
in	O
Western	O
Europe	O
.	O

ABSTRACT	O
:	O
Fecal	O
samples	O
of	O
211	O
bats	O
representing	O
13	O
different	O
bat	B-ENZY
species	O
from	O
31	O
locations	O
in	O
the	O
Netherlands	O
were	O
analyzed	O
for	O
the	O
presence	O
of	O
coronaviruses	O
(	O
CoV	O
)	O
using	O
a	O
genus	O
-	O
wide	O
reverse	O
transcription	O
(	O
RT	O
)-	O
polymerase	O
chain	O
reaction	O
.	O

Molecular	O
clock	O
analysis	O
showed	O
that	O
SARSr	O
-	O
CoVs	O
were	O
newly	O
emerged	O
viruses	O
with	O
the	O
time	O
of	O
the	O
most	O
recent	O
common	O
ancestor	O
(	O
tMRCA	O
)	O
at	O
1972	O
,	O
which	O
diverged	O
between	O
civet	O
and	O
bat	B-ENZY
strains	O
in	O
1995	O
.	O

BAL	B-ENZY
samples	O
underwent	O
multiplex	O
testing	O
for	O
a	O
panel	O
of	O
19	O
respiratory	O
viral	O
types	O
/	O
subtypes	O
using	O
the	O
Luminex	O
xTAG	O
respiratory	O
virus	O
panel	O
assay	O
.	O

A	O
respiratory	O
virus	O
was	O
isolated	O
in	O
48	O
of	O
93	O
(	O
51	O
.	O
6	O
%)	O
patients	O
on	O
at	O
least	O
one	O
BAL	B-ENZY
sample	O
.	O

TITLE	O
:	O
Classification	O
of	O
IBV	O
S1	O
genotypes	O
by	O
direct	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
and	O
relationship	O
between	O
serotypes	O
and	O
genotypes	O
of	O
strains	O
isolated	O
between	O
1998	O
and	O
2008	O
in	O
Japan	O
.	O

ABSTRACT	O
:	O
MLK3	O
(	O
mixed	O
lineage	O
kinase	O
3	O
)	O
is	O
a	O
MAP3K	B-ENZY
[	O
MAPK	B-ENZY
(	O
mitogen	B-ENZY
-	I-ENZY
activated	I-ENZY
protein	I-ENZY
kinase	I-ENZY
)	O
kinase	O
kinase	O
]	O
that	O
activates	O
multiple	O
MAPK	B-ENZY
pathways	O
,	O
including	O
the	O
JNK	B-ENZY
(	O
c	B-ENZY
-	I-ENZY
Jun	I-ENZY
N	I-ENZY
-	I-ENZY
terminal	I-ENZY
kinase	I-ENZY
)	O
pathway	O
.	O

Five	O
bacterial	O
species	O
,	O
five	O
viruses	O
and	O
two	O
Mycoplasma	O
spp	B-ENZY
.	O
were	O
detected	O
in	O
different	O
combinations	O
.	O

Our	O
data	O
have	O
suggested	O
that	O
nitric	O
oxide	O
(	O
NO	O
),	O
inducible	O
NO	O
synthase	O
(	O
iNOS	O
),	O
phospholipase	B-ENZY
A2	I-ENZY
,	O
free	O
radical	O
and	O
inflammatory	O
cytokines	O
(	O
tumor	O
necrosis	O
factor	O
alpha	O
,	O
interleukin	O
-	O
1beta	O
and	O
interleukin	O
-	O
6	O
)	O
are	O
involved	O
in	O
the	O
biochemical	O
phase	O
of	O
FES	O
with	O
ARDS	O
.	O

A	O
rare	O
side	O
-	O
effect	O
of	O
oseltamivir	O
treatment	O
reported	O
in	O
post	O
-	O
marketing	O
surveillance	O
is	O
tongue	O
and	O
lip	B-ENZY
swelling	O
/	O
angioedema	O
.	O

p42	O
is	O
a	O
subunit	O
of	O
the	O
26S	O
proteasome	B-ENZY
;	O
this	O
large	O
,	O
multi	O
-	O
protein	O
complex	O
is	O
a	O
component	O
of	O
the	O
ubiquitin	O
-	O
proteasome	B-ENZY
pathway	O
,	O
which	O
is	O
involved	O
in	O
a	O
variety	O
of	O
basic	O
cellular	O
processes	O
and	O
inflammatory	O
responses	O
.	O

Neither	O
protein	B-ENZY
kinase	I-ENZY
R	O
,	O
which	O
phosphorylates	O
eukaryotic	O
initiation	O
factor	O
2	O
,	O
nor	O
oligoadenylate	O
synthetase	O
,	O
which	O
activates	O
RNase	B-ENZY
L	O
,	O
was	O
differentially	O
activated	O
in	O
IFN	O
-	O
treated	O
cells	O
infected	O
with	O
MHV	O
-	O
A59	O
or	O
MHV	O
-	O
S	O
.	O
Thus	O
,	O
the	O
major	O
IFN	O
-	O
induced	O
antiviral	O
activities	O
that	O
are	O
specifically	O
inhibited	O
by	O
MHV	O
,	O
and	O
possibly	O
by	O
other	O
coronaviruses	O
,	O
remain	O
to	O
be	O
identified	O
.	O

ABSTRACT	O
:	O
In	O
the	O
management	O
of	O
patients	O
with	O
severe	O
acute	O
lung	O
injury	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
clinicians	O
are	O
sometimes	O
challenged	O
to	O
maintain	O
acceptable	O
gas	B-ENZY
exchange	O
while	O
avoiding	O
harmful	O
mechanical	O
ventilation	O
practices	O
.	O

TITLE	O
:	O
Angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
)	O
proteins	O
of	O
different	O
bat	B-ENZY
species	O
confer	O
variable	O
susceptibility	O
to	O
SARS	O
-	O
CoV	O
entry	O
.	O

Mutagenesis	O
indicated	O
that	O
a	O
single	O
N	O
-	O
linked	O
glycosylation	O
site	O
,	O
N330	O
,	O
was	O
critical	O
for	O
the	O
specific	O
interactions	O
between	O
MBL	O
and	O
SARS	O
-	O
S	O
.	O
Despite	O
the	O
proximity	O
of	O
N330	O
to	O
the	O
receptor	O
-	O
binding	O
motif	O
of	O
SARS	O
-	O
S	O
,	O
MBL	O
did	O
not	O
affect	O
interactions	O
with	O
the	O
ACE2	O
receptor	O
or	O
cathepsin	B-ENZY
L	I-ENZY
-	O
mediated	O
activation	O
of	O
SARS	O
-	O
S	O
-	O
driven	O
membrane	O
fusion	O
.	O

These	O
observations	O
indicate	O
that	O
the	O
covalent	O
linkage	O
between	O
the	O
chymotrypsin	B-ENZY
like	O
and	O
the	O
extra	O
domain	O
is	O
essential	O
for	O
enzymatic	O
activity	O
of	O
the	O
main	O
coronavirus	O
protease	O
and	O
for	O
the	O
integrity	O
of	O
its	O
quaternary	O
structure	O
.	O

GCS	O
score	O
and	O
the	O
need	O
for	O
CPR	B-ENZY
at	O
the	O
scene	O
of	O
injury	O
were	O
associated	O
with	O
eventual	O
mortality	O
because	O
of	O
anoxic	O
brain	O
injury	O
in	O
all	O
cases	O
.	O

TITLE	O
:	O
Binding	O
characterization	O
of	O
determinants	O
in	O
porcine	O
aminopeptidase	B-ENZY
N	I-ENZY
,	O
the	O
cellular	O
receptor	O
for	O
transmissible	O
gastroenteritis	O
virus	O
.	O

ABSTRACT	O
:	O
Four	O
truncated	O
porcine	O
aminopeptidase	B-ENZY
N	I-ENZY
(	O
pAPN	O
,	O
a	O
cellular	O
receptor	O
for	O
porcine	O
coronaviruses	O
)	O
proteins	O
were	O
expressed	O
in	O
prokaryotic	O
cells	O
.	O

Intra	O
-	O
abdominal	O
hypertension	O
(	O
IAH	O
)	O
and	O
abdominal	O
compartment	O
syndrome	O
(	O
ACS	B-ENZY
)	O
are	O
increasingly	O
recognized	O
and	O
treatable	O
complications	O
of	O
severe	O
illness	O
in	O
medical	O
patients	O
,	O
and	O
are	O
independent	O
predictors	O
of	O
mortality	O
.	O

To	O
explore	O
the	O
link	O
between	O
coronavirus	O
infection	O
and	O
the	O
ubiquitin	O
system	O
,	O
we	O
asked	O
whether	O
protein	O
degradation	O
by	O
the	O
26S	O
proteasome	B-ENZY
plays	O
a	O
role	O
in	O
severe	O
coronavirus	O
infections	O
using	O
a	O
murine	O
model	O
of	O
SARS	O
-	O
like	O
pneumonitis	O
induced	O
by	O
murine	O
hepatitis	O
virus	O
strain	O
1	O
(	O
MHV	O
-	O
1	O
).	O

Proteasome	B-ENZY
inhibition	O
also	O
blocked	O
viral	O
cytotoxicity	O
in	O
macrophages	O
,	O
as	O
well	O
as	O
the	O
induction	O
of	O
inflammatory	O
mediators	O
such	O
as	O
IP	O
-	O
10	O
,	O
gamma	O
interferon	O
(	O
IFN	O
-	O
	O
),	O
and	O
monocyte	O
chemoattractant	O
protein	O
1	O
(	O
MCP	O
-	O
1	O
).	O

These	O
data	O
demonstrate	O
that	O
inhibition	O
of	O
the	O
cellular	O
proteasome	B-ENZY
attenuates	O
pneumonitis	O
and	O
cytokine	O
gene	O
expression	O
in	O
vivo	O
by	O
reducing	O
MHV	O
-	O
1	O
replication	O
and	O
the	O
resulting	O
inflammatory	O
response	O
.	O

Empirical	O
evidence	O
is	O
drawn	O
from	O
a	O
number	O
of	O
cases	O
,	O
including	O
Chernobyl	O
;	O
Goiania	O
,	O
Brazil	O
;	O
the	O
sarin	O
gas	B-ENZY
attack	O
in	O
Tokyo	O
;	O
the	O
anthrax	O
attacks	O
in	O
the	O
USA	O
;	O
Three	O
Mile	O
Island	O
;	O
and	O
by	O
features	O
of	O
the	O
2003	O
severe	O
acute	O
respiratory	O
syndrome	O
pandemic	O
.	O

ABSTRACT	O
:	O
The	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
8b	O
protein	O
,	O
which	O
is	O
not	O
expressed	O
by	O
other	O
known	O
coronaviruses	O
,	O
can	O
down	O
-	O
regulate	O
the	O
envelope	O
(	O
E	O
)	O
protein	O
via	O
a	O
proteasome	B-ENZY
-	O
dependent	O
pathway	O
.	O

Coronavirus	O
consensus	O
PCR	O
and	O
unbiased	O
high	O
-	O
throughput	O
pyrosequencing	O
revealed	O
the	O
presence	O
of	O
coronavirus	O
sequences	O
related	O
to	O
those	O
of	O
SARS	O
-	O
CoV	O
in	O
a	O
Commerson	O
'	O
s	O
leaf	O
-	O
nosed	O
bat	B-ENZY
(	O
Hipposideros	O
commersoni	O
).	O

In	O
serial	O
blood	O
examinations	O
of	O
the	O
effusive	O
group	O
,	O
anaemia	O
and	O
increases	O
in	O
bilirubin	O
and	O
aspartate	B-ENZY
aminotransferase	I-ENZY
(	O
AST	B-ENZY
)	O
were	O
observed	O
from	O
2	O
weeks	O
to	O
0	O
-	O
3	O
days	O
before	O
death	O
.	O

Trypsin	B-ENZY
treatment	O
of	O
receptor	O
-	O
associated	O
SARS	O
-	O
CoV	O
pseudovirions	O
,	O
which	O
bypasses	O
their	O
dependence	O
on	O
lysosomal	O
cathepsin	B-ENZY
L	I-ENZY
,	O
also	O
bypassed	O
IFITM	O
-	O
mediated	O
restriction	O
.	O

TITLE	O
:	O
Severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
papain	B-ENZY
-	O
like	O
protease	O
suppressed	O
alpha	O
interferon	O
-	O
induced	O
responses	O
through	O
downregulation	O
of	O
extracellular	B-ENZY
signal	I-ENZY
-	I-ENZY
regulated	I-ENZY
kinase	I-ENZY
1	O
-	O
mediated	O
signalling	O
pathways	O
.	O

PLpro	O
antagonized	O
IFN	O
-	O
	O
-	O
induced	O
responses	O
such	O
as	O
interferon	O
-	O
stimulated	O
response	O
element	O
-	O
and	O
AP	O
-	O
1	O
-	O
driven	O
promoter	O
activation	O
,	O
protein	B-ENZY
kinase	I-ENZY
R	O
,	O
2	O
'-	O
5	O
'-	O
oligoadenylate	O
synthetase	O
(	O
OAS	O
),	O
interleukin	O
(	O
IL	O
)-	O
6	O
and	O
IL	O
-	O
8	O
expression	O
,	O
and	O
signal	O
transducers	O
and	O
activators	O
of	O
transcription	O
(	O
STAT	O
)	O
1	O
(	O
Tyr701	O
),	O
STAT1	O
(	O
Ser727	O
)	O
and	O
c	O
-	O
Jun	O
phosphorylation	O
.	O

Gas	B-ENZY
exchange	O
,	O
hemodynamics	O
,	O
hemolysis	O
,	O
and	O
coagulation	O
activation	O
were	O
examined	O
.	O

Although	O
all	O
RT	O
inhibitors	O
approved	O
for	O
therapy	O
target	O
DNA	O
polymerase	O
activity	O
,	O
the	O
search	O
for	O
new	O
RT	O
inhibitors	O
that	O
target	O
the	O
RNase	B-ENZY
H	I-ENZY
function	O
and	O
are	O
possibly	O
active	O
on	O
RTs	O
resistant	O
to	O
the	O
known	O
non	O
-	O
nucleoside	O
inhibitors	O
(	O
NNRTI	O
)	O
is	O
a	O
viable	O
approach	O
for	O
anti	O
-	O
HIV	O
drug	O
development	O
.	O

We	O
have	O
previously	O
shown	O
that	O
papain	B-ENZY
-	O
like	O
protease	O
domain	O
2	O
(	O
PLP2	O
),	O
a	O
catalytic	O
domain	O
of	O
the	O
nonstructural	O
protein	O
3	O
(	O
nsp3	O
)	O
of	O
MHV	O
-	O
A59	O
,	O
encodes	O
a	O
deubiquitinase	O
(	O
DUB	O
)	O
and	O
inactivates	O
IFN	O
regulatory	O
factor	O
3	O
(	O
IRF3	O
)	O
thereby	O
the	O
type	O
I	O
interferon	O
(	O
IFN	O
)	O
response	O
.	O

Overexpression	O
experiments	O
showed	O
that	O
PLP2	O
deubiquitinated	O
TBK1	B-ENZY
and	O
reduced	O
its	O
kinase	O
activity	O
,	O
hence	O
inhibited	O
IFN	O
-	O
	O
reporter	O
activity	O
.	O

The	O
viral	O
genome	O
was	O
amplified	O
by	O
real	O
time	O
reverse	B-ENZY
transcriptase	I-ENZY
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
from	O
a	O
nasopharyngeal	O
swab	O
specimen	O
.	O

H1N1	O
+	O
patients	O
were	O
relatively	O
younger	O
in	O
age	O
(	O
34	O
.	O
2	O
	O
12	O
.	O
9	O
years	O
vs	O
.	O
42	O
.	O
8	O
	O
18	O
.	O
1	O
,	O
P	O
=	O
0	O
.	O
005	O
)	O
but	O
presented	O
with	O
significantly	O
lower	O
PaO	B-ENZY
(	O
2	O
):	O
FiO	O
(	O
2	O
)	O
ratio	O
(	O
87	O
.	O
3	O
	O
48	O
.	O
7	O
vs	O
.	O
114	O
	O
51	O
.	O
7	O
)	O
in	O
comparison	O
to	O
those	O
who	O
subsequently	O
tested	O
as	O
H1N1	O
.	O

We	O
found	O
that	O
R667	O
was	O
dispensable	O
for	O
SARS	O
-	O
S	O
-	O
driven	O
virus	O
-	O
cell	O
fusion	O
and	O
for	O
SARS	O
-	O
S	O
-	O
activation	O
by	O
trypsin	B-ENZY
and	O
cathepsin	B-ENZY
L	I-ENZY
in	O
a	O
virus	O
-	O
virus	O
fusion	O
assay	O
.	O

Mutation	O
T760R	O
,	O
which	O
optimizes	O
the	O
minimal	O
furin	B-ENZY
consensus	O
motif	O
758	O
-	O
RXXR	O
-	O
762	O
,	O
and	O
furin	B-ENZY
overexpression	O
augmented	O
SARS	O
-	O
S	O
activity	O
,	O
but	O
did	O
not	O
result	O
in	O
detectable	O
SARS	O
-	O
S	O
cleavage	O
.	O

Samples	O
from	O
dairy	O
beef	O
properties	O
were	O
more	O
likely	O
to	O
have	O
multiple	O
pathogens	O
than	O
dairy	O
properties	O
(	O
P	O
<	O
0	O
.	O
05	O
),	O
whereas	O
rotavirus	O
and	O
Salmonella	O
spp	B-ENZY
.	O

TITLE	O
:	O
SARS	O
-	O
CoV	O
accessory	O
protein	O
3b	O
induces	O
AP	O
-	O
1	O
transcriptional	O
activity	O
through	O
activation	O
of	O
JNK	B-ENZY
and	O
ERK	B-ENZY
pathways	O
.	O

Starting	O
from	O
a	O
Pplat	O
/	O
positive	O
end	O
-	O
expiratory	O
pressure	O
(	O
PEEP	O
)	O
of	O
40	O
/	O
25	O
,	O
we	O
sequentially	O
increased	O
airway	O
pressure	O
in	O
5	O
cmH	O
(	O
2	O
)	O
O	O
steps	O
until	O
a	O
PaO	B-ENZY
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
of	O
350	O
mmHg	O
or	O
a	O
Pplat	O
/	O
PEEP	O
of	O
60	O
/	O
40	O
cmH	O
(	O
2	O
)	O
O	O
was	O
reached	O
.	O

An	O
intra	O
-	O
arterial	O
catheter	O
continuously	O
displayed	O
blood	O
gas	B-ENZY
measures	O
.	O

Following	O
admission	O
to	O
the	O
intensive	O
care	O
unit	O
,	O
hypoxia	O
became	O
critical	O
,	O
with	O
a	O
PaO	B-ENZY
(	O
2	O
)/	O
F	O
(	O
I	O
)	O
O	O
(	O
2	O
)	O
value	O
of	O
52	O
even	O
after	O
recruitment	O
maneuvers	O
.	O

Unfortunately	O
,	O
little	O
is	O
known	O
about	O
maintenance	O
mechanisms	O
for	O
any	O
pathogen	O
in	O
bat	B-ENZY
populations	O
.	O

The	O
present	O
study	O
describes	O
the	O
mode	O
of	O
action	O
of	O
trypsin	B-ENZY
in	O
enhancing	O
PEDV	O
infection	O
in	O
Vero	O
cells	O
during	O
different	O
stage	O
of	O
the	O
virus	O
life	O
cycle	O
.	O

However	O
,	O
trypsin	B-ENZY
treatment	O
of	O
viruses	O
before	O
receptor	O
binding	O
did	O
not	O
enhance	O
infectivity	O
,	O
indicating	O
that	O
receptor	O
binding	O
is	O
essentially	O
required	O
for	O
trypsin	B-ENZY
-	O
mediated	O
entry	O
upon	O
PEDV	O
infection	O
.	O

A	O
novel	O
generic	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)-	O
based	O
assay	O
using	O
degenerate	O
primers	O
identified	O
human	O
coronavirus	O
(	O
CoV	O
)	O
HKU1	O
RNA	O
in	O
BAL	B-ENZY
fluid	O
at	O
autopsy	O
.	O

To	O
elucidate	O
the	O
biogeographic	O
origin	O
of	O
SARS	O
-	O
CoV	O
and	O
investigate	O
the	O
role	O
that	O
bats	O
played	O
in	O
its	O
emergence	O
,	O
we	O
amplified	O
coronavirus	O
sequences	O
from	O
bat	B-ENZY
species	O
captured	O
throughout	O
Thailand	O
and	O
assessed	O
the	O
phylogenetic	O
relationships	O
to	O
each	O
other	O
and	O
to	O
other	O
published	O
coronavirus	O
sequences	O
.	O

However	O
,	O
the	O
precursor	O
of	O
the	O
SARS	O
-	O
CoV	O
remains	O
in	O
its	O
natural	O
bat	B-ENZY
reservoir	O
,	O
and	O
reemergence	O
of	O
a	O
human	O
-	O
adapted	O
SARS	O
-	O
like	O
coronavirus	O
remains	O
a	O
plausible	O
public	O
health	O
concern	O
.	O

TITLE	O
:	O
Analysis	O
of	O
concentration	O
fluctuations	O
in	O
gas	B-ENZY
dispersion	O
around	O
high	O
-	O
rise	O
building	O
for	O
different	O
incident	O
wind	O
directions	O
.	O

Tracer	O
gas	B-ENZY
was	O
continuously	O
released	O
from	O
a	O
point	O
source	O
located	O
at	O
different	O
positions	O
,	O
and	O
a	O
time	O
series	O
of	O
fluctuating	O
concentrations	O
were	O
recorded	O
at	O
a	O
large	O
number	O
of	O
points	O
using	O
fast	O
flame	O
ionization	O
detectors	O
.	O

In	O
contrast	O
,	O
adults	O
who	O
reported	O
recurrent	O
,	O
severe	O
episodes	O
of	O
wheezing	O
(	O
N	O
=	O
34	O
),	O
regardless	O
of	O
asthma	O
,	O
had	O
twice	O
the	O
rates	O
of	O
pain	O
and	O
ACS	B-ENZY
,	O
decreased	O
lung	O
function	O
and	O
increased	O
risk	O
of	O
death	O
compared	O
with	O
adults	O
without	O
recurrent	O
,	O
severe	O
wheezing	O
.	O

Finally	O
,	O
the	O
changes	O
of	O
arterial	O
blood	O
gases	O
which	O
contained	O
hydrogen	O
ion	O
concentration	O
(	O
pH	O
),	O
arterial	O
oxygen	O
tension	O
(	O
PaO	B-ENZY
(	O
2	O
))	O
and	O
arterial	O
carbon	O
dioxide	O
tension	O
(	O
PaCO	O
(	O
2	O
))	O
were	O
measured	O
and	O
the	O
measurement	O
of	O
extravascular	O
lung	O
water	O
(	O
EVLW	O
)	O
was	O
observed	O
.	O

Nonconventional	O
ventilatory	O
treatments	O
such	O
as	O
prone	O
positioning	O
,	O
high	O
frequency	O
oscillatory	O
ventilation	O
(	O
HFOV	O
),	O
and	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
)	O
aim	O
to	O
restore	O
gas	B-ENZY
exchange	O
while	O
further	O
decreasing	O
ventilator	O
induced	O
lung	O
injury	O
.	O

TITLE	O
:	O
Detection	O
of	O
bat	B-ENZY
coronaviruses	O
from	O
Miniopterus	O
fuliginosus	O
in	O
Japan	O
.	O

It	O
is	O
mainly	O
characterized	O
by	O
hyperthermia	O
,	O
altered	O
mental	O
state	O
,	O
hemodynamic	O
dysregulation	O
,	O
elevated	O
serum	O
creatine	B-ENZY
kinase	I-ENZY
,	O
and	O
rigors	O
.	O

Treatment	O
of	O
the	O
cells	O
with	O
heparinase	B-ENZY
or	O
exogenous	O
heparin	O
prevented	O
binding	O
of	O
spike	O
protein	O
to	O
host	O
cells	O
and	O
inhibited	O
SARS	O
pseudovirus	O
infection	O
,	O
demonstrating	O
that	O
HSPGs	O
provide	O
the	O
binding	O
sites	O
for	O
SARS	O
-	O
CoV	O
invasion	O
at	O
the	O
early	O
attachment	O
phase	O
.	O

After	O
adjusting	O
for	O
age	O
and	O
sex	O
,	O
only	O
rs2248690	O
(	O
AOR	B-ENZY
,	O
1	O
.	O
63	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
30	O
-	O
2	O
.	O
04	O
)	O
was	O
found	O
to	O
be	O
associated	O
with	O
SARS	O
susceptibility	O
.	O

While	O
antibodies	O
against	O
Feline	O
parvovirus	O
and	O
Feline	O
coronavirus	O
(	O
FCoV	O
),	O
Feline	O
calicivirus	O
and	O
Bartonella	O
spp	B-ENZY
.	O
were	O
frequently	O
detected	O
by	O
serologic	O
tests	O
,	O
antibodies	O
against	O
Felid	O
herpesvirus	O
1	O
or	O
infection	O
with	O
hemotropic	O
mycoplasmas	O
were	O
less	O
prevalent	O
.	O

No	O
Anaplasma	O
phagocytophilum	O
and	O
Theileria	O
spp	B-ENZY
.	O

The	O
PAC	O
group	O
had	O
an	O
increased	O
risk	O
of	O
all	O
-	O
cause	O
mortality	O
,	O
3	O
.	O
5	O
%	O
vs	O
1	O
.	O
7	O
%	O
(	O
AOR	B-ENZY
,	O
2	O
.	O
08	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
11	O
to	O
3	O
.	O
88	O
;	O
P	O
=	O
0	O
.	O
02	O
)	O
and	O
an	O
increased	O
risk	O
of	O
cardiac	O
(	O
AOR	B-ENZY
,	O
1	O
.	O
58	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
14	O
to	O
2	O
.	O
20	O
;	O
P	O
=	O
0	O
.	O
007	O
),	O
cerebral	O
(	O
AOR	B-ENZY
,	O
2	O
.	O
02	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
08	O
to	O
3	O
.	O
77	O
;	O
P	O
=	O
0	O
.	O
03	O
)	O
and	O
renal	O
(	O
AOR	B-ENZY
,	O
2	O
.	O
47	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
68	O
to	O
3	O
.	O
62	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
morbid	O
outcomes	O
.	O

In	O
addition	O
,	O
unlike	O
the	O
ADKs	O
which	O
showed	O
selective	O
inhibition	O
against	O
the	O
helicase	O
activity	O
of	O
the	O
SCV	O
NTPase	B-ENZY
/	O
helicase	O
,	O
the	O
5	O
-	O
hydroxychromones	O
(	O
5b	O
-	O
5f	O
)	O
were	O
active	O
against	O
both	O
NTPase	B-ENZY
and	O
helicase	O
activities	O
of	O
the	O
target	O
enzyme	O
.	O

The	O
bronchoscopic	O
grading	O
of	O
inhalation	O
injury	O
moderately	O
correlates	O
with	O
early	O
indices	O
of	O
impaired	O
gas	B-ENZY
exchange	O
in	O
this	O
cohort	O
and	O
may	O
be	O
a	O
promising	O
tool	O
for	O
staging	O
lower	O
airway	O
injury	O
.	O

TITLE	O
:	O
Comparison	O
of	O
SARS	O
and	O
NL63	O
papain	B-ENZY
-	O
like	O
protease	O
binding	O
sites	O
and	O
binding	O
site	O
dynamics	O
:	O
inhibitor	O
design	O
implications	O
.	O

ABSTRACT	O
:	O
The	O
D	O
allele	O
of	O
the	O
insertion	O
/	O
deletion	O
(	O
I	O
/	O
D	O
)	O
polymorphism	O
of	O
a	O
287	O
-	O
bp	O
sequence	O
in	O
the	O
angiotensin	O
-	O
converting	O
enzyme	O
(	O
ACE	B-ENZY
)	O
gene	O
has	O
been	O
associated	O
with	O
an	O
increased	O
activity	O
of	O
this	O
enzyme	O
.	O

ABSTRACT	O
:	O
The	O
design	O
and	O
evaluation	O
of	O
low	O
molecular	O
weight	O
peptide	O
-	O
based	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
chymotrypsin	B-ENZY
-	O
like	O
protease	O
(	O
3CL	O
)	O
protease	O
inhibitors	O
are	O
described	O
.	O

Patients	O
'	O
lungs	O
were	O
ventilated	O
by	O
a	O
volume	O
assist	O
-	O
controlled	O
mode	O
according	O
to	O
the	O
ARDS	O
Clinical	O
Network	O
Mechanical	O
Ventilation	O
Protocol	O
(	O
http	O
://	O
www	O
.	O
ardsnet	O
.	O
org	O
/)	O
with	O
the	O
goal	O
SpO	O
(	O
2	O
)	O
of	O
88	O
-	O
95	O
%	O
(	O
or	O
PaO	B-ENZY
(	O
2	O
)	O
55	O
-	O
80	O
mmHg	O
)	O
and	O
goal	O
plateau	O
pressure	O
	O
35	O
cm	O
H	O
(	O
2	O
)	O
O	O
.	O
Open	O
-	O
label	O
boluses	O
of	O
cisatracurium	O
20	O
mg	O
(	O
maximum	O
of	O
two	O
per	O
24	O
-	O
hr	O
period	O
)	O
were	O
allowed	O
if	O
plateau	O
pressures	O
remained	O
>	O
32	O
cm	O
H	O
(	O
2	O
)	O
O	O
despite	O
increased	O
sedation	O
and	O
despite	O
decreased	O
PEEP	O
and	O
decreased	O
tidal	O
volumes	O
.	O

TITLE	O
:	O
Aerosolized	O
human	O
extracellular	O
superoxide	B-ENZY
dismutase	I-ENZY
prevents	O
hyperoxia	O
-	O
induced	O
lung	O
injury	O
.	O

The	O
increase	O
in	O
pulmonary	O
microvascular	O
shunt	O
fraction	O
and	O
airway	O
obstruction	O
in	O
bronchi	O
and	O
bronchiole	O
,	O
as	O
well	O
as	O
lung	O
3	O
-	O
nitrotyrosine	O
,	O
lung	O
myeloperoxidase	B-ENZY
,	O
cardiac	O
3	O
-	O
nitrotyrosine	O
,	O
and	O
cardiac	O
malondialdehyde	O
levels	O
,	O
was	O
significantly	O
reduced	O
as	O
compared	O
with	O
controls	O
(	O
P	O
<	O
0	O
.	O
05	O
each	O
).	O

The	O
SARS	O
-	O
CoV	O
papain	B-ENZY
-	O
like	O
protease	O
(	O
PLP	O
)	O
is	O
an	O
attractive	O
target	O
for	O
pharmaceutical	O
development	O
because	O
it	O
is	O
essential	O
for	O
virus	O
replication	O
and	O
is	O
conserved	O
among	O
human	O
coronaviruses	O
.	O

The	O
remaining	O
12	O
patients	O
were	O
transferred	O
on	O
veno	O
-	O
venous	O
ECMO	O
with	O
extracorporeal	O
blood	O
flow	O
2	O
.	O
7	O
	O
1	O
L	O
	O
min	O
	O
	O
,	O
gas	B-ENZY
flow	O
3	O
.	O
8	O
	O
1	O
.	O
8	O
L	O
	O
min	O
	O
	O
,	O
and	O
FiO	O
1	O
.	O

TITLE	O
:	O
SARS	O
-	O
CoV	O
nucleocapsid	O
protein	O
interacts	O
with	O
cellular	O
pyruvate	B-ENZY
kinase	I-ENZY
protein	O
and	O
inhibits	O
its	O
activity	O
.	O

Pyruvate	B-ENZY
kinase	I-ENZY
(	O
liver	O
)	O
was	O
found	O
to	O
interact	O
with	O
SARS	O
-	O
CoV	O
nucleocapsid	O
protein	O
in	O
this	O
experiment	O
.	O

The	O
initial	O
laboratory	O
profile	O
showed	O
only	O
an	O
increase	O
in	O
alanine	B-ENZY
aminotransferase	I-ENZY
enzyme	O
activity	O
.	O

Sputum	O
culture	O
revealed	O
the	O
presence	O
of	O
MRSA	O
,	O
and	O
HSV	O
was	O
isolated	O
in	O
broncho	O
-	O
alveoler	O
lavage	O
(	O
BAL	B-ENZY
)	O
fluid	O
.	O

Inhibition	O
of	O
the	O
mitogen	O
-	O
activated	O
protein	O
/	O
extracellular	B-ENZY
signal	I-ENZY
-	I-ENZY
regulated	I-ENZY
kinase	I-ENZY
(	O
MEK	B-ENZY
/	O
ERK	B-ENZY
)	O
and	O
phosphoinositide	B-ENZY
3	I-ENZY
-	I-ENZY
kinase	I-ENZY
(	O
PI3K	O
/	O
Akt	O
)	O
signaling	O
pathways	O
by	O
chemical	O
inhibitors	O
and	O
knockdown	O
of	O
GADD153	O
by	O
siRNA	O
demonstrated	O
the	O
involvement	O
of	O
ER	O
-	O
stress	O
response	O
in	O
regulation	O
of	O
IBV	O
-	O
induced	O
Mcl	O
-	O
1	O
expression	O
.	O

to	O
achieve	O
blood	O
alcohol	O
levels	O
associated	O
with	O
moderate	O
to	O
severe	O
intoxication	O
and	O
measured	O
the	O
rate	O
of	O
alveolar	O
fluid	O
clearance	O
and	O
Na	O
,	O
K	O
-	O
ATPase	B-ENZY
expression	O
in	O
peripheral	O
lung	O
tissue	O
and	O
assessed	O
the	O
effect	O
of	O
alcohol	O
on	O
survival	O
during	O
exposure	O
to	O
hyperoxia	O
.	O

In	O
primary	O
rat	O
alveolar	O
type	O
II	O
cells	O
alcohol	O
and	O
adenosine	O
decreased	O
the	O
abundance	O
of	O
the	O
Na	O
,	O
K	O
-	O
ATPase	B-ENZY
at	O
the	O
basolateral	O
membrane	O
via	O
a	O
mechanism	O
that	O
required	O
activation	O
of	O
the	O
AMPK	B-ENZY
.	O

Mini	O
BAL	B-ENZY
was	O
performed	O
using	O
standardized	O
protocols	O
.	O

Most	O
differences	O
between	O
the	O
bat	B-ENZY
-	O
SARS	O
-	O
CoV	O
and	O
SARS	O
-	O
CoV	O
genomes	O
were	O
observed	O
in	O
the	O
spike	O
gene	O
.	O

Here	O
we	O
show	O
that	O
human	O
coronavirus	O
(	O
HCoV	O
)	O
NL63	O
and	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
CoV	O
papain	B-ENZY
-	O
like	O
proteases	O
(	O
PLP	O
)	O
antagonize	O
innate	O
immune	O
signaling	O
mediated	O
by	O
STING	O
(	O
stimulator	O
of	O
interferon	O
genes	O
,	O
also	O
known	O
as	O
MITA	O
/	O
ERIS	O
/	O
MYPS	O
).	O

As	O
compared	O
to	O
that	O
of	O
pre	O
-	O
treatment	O
period	O
,	O
white	O
blood	O
cells	O
[	O
WBC	O
,	O
	O
10	O
(	O
9	O
)/	O
L	O
:	O
12	O
.	O
18	O
	O
4	O
.	O
76	O
vs	O
.	O
21	O
.	O
93	O
	O
6	O
.	O
21	O
],	O
neutrophil	O
percentage	O
(	O
0	O
.	O
87	O
	O
0	O
.	O
05	O
vs	O
.	O
0	O
.	O
92	O
	O
0	O
.	O
03	O
),	O
hemoglobin	O
(	O
Hb	O
,	O
g	O
/	O
L	O
:	O
128	O
.	O
12	O
	O
25	O
.	O
65	O
vs	O
.	O
173	O
.	O
71	O
	O
23	O
.	O
53	O
),	O
blood	O
platelet	O
count	O
[	O
PLT	O
,	O
10	O
(	O
9	O
)/	O
L	O
:	O
165	O
.	O
12	O
	O
31	O
.	O
70	O
vs	O
.	O
254	O
.	O
47	O
	O
70	O
.	O
80	O
],	O
alanine	B-ENZY
transaminase	I-ENZY
(	O
ALT	O
,	O
U	O
/	O
L	O
:	O
70	O
.	O
71	O
	O
46	O
.	O
70	O
vs	O
.	O
212	O
.	O
71	O
	O
141	O
.	O
34	O
),	O
aspartate	B-ENZY
aminotransferase	I-ENZY
(	O
AST	B-ENZY
,	O
U	O
/	O
L	O
:	O
52	O
.	O
47	O
	O
34	O
.	O
68	O
vs	O
.	O
82	O
.	O
41	O
	O
34	O
.	O
60	O
),	O
blood	O
urea	O
nitrogen	O
(	O
BUN	O
,	O
mmol	O
/	O
L	O
:	O
5	O
.	O
83	O
	O
4	O
.	O
09	O
vs	O
.	O
7	O
.	O
89	O
	O
5	O
.	O
96	O
),	O
serum	O
creatinine	O
(	O
SCr	O
,	O
mol	O
/	O
L	O
:	O
48	O
.	O
13	O
	O
14	O
.	O
97	O
vs	O
.	O
67	O
.	O
25	O
	O
24	O
.	O
29	O
),	O
lactate	O
dehydrogenase	O
(	O
LDH	O
,	O
U	O
/	O
L	O
:	O
280	O
.	O
10	O
	O
81	O
.	O
77	O
vs	O
.	O
586	O
.	O
35	O
	O
186	O
.	O
71	O
),	O
creatine	B-ENZY
kinase	I-ENZY
(	O
CK	O
,	O
U	O
/	O
L	O
:	O
199	O
.	O
12	O
	O
106	O
.	O
75	O
vs	O
.	O
683	O
.	O
00	O
	O
323	O
.	O
21	O
),	O
MB	O
isoenzyme	O
of	O
creatine	B-ENZY
kinase	I-ENZY
(	O
CK	O
-	O
MB	O
,	O
U	O
/	O
L	O
:	O
26	O
.	O
94	O
	O
9	O
.	O
13	O
vs	O
.	O
45	O
.	O
59	O
	O
11	O
.	O
21	O
),	O
serum	O
chlorine	O
anion	O
[	O
Cl	O
(-),	O
mmol	O
/	O
L	O
:	O
95	O
.	O
88	O
	O
6	O
.	O
06	O
vs	O
.	O
102	O
.	O
29	O
	O
7	O
.	O
28	O
],	O
respiratory	O
rate	O
(	O
RR	O
,	O
beats	O
/	O
min	O
:	O
20	O
.	O
88	O
	O
4	O
.	O
30	O
vs	O
.	O
30	O
.	O
06	O
	O
5	O
.	O
78	O
),	O
heart	O
rate	O
(	O
HR	O
,	O
beats	O
/	O
min	O
:	O
82	O
.	O
76	O
	O
17	O
.	O
16	O
vs	O
.	O
113	O
.	O
35	O
	O
16	O
.	O
90	O
),	O
blood	O
pH	O
value	O
(	O
7	O
.	O
34	O
	O
0	O
.	O
44	O
vs	O
.	O
7	O
.	O
39	O
	O
0	O
.	O
03	O
)	O
were	O
all	O
decreased	O
(	O
P	O
<	O
0	O
.	O
05	O
or	O
P	O
<	O
0	O
.	O
01	O
).	O

ABSTRACT	O
:	O
Compare	O
real	O
-	O
time	O
reverse	O
transcription	O
polymerase	O
chain	O
reaction	O
(	O
qRT	O
-	O
PCR	O
),	O
a	O
commercially	O
available	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
and	O
lateral	O
flow	O
immunochromatography	O
assay	O
(	O
LAT	B-ENZY
)	O
for	O
the	O
detection	O
of	O
rotavirus	O
and	O
coronavirus	O
in	O
faecal	O
samples	O
collected	O
from	O
diarrhoeic	O
calves	O
.	O

TITLE	O
:	O
Generation	O
of	O
a	O
mouse	O
scFv	O
library	O
specific	O
for	O
porcine	O
aminopeptidase	B-ENZY
N	I-ENZY
using	O
the	O
T7	O
phage	O
display	O
system	O
.	O

In	O
the	O
absence	O
of	O
TMPRSS2	O
,	O
SARS	O
-	O
CoV	O
achieves	O
cell	O
entry	O
via	O
an	O
endosomal	O
pathway	O
in	O
which	O
cathepsin	B-ENZY
L	I-ENZY
may	O
play	O
an	O
important	O
role	O
,	O
i	O
.	O
e	O
.,	O
the	O
activation	O
of	O
spike	O
protein	O
fusogenicity	O
.	O

ABSTRACT	O
:	O
Abdominal	O
compartment	O
syndrome	O
(	O
ACS	B-ENZY
)	O
is	O
defined	O
as	O
an	O
elevated	O
intraabdominal	O
pressure	O
with	O
evidence	O
of	O
organ	O
dysfunction	O
.	O

TITLE	O
:	O
Development	O
of	O
a	O
series	O
of	O
3	O
-	O
hydroxyquinolin	O
-	O
2	O
(	O
1H	O
)-	O
ones	O
as	O
selective	O
inhibitors	O
of	O
HIV	O
-	O
1	O
reverse	B-ENZY
transcriptase	I-ENZY
associated	O
RNase	B-ENZY
H	I-ENZY
activity	O
.	O

Numerous	O
studies	O
have	O
been	O
carried	O
out	O
to	O
identify	O
new	O
bat	B-ENZY
viruses	O
related	O
to	O
SARS	O
-	O
coronavirus	O
(	O
bat	B-ENZY
-	O
SARS	O
-	O
like	O
CoVs	O
)	O
using	O
a	O
reverse	O
-	O
transcribed	O
-	O
polymerase	O
chain	O
reaction	O
assay	O
.	O

An	O
ns2	O
mutant	O
virus	O
was	O
unable	O
to	O
replicate	O
in	O
the	O
liver	O
or	O
induce	O
hepatitis	O
in	O
wild	O
-	O
type	O
mice	O
,	O
but	O
was	O
highly	O
pathogenic	O
in	O
RNase	B-ENZY
L	O
deficient	O
mice	O
.	O

In	O
fact	O
,	O
m	B-ENZY
-	I-ENZY
calpain	I-ENZY
inhibition	O
with	O
MDL28170	O
resulted	O
in	O
an	O
even	O
more	O
pronounced	O
inhibition	O
of	O
SARS	O
-	O
CoV	O
replication	O
(>	O
7	O
orders	O
of	O
magnitude	O
)	O
than	O
did	O
MG132	O
.	O

Other	O
enteropathogens	O
identified	O
in	O
cats	O
with	O
and	O
without	O
diarrhea	O
included	O
Clostridium	O
perfringens	O
enterotoxin	O
A	O
(	O
42	O
%	O
and	O
50	O
%,	O
respectively	O
),	O
Cryptosporidium	O
spp	B-ENZY
(	O
10	O
%	O
and	O
20	O
%,	O
respectively	O
),	O
Giardia	O
spp	B-ENZY
(	O
20	O
%	O
and	O
8	O
%,	O
respectively	O
),	O
Cystoisospora	O
spp	B-ENZY
(	O
14	O
%	O
and	O
10	O
%,	O
respectively	O
),	O
hookworms	O
(	O
10	O
%	O
and	O
18	O
%,	O
respectively	O
),	O
ascarids	O
(	O
6	O
%	O
and	O
16	O
%,	O
respectively	O
),	O
Salmonella	O
spp	B-ENZY
(	O
6	O
%	O
and	O
4	O
%,	O
respectively	O
),	O
astrovirus	O
(	O
8	O
%	O
and	O
2	O
%,	O
respectively	O
),	O
feline	O
panleukopenia	O
virus	O
(	O
4	O
%	O
and	O
4	O
%,	O
respectively	O
),	O
calicivirus	O
(	O
0	O
%	O
and	O
2	O
%,	O
respectively	O
),	O
and	O
Spirometra	O
spp	B-ENZY
(	O
0	O
%	O
and	O
2	O
%,	O
respectively	O
).	O

Impaired	O
gas	B-ENZY
exchange	O
in	O
influenza	O
-	O
infected	O
mice	O
was	O
accompanied	O
by	O
progressive	O
hemoglobin	O
desaturation	O
,	O
hypercapnia	O
,	O
uncompensated	O
respiratory	O
acidosis	O
,	O
hyperkalemia	O
,	O
and	O
polycythemia	O
.	O

In	O
""""	O
spike	O
-	O
in	O
""""	O
experiments	O
using	O
serial	O
dilutions	O
of	O
each	O
pathogen	O
,	O
the	O
analytical	O
sensitivity	O
was	O
determined	O
to	O
be	O
<	O
10	O
TCID	O
(	O
50	O
)/	O
ml	O
for	O
BCV	O
and	O
BRV	O
,	O
and	O
<	O
20	O
oocysts	O
for	O
Cryptosporidium	O
spp	B-ENZY
.	O

Myeloperoxidase	B-ENZY
(	O
MPO	O
)	O
activity	O
in	O
lung	O
tissue	O
was	O
reduced	O
in	O
the	O
MCR	O
-	O
LPS	O
and	O
LPS	O
-	O
MCR	O
groups	O
at	O
16h	O
after	O
LPS	O
administration	O
.	O

RESULTS	O
:	O
The	O
levels	O
of	O
creatine	B-ENZY
kinase	I-ENZY
(	O
CK	B-ENZY
),	O
creatine	B-ENZY
kinase	I-ENZY
-	O
MB	O
(	O
CK	B-ENZY
-	O
MB	O
)	O
and	O
cardiac	O
troponin	O
I	O
(	O
cTnI	O
)	O
in	O
milder	O
,	O
moderate	O
and	O
severe	O
poisoning	O
groups	O
were	O
significantly	O
elevated	O
compared	O
by	O
the	O
healthy	O
control	O
group	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

TITLE	O
:	O
Recent	O
transmission	O
of	O
a	O
novel	O
alphacoronavirus	O
,	O
bat	B-ENZY
coronavirus	O
HKU10	O
,	O
from	O
Leschenault	O
'	O
s	O
rousettes	O
to	O
pomona	O
leaf	O
-	O
nosed	O
bats	O
:	O
first	O
evidence	O
of	O
interspecies	O
transmission	O
of	O
coronavirus	O
between	O
bats	O
of	O
different	O
suborders	O
.	O

Results	O
point	O
to	O
SARS	O
-	O
CoV	O
PLpro	O
triggering	O
TGF	O
-	O
1	O
production	O
via	O
ubiquitin	O
proteasome	B-ENZY
,	O
p38	O
MAPK	B-ENZY
,	O
and	O
ERK1	O
/	O
2	O
-	O
mediated	O
signaling	O
.	O

Accompanying	O
MHV	O
-	O
1	O
infection	O
we	O
observe	O
an	O
increase	O
in	O
the	O
number	O
of	O
neutrophils	O
infiltrating	O
the	O
BAL	B-ENZY
and	O
an	O
increase	O
in	O
the	O
percentage	O
of	O
neutrophils	O
in	O
the	O
lung	O
draining	O
lymph	O
nodes	O
of	O
ps20	O
(-/-)	O
compared	O
with	O
ps20	O
(+/+)	O
mice	O
.	O

Further	O
,	O
we	O
developed	O
immortalized	O
bat	B-ENZY
cell	O
lines	O
from	O
the	O
lungs	O
of	O
this	O
bat	B-ENZY
species	O
to	O
determine	O
if	O
these	O
cells	O
were	O
capable	O
of	O
supporting	O
infection	O
with	O
HCoVs	O
.	O

While	O
SARS	O
-	O
CoV	O
,	O
mouse	O
-	O
adapted	O
SARS	O
-	O
CoV	O
(	O
MA15	O
),	O
and	O
chimeric	O
SARS	O
-	O
CoVs	O
bearing	O
the	O
spike	O
genes	O
of	O
early	O
human	O
strains	O
replicated	O
inefficiently	O
,	O
HCoV	O
-	O
NL63	O
replicated	O
for	O
multiple	O
passages	O
in	O
the	O
immortalized	O
lung	O
cells	O
from	O
this	O
bat	B-ENZY
species	O
.	O

Interestingly	O
,	O
cellular	O
furin	B-ENZY
abundance	O
in	O
five	O
human	O
cell	O
lines	O
was	O
shown	O
to	O
be	O
strongly	O
correlated	O
with	O
productive	O
IBV	O
infection	O
.	O

Cleavage	O
of	O
IBV	O
spike	O
protein	O
by	O
furin	B-ENZY
may	O
contribute	O
to	O
the	O
productive	O
IBV	O
infection	O
in	O
these	O
cells	O
.	O

RESULTS	O
:	O
BCoV	O
was	O
detected	O
in	O
nasal	O
swabs	O
and	O
pulmonary	O
lesions	O
using	O
real	O
-	O
time	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
chain	O
reaction	O
(	O
qRT	O
-	O
PCR	O
)	O
assay	O
and	O
virus	O
isolation	O
.	O

ABSTRACT	O
:	O
Epoprostenol	O
(	O
Flolan	O
),	O
an	O
inhalational	O
epoprostenol	O
vasodilator	O
,	O
increases	O
pulmonary	O
arterial	O
flow	O
and	O
decreases	O
pulmonary	O
pressures	O
,	O
thereby	O
improving	O
gas	B-ENZY
exchange	O
and	O
arterial	O
oxygenation	O
.	O

ABSTRACT	O
:	O
The	O
HIV	O
-	O
1	O
reverse	B-ENZY
transcriptase	I-ENZY
(	O
RT	O
)	O
is	O
one	O
of	O
the	O
most	O
attracting	O
targets	O
for	O
the	O
development	O
of	O
early	O
phase	O
infection	O
inhibitors	O
.	O

So	O
far	O
,	O
no	O
drugs	O
are	O
available	O
for	O
the	O
inhibition	O
of	O
the	O
RT	O
associated	O
ribonuclease	B-ENZY
H	I-ENZY
function	O
(	O
RNase	B-ENZY
H	I-ENZY
),	O
which	O
plays	O
an	O
essential	O
role	O
in	O
the	O
HIV	O
replication	O
cycle	O
.	O

Six	O
series	O
of	O
new	O
AQ	O
derivatives	O
with	O
various	O
substituents	O
at	O
positions	O
1	O
,	O
2	O
,	O
3	O
and	O
4	O
of	O
the	O
AQ	O
ring	O
were	O
tested	O
,	O
and	O
new	O
analogs	O
able	O
to	O
inhibit	O
HIV	O
-	O
1	O
RT	O
-	O
associated	O
RNase	B-ENZY
H	I-ENZY
activity	O
in	O
the	O
low	O
micromolar	O
range	O
were	O
found	O
.	O

RESULTS	O
:	O
Six	O
series	O
of	O
new	O
AQ	O
derivatives	O
with	O
various	O
substituents	O
at	O
positions	O
1	O
,	O
2	O
,	O
3	O
and	O
4	O
of	O
the	O
AQ	O
ring	O
were	O
tested	O
,	O
and	O
new	O
analogs	O
able	O
to	O
inhibit	O
HIV	O
-	O
1	O
RT	O
-	O
associated	O
RNase	B-ENZY
H	I-ENZY
activity	O
in	O
the	O
low	O
micromolar	O
range	O
were	O
found	O
.	O

The	O
limit	O
of	O
detection	O
(	O
LOD	B-ENZY
)	O
was	O
1	O
.	O
31	O
plaque	O
-	O
forming	O
units	O
(	O
PFU	O
)/	O
mL	O
for	O
human	O
rhinoviruses	O
(	O
hRVs	O
),	O
4	O
.	O
93	O
PFU	O
/	O
mL	O
for	O
human	O
coronavirus	O
HCoV	O
-	O
229E	O
/	O
NL63	O
,	O
2	O
.	O
67	O
PFU	O
/	O
mL	O
for	O
human	O
coronavirus	O
HCoV	O
-	O
OC43	O
,	O
18	O
.	O
20	O
PFU	O
/	O
mL	O
for	O
parainfluenza	O
virus	O
1	O
(	O
PIV	O
)-	O
1	O
,	O
24	O
.	O
57	O
PFU	O
/	O
mL	O
for	O
PIV	O
-	O
2	O
,	O
1	O
.	O
73	O
PFU	O
/	O
mL	O
for	O
PIV	O
-	O
3	O
,	O
1	O
.	O
79	O
PFU	O
/	O
mL	O
for	O
influenza	O
virus	O
group	O
(	O
Flu	O
)	O
A	O
,	O
59	O
.	O
51	O
PFU	O
/	O
mL	O
for	O
FluB	O
,	O
5	O
.	O
46	O
PFU	O
/	O
mL	O
for	O
human	O
respiratory	O
syncytial	O
virus	O
(	O
hRSV	O
)-	O
A	O
,	O
17	O
.	O
23	O
PFU	O
/	O
mL	O
for	O
hRSV	O
-	O
B	O
,	O
9	O
.	O
99	O
PFU	O
/	O
mL	O
for	O
human	O
adenovirus	O
(	O
ADVs	O
).	O

Clinical	O
and	O
radiological	O
examination	O
revealed	O
a	O
shocked	O
patient	O
with	O
dramatic	O
free	O
intra	O
-	O
abdominal	O
gas	B-ENZY
and	O
signs	O
of	O
abdominal	O
compartment	O
syndrome	O
,	O
which	O
was	O
treated	O
with	O
needle	O
decompression	O
.	O

HCoV	O
-	O
EMC	O
/	O
2012	O
may	O
be	O
most	O
closely	O
related	O
to	O
a	O
coronavirus	O
detected	O
in	O
Pipistrellus	O
pipistrellus	O
in	O
The	O
Netherlands	O
,	O
but	O
because	O
only	O
a	O
short	O
sequence	O
from	O
the	O
most	O
conserved	O
part	O
of	O
the	O
RNA	O
-	O
dependent	O
RNA	O
polymerase	O
-	O
encoding	O
region	O
of	O
the	O
genome	O
was	O
reported	O
for	O
this	O
bat	B-ENZY
virus	O
,	O
its	O
genetic	O
distance	O
from	O
HCoV	O
-	O
EMC	O
remains	O
uncertain	O
.	O

TITLE	O
:	O
Comparative	O
analysis	O
of	O
bat	B-ENZY
genomes	O
provides	O
insight	O
into	O
the	O
evolution	O
of	O
flight	O
and	O
immunity	O
.	O

To	O
identify	O
genetic	O
changes	O
associated	O
with	O
the	O
development	O
of	O
bat	B-ENZY
-	O
specific	O
traits	O
,	O
we	O
performed	O
whole	O
-	O
genome	O
sequencing	O
and	O
comparative	O
analyses	O
of	O
two	O
distantly	O
related	O
species	O
,	O
fruit	O
bat	B-ENZY
Pteropus	O
alecto	O
and	O
insectivorous	O
bat	B-ENZY
Myotis	O
davidii	O
.	O

The	O
retrospective	O
observational	O
study	O
included	O
all	O
mechanically	O
ventilated	O
adult	O
patients	O
of	O
three	O
university	O
-	O
affiliated	O
hospitals	O
between	O
November	O
1	O
,	O
2009	O
and	O
March	O
1	O
2010	O
who	O
had	O
2009	O
H1N1	O
influenza	O
infection	O
confirmed	O
by	O
real	O
-	O
time	O
reverse	B-ENZY
transcriptase	I-ENZY
-	O
polymerase	O
-	O
chain	O
-	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
from	O
nasopharyngeal	O
swab	O
specimens	O
and	O
respiratory	O
secretions	O
.	O

The	O
data	O
included	O
general	O
condition	O
before	O
EMCO	O
,	O
blood	O
gas	B-ENZY
analysis	O
,	O
hemodynamics	O
,	O
ventilator	O
settings	O
of	O
mechanical	O
ventilation	O
and	O
complications	O
during	O
ECMO	O
.	O

Unlike	O
SARS	O
-	O
CoV	O
,	O
HCoV	O
-	O
EMC	O
can	O
directly	O
infect	O
bat	B-ENZY
cells	O
.	O

ABSTRACT	O
:	O
Angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
)	O
is	O
a	O
negative	O
regulator	O
of	O
the	O
renin	B-ENZY
-	O
angiotensin	O
system	O
,	O
and	O
functions	O
as	O
the	O
key	O
SARS	O
coronavirus	O
receptor	O
and	O
stabilizer	O
of	O
neutral	O
amino	O
acid	O
transporters	O
.	O

We	O
genotyped	O
the	O
insertion	O
/	O
deletion	O
polymorphism	O
of	O
the	O
angiotensin	O
-	O
converting	O
enzyme	O
(	O
ACE	B-ENZY
)	O
gene	O
(	O
polymerase	O
chain	O
reaction	O
)	O
and	O
the	O
following	O
single	O
-	O
nucleotide	O
polymorphisms	O
(	O
TaqMan	O
SNP	O
genotyping	O
assay	O
):	O
tumor	O
necrosis	O
factor	O
	O
-	O
376	O
G	O
/	O
A	O
,	O
-	O
308	O
G	O
/	O
A	O
,	O
and	O
-	O
238	O
G	O
/	O
A	O
;	O
interleukin	O
8	O
-	O
251	O
T	O
/	O
A	O
;	O
pre	O
-	O
B	O
cell	O
colony	O
-	O
enhancing	O
factor	O
-	O
1001	O
G	O
/	O
T	O
;	O
and	O
vascular	O
endothelial	O
growth	O
factor	O
+	O
405	O
C	O
/	O
G	O
and	O
+	O
936	O
C	O
/	O
T	O
.	O
Polymorphisms	O
were	O
selected	O
based	O
on	O
reports	O
on	O
their	O
association	O
with	O
ARDS	O
.	O

The	O
presence	O
of	O
the	O
allele	O
D	O
of	O
the	O
ACE	B-ENZY
gene	O
is	O
associated	O
with	O
ARDS	O
in	O
patients	O
with	O
severe	O
sepsis	O
.	O

After	O
adjustment	O
for	O
those	O
variables	O
,	O
the	O
presence	O
of	O
the	O
allele	O
D	O
of	O
the	O
ACE	B-ENZY
gene	O
(	O
odds	O
ratio	O
,	O
4	O
.	O
75	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1	O
.	O
02	O
-	O
22	O
.	O
20	O
;	O
P	O
=	O
0	O
.	O
048	O
)	O
was	O
significantly	O
associated	O
with	O
the	O
diagnosis	O
of	O
ARDS	O
.	O

TITLE	O
:	O
Deubiquitinase	O
function	O
of	O
arterivirus	O
papain	B-ENZY
-	O
like	O
protease	O
2	O
suppresses	O
the	O
innate	O
immune	O
response	O
in	O
infected	O
host	O
cells	O
.	O

IAH	O
and	O
ACS	B-ENZY
are	O
relatively	O
frequent	O
findings	O
in	O
patiens	O
with	O
severe	O
acute	O
pancreatitis	O
(	O
SAP	O
)	O
and	O
are	O
associated	O
with	O
deterioration	O
in	O
organ	O
functions	O
.	O

ABSTRACT	O
:	O
In	O
continuation	O
of	O
our	O
efforts	O
toward	O
identification	O
and	O
optimization	O
of	O
novel	O
non	O
-	O
nucleoside	O
reverse	B-ENZY
transcriptase	I-ENZY
inhibitors	O
(	O
NNRTIs	O
),	O
we	O
have	O
employed	O
a	O
structure	O
-	O
based	O
bioisosterism	O
strategy	O
,	O
with	O
which	O
a	O
new	O
series	O
of	O
diarylpyridazine	O
(	O
DAPD	O
)	O
derivatives	O
were	O
synthesized	O
and	O
evaluated	O
for	O
their	O
anti	O
-	O
HIV	O
-	O
1	O
(	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
)	O
activity	O
.	O

BOS	O
,	O
but	O
especially	O
RAS	O
patients	O
,	O
experienced	O
more	O
frequent	O
episodes	O
of	O
increased	O
BAL	B-ENZY
eosinophilia	O
(	O
2	O
%;	O
P	O
<	O
0	O
.	O
0001	O
).	O

Eight	O
markers	O
(	O
Bartonella	O
spp	B-ENZY
,	O
CD11d	O
,	O
high	O
molecular	O
weight	O
cytokeratins	O
,	O
feline	O
coronavirus	O
,	O
GATA	O
-	O
4	O
,	O
insulin	O
,	O
p63	O
,	O
progesterone	O
receptor	O
)	O
had	O
minimal	O
decrease	O
in	O
immunoreactivity	O
,	O
regardless	O
of	O
treatment	O
.	O

The	O
sequences	O
clustered	O
along	O
with	O
bat	B-ENZY
alphacoronaviruses	O
,	O
forming	O
a	O
subcluster	O
within	O
this	O
group	O
.	O

Here	O
,	O
we	O
explore	O
the	O
viruses	O
of	O
Eidolon	O
helvum	O
,	O
an	O
Old	O
World	O
fruit	O
bat	B-ENZY
species	O
widely	O
distributed	O
in	O
Africa	O
that	O
lives	O
in	O
close	O
proximity	O
to	O
humans	O
.	O

Acute	O
exposure	O
to	O
high	O
concentration	O
of	O
chlorine	O
gas	B-ENZY
causes	O
both	O
significant	O
short	O
and	O
long	O
term	O
respiratory	O
health	O
effects	O
.	O

Supportive	O
care	O
,	O
principally	O
with	O
mechanical	O
ventilation	O
,	O
remains	O
the	O
cornerstone	O
of	O
therapy	O
-	O
although	O
the	O
goals	O
of	O
this	O
support	O
have	O
changed	O
in	O
recent	O
years	O
-	O
from	O
maintaining	O
normal	O
physiological	O
parameters	O
to	O
avoiding	O
ventilator	O
-	O
induced	O
lung	O
injury	O
while	O
providing	O
adequate	O
gas	B-ENZY
exchange	O
.	O

These	O
findings	O
provide	O
new	O
insights	O
into	O
the	O
function	O
of	O
p53	O
and	O
p38	O
MAPK	B-ENZY
in	O
the	O
interaction	O
of	O
TGEV	O
with	O
host	O
cells	O
.	O

TITLE	O
:	O
Upregulation	O
of	O
CHOP	O
/	O
GADD153	O
during	O
coronavirus	O
infectious	O
bronchitis	O
virus	O
infection	O
modulates	O
apoptosis	O
by	O
restricting	O
activation	O
of	O
the	O
extracellular	B-ENZY
signal	I-ENZY
-	I-ENZY
regulated	I-ENZY
kinase	I-ENZY
pathway	O
.	O

TITLE	O
:	O
Suppression	O
of	O
coronavirus	O
replication	O
by	O
cyclophilin	B-ENZY
inhibitors	O
.	O

ABSTRACT	O
:	O
Non	O
-	O
invasive	O
ventilation	O
(	O
NIV	O
)	O
is	O
contraindicated	O
or	O
at	O
least	O
not	O
recommended	O
in	O
patients	O
with	O
altered	O
consciousness	O
syndrome	O
(	O
ACS	B-ENZY
)	O
given	O
to	O
the	O
poor	O
compliance	O
of	O
confused	O
/	O
agitated	O
patients	O
,	O
difficult	O
management	O
of	O
accumulated	O
secretion	O
in	O
depressed	O
cough	O
reflex	O
,	O
and	O
risk	O
of	O
aspirative	O
pneumonia	O
in	O
absence	O
of	O
airways	O
protection	O
.	O

ABSTRACT	O
:	O
While	O
the	O
novel	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
is	O
closely	O
related	O
to	O
Tylonycteris	O
bat	B-ENZY
CoV	O
HKU4	O
(	O
Ty	O
-	O
BatCoV	O
HKU4	O
)	O
and	O
Pipistrellus	O
bat	B-ENZY
CoV	O
HKU5	O
(	O
Pi	O
-	O
BatCoV	O
HKU5	O
)	O
in	O
bats	O
from	O
Hong	O
Kong	O
,	O
and	O
other	O
potential	O
lineage	O
C	O
betacoronaviruses	O
in	O
bats	O
from	O
Africa	O
,	O
Europe	O
,	O
and	O
America	O
,	O
its	O
animal	O
origin	O
remains	O
obscure	O
.	O

Ty	O
-	O
BatCoV	O
HKU4	O
and	O
Pi	O
-	O
BatCoV	O
HKU5	O
were	O
detected	O
in	O
29	O
%	O
and	O
25	O
%	O
of	O
alimentary	O
samples	O
from	O
lesser	O
bamboo	O
bat	B-ENZY
(	O
Tylonycteris	O
pachypus	O
)	O
and	O
Japanese	O
pipistrelle	O
(	O
Pipistrellus	O
abramus	O
),	O
respectively	O
.	O

All	O
FECVs	O
had	O
a	O
conserved	O
furin	B-ENZY
cleavage	O
motif	O
.	O

ABSTRACT	O
:	O
We	O
previously	O
developed	O
two	O
potent	O
chemical	O
classes	O
that	O
inhibit	O
the	O
essential	O
papain	B-ENZY
-	O
like	O
protease	O
(	O
PLpro	O
)	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
.	O

XILP	O
reduced	O
the	O
activity	O
of	O
HIV	O
-	O
1	O
reverse	B-ENZY
transcriptase	I-ENZY
with	O
an	O
IC50	O
of	O
11	O
.	O
1M	O
,	O
but	O
lacked	O
inhibitory	O
activity	O
toward	O
HIV	O
-	O
1	O
integrase	O
and	O
SARS	O
coronavirus	O
proteinase	O
.	O

Some	O
of	O
these	O
viruses	O
are	O
also	O
equipped	O
with	O
a	O
neuraminidase	B-ENZY
or	O
a	O
sialyl	O
-	O
O	O
-	O
acetyl	O
-	O
esterase	O
.	O

Whereas	O
sialic	O
acid	O
is	O
the	O
only	O
receptor	O
determinant	O
known	O
so	O
far	O
for	O
IBV	O
,	O
TGEV	O
requires	O
interaction	O
with	O
its	O
receptor	O
aminopeptidase	B-ENZY
N	I-ENZY
to	O
initiate	O
infection	O
of	O
cells	O
.	O

Prior	O
to	O
the	O
outbreak	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
),	O
about	O
60	O
bat	B-ENZY
virus	O
species	O
had	O
been	O
reported	O
.	O

The	O
pathogenesis	O
and	O
potential	O
threat	O
of	O
bat	B-ENZY
-	O
borne	O
viruses	O
to	O
public	O
health	O
remains	O
largely	O
unknown	O
.	O

Recent	O
advances	O
in	O
extracorporeal	O
gas	B-ENZY
exchange	O
technology	O
have	O
led	O
to	O
the	O
development	O
of	O
systems	O
designed	O
to	O
be	O
safer	O
and	O
simpler	O
by	O
focusing	O
on	O
the	O
clinical	O
benefits	O
of	O
partial	O
extracorporeal	O
carbon	O
dioxide	O
removal	O
(	O
ECCO	O

It	O
is	O
now	O
clear	O
that	O
MERS	O
-	O
CoV	O
is	O
transmissible	O
from	O
person	O
to	O
person	O
,	O
and	O
its	O
close	O
relationship	O
with	O
several	O
bat	B-ENZY
coronaviruses	O
suggests	O
that	O
these	O
animals	O
may	O
be	O
the	O
ultimate	O
source	O
of	O
the	O
infection	O
.	O

TITLE	O
:	O
Arginase	B-ENZY
1	O
:	O
an	O
unexpected	O
mediator	O
of	O
pulmonary	O
capillary	O
barrier	O
dysfunction	O
in	O
models	O
of	O
acute	O
lung	O
injury	O
.	O

Upon	O
activation	O
,	O
arginase	B-ENZY
competes	O
with	O
eNOS	O
for	O
the	O
substrate	O
l	O
-	O
arginine	O
,	O
as	O
such	O
impairing	O
eNOS	O
-	O
dependent	O
NO	O
generation	O
and	O
promoting	O
reactive	O
oxygen	O
species	O
generation	O
by	O
the	O
enzyme	O
.	O

This	O
mini	O
-	O
review	O
will	O
discuss	O
recent	O
findings	O
regarding	O
the	O
interaction	O
between	O
bacterial	O
toxins	O
and	O
arginase	B-ENZY
during	O
acute	O
lung	O
injury	O
and	O
will	O
as	O
such	O
address	O
the	O
role	O
of	O
arginase	B-ENZY
in	O
bacterial	O
toxin	O
-	O
induced	O
pulmonary	O
endothelial	O
barrier	O
dysfunction	O
.	O

Mammalian	O
coronaviruses	O
including	O
those	O
infect	O
humans	O
are	O
evolved	O
from	O
bat	B-ENZY
coronaviruses	O
.	O

Novel	O
circuit	O
components	O
for	O
temporary	O
MCS	B-ENZY
with	O
improved	O
haemodynamic	O
properties	O
may	O
improve	O
patients	O
'	O
outcome	O
and	O
reduce	O
system	O
-	O
related	O
morbidities	O
.	O

CONCLUSIONS	O
:	O
The	O
use	O
of	O
the	O
Deltastream	O
DP3	O
seems	O
to	O
be	O
safe	O
and	O
effective	O
for	O
MCS	B-ENZY
in	O
children	O
and	O
may	O
show	O
a	O
low	O
degree	O
of	O
haemolysis	O
.	O

In	O
this	O
commentary	O
,	O
the	O
authors	O
discuss	O
the	O
rationale	O
,	O
based	O
on	O
the	O
physiologic	O
principle	O
of	O
targeting	O
both	O
vital	O
organs	O
,	O
of	O
applying	O
high	O
-	O
frequency	O
oscillation	O
and	O
tracheal	O
gas	B-ENZY
insufflation	O
in	O
acute	O
respiratory	O
distress	O
syndrome	O
patients	O
with	O
traumatic	O
brain	O
injury	O
.	O

To	O
date	O
,	O
there	O
are	O
no	O
antiviral	O
drugs	O
or	O
specific	O
therapies	O
to	O
treat	O
MERS	O
-	O
CoV	O
.	O
To	O
rapidly	O
identify	O
potential	O
inhibitors	O
of	O
MERS	O
-	O
CoV	O
replication	O
,	O
we	O
expressed	O
the	O
papain	B-ENZY
-	O
like	O
protease	O
(	O
PLpro	O
)	O
and	O
the	O
3	O
-	O
chymotrypsin	B-ENZY
-	O
like	O
protease	O
(	O
3CLpro	O
)	O
from	O
MERS	O
-	O
CoV	O
and	O
developed	O
luciferase	B-ENZY
-	O
based	O
biosensors	O
to	O
monitor	O
protease	O
activity	O
in	O
cells	O
.	O

IL	O
-	O
21	O
receptor	O
deficiency	O
did	O
not	O
affect	O
peripheral	O
T	O
cell	O
activation	O
or	O
trafficking	O
,	O
but	O
dampened	O
granzyme	B-ENZY
B	I-ENZY
,	O
gamma	O
interferon	O
and	O
IL	O
-	O
10	O
expression	O
by	O
CNS	O
T	O
cells	O
and	O
reduced	O
serum	O
and	O
intrathecal	O
humoral	O
responses	O
.	O

Research	O
during	O
the	O
past	O
ten	O
years	O
has	O
revealed	O
the	O
existence	O
of	O
a	O
diverse	O
pool	O
of	O
coronaviruses	O
circulating	O
among	O
various	O
bat	B-ENZY
species	O
and	O
other	O
animals	O
,	O
suggesting	O
that	O
further	O
introductions	O
of	O
highly	O
pathogenic	O
coronaviruses	O
into	O
the	O
human	O
population	O
are	O
not	O
merely	O
probable	O
,	O
but	O
inevitable	O
.	O

Respiratory	O
viruses	O
were	O
identified	O
in	O
174	O
encounters	O
,	O
34	O
of	O
these	O
via	O
BAL	B-ENZY
.	O

This	O
led	O
to	O
a	O
""""	O
sponge	O
model	O
""""	O
as	O
a	O
wet	O
sponge	O
,	O
similar	O
to	O
a	O
heavy	O
edematous	O
lung	O
,	O
squeezes	O
out	O
the	O
gas	B-ENZY
in	O
the	O
most	O
dependent	O
regions	O
,	O
due	O
to	O
the	O
weight	O
-	O
related	O
increase	O
of	O
the	O
compressive	O
forces	O
.	O

To	O
test	O
for	O
conservation	O
of	O
nsp5	O
structure	O
-	O
function	O
determinants	O
,	O
we	O
engineered	O
chimeric	O
betacoronavirus	O
murine	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
genomes	O
encoding	O
nsp5	O
proteases	O
of	O
human	O
and	O
bat	B-ENZY
alphacoronaviruses	O
and	O
betacoronaviruses	O
.	O

The	O
present	O
study	O
describes	O
a	O
dynamic	O
mechanism	O
in	O
which	O
LIM	O
kinase	O
1	O
(	O
LIMK1	O
),	O
a	O
cofilin	O
kinase	O
,	O
and	O
slingshot	O
-	O
1Long	O
(	O
SSH	O
-	O
1L	O
),	O
a	O
cofilin	O
phosphatase	O
,	O
are	O
engaged	O
by	O
procoagulant	O
and	O
proinflammatory	O
mediator	O
thrombin	B-ENZY
to	O
regulate	O
these	O
responses	O
.	O

Fecal	O
samples	O
at	O
enrollment	O
and	O
exit	O
were	O
tested	O
for	O
E	O
.	O
coli	O
K99	O
,	O
Cryptosporidium	O
spp	B-ENZY
.,	O
rotavirus	O
and	O
coronavirus	O
.	O

MAb	O
2	O
-	O
4	O
exhibited	O
high	O
neutralizing	O
activity	O
against	O
natural	O
TNF	O
-	O
alpha	O
derived	O
from	O
FIPV	O
-	O
infected	O
macrophages	O
,	O
and	O
was	O
confirmed	O
to	O
inhibit	O
the	O
following	O
feline	O
TNF	O
-	O
alpha	O
-	O
induced	O
conditions	O
in	O
vitro	O
:	O
(	O
i	O
)	O
an	O
increase	O
in	O
the	O
survival	O
rate	O
of	O
neutrophils	O
from	O
cats	O
with	O
FIP	O
,	O
(	O
ii	O
)	O
aminopeptidase	B-ENZY
N	I-ENZY
(	O
APN	O
)	O
mRNA	O
expression	O
in	O
macrophages	O
,	O
and	O
(	O
iii	O
)	O
apoptosis	O
of	O
a	O
feline	O
T	O
-	O
lymphocyte	O
cell	O
line	O
.	O

MERS	O
pseudovirions	O
released	O
from	O
293T	O
cells	O
contained	O
only	O
uncleaved	O
S	O
,	O
and	O
pseudovirus	O
entry	O
was	O
blocked	O
by	O
lysosomotropic	O
reagents	O
NH4Cl	O
and	O
bafilomycin	O
and	O
inhibitors	O
of	O
cathepsin	B-ENZY
L	I-ENZY
.	O
However	O
,	O
when	O
MERS	O
pseudovirions	O
with	O
uncleaved	O
S	O
protein	O
were	O
adsorbed	O
at	O
4	O
	O
C	O
to	O
Vero	O
E6	O
cells	O
,	O
brief	O
trypsin	B-ENZY
treatment	O
at	O
neutral	O
pH	O
triggered	O
virus	O
entry	O
at	O
the	O
plasma	O
membrane	O
and	O
syncytia	O
formation	O
.	O

ABSTRACT	O
:	O
The	O
purified	O
C	O
subunit	O
of	O
the	O
recombinant	O
porcine	O
aminopeptidase	B-ENZY
N	I-ENZY
(	O
rpAPN	O
-	O
C	O
)	O
protein	O
was	O
used	O
as	O
an	O
immobilized	O
target	O
to	O
screen	O
potential	O
ligands	O
against	O
rpAPN	O
-	O
C	O
from	O
a	O
12	O
-	O
mer	O
phage	O
display	O
random	O
peptide	O
library	O
.	O

The	O
demographic	O
characteristics	O
of	O
patients	O
with	O
and	O
without	O
ACS	B-ENZY
were	O
similar	O
.	O

Among	O
trauma	O
and	O
surgical	O
patients	O
,	O
large	O
volume	O
crystalloid	O
resuscitation	O
and	O
markers	O
of	O
shock	O
/	O
hypotension	O
and	O
metabolic	O
derangement	O
/	O
organ	O
failure	O
were	O
risk	O
factors	O
for	O
IAH	O
and	O
ACS	B-ENZY
while	O
increased	O
disease	O
severity	O
scores	O
and	O
elevated	O
creatinine	O
were	O
risk	O
factors	O
for	O
ACS	B-ENZY
in	O
severe	O
acute	O
pancreatitis	O
patients	O
.	O

Furthermore	O
,	O
patients	O
experiencing	O
impaired	O
general	O
condition	O
at	O
follow	O
-	O
up	O
had	O
significantly	O
lower	O
gas	B-ENZY
diffusing	O
capacity	O
and	O
higher	O
pulmonary	O
vascular	O
resistance	O
,	O
compared	O
to	O
those	O
feeling	O
fully	O
recovered	O
.	O

TITLE	O
:	O
Ecology	O
,	O
evolution	O
and	O
classification	O
of	O
bat	B-ENZY
coronaviruses	O
in	O
the	O
aftermath	O
of	O
SARS	O
.	O

Blood	O
gas	B-ENZY
containing	O
,	O
A	O
-	O
aDO2	O
and	O
RI	O
were	O
studied	O
.	O

FiO	O
(	O
2	O
)	O
level	O
independently	O
predicted	O
outcome	O
in	O
infants	O
with	O
RSV	O
-	O
induced	O
ARDS	O
,	O
whereas	O
both	O
PEEP	O
and	O
the	O
PaO	B-ENZY
(	O
2	O
)/	O
FiO	O
(	O
2	O
)	O
ratio	O
did	O
not	O
.	O

ABSTRACT	O
:	O
Inhibiting	O
human	O
neutrophil	B-ENZY
elastase	I-ENZY
(	O
HNE	O
)	O
is	O
a	O
promising	O
strategy	O
for	O
treating	O
inflammatory	O
lung	O
diseases	O
,	O
such	O
as	O
H1N1	O
and	O
SARS	O
virus	O
infections	O
.	O

CPV	O
-	O
2	O
was	O
the	O
most	O
prevalent	O
pathogen	O
in	O
the	O
dual	O
co	O
-	O
infections	O
,	O
associated	O
with	O
CPA	O
,	O
Cryptosporidium	O
spp	B-ENZY
.,	O
or	O
Giardia	O
spp	B-ENZY
.	O

The	O
environmental	O
origin	O
of	O
MERS	O
-	O
CoV	O
is	O
as	O
yet	O
unknown	O
;	O
however	O
,	O
its	O
genome	O
sequence	O
is	O
closely	O
related	O
to	O
those	O
of	O
two	O
bat	B-ENZY
coronaviruses	O
,	O
named	O
BtCoV	O
-	O
HKU4	O
and	O
BtCoV	O
-	O
HKU5	O
,	O
which	O
were	O
derived	O
from	O
Chinese	O
bat	B-ENZY
samples	O
.	O

In	O
this	O
study	O
,	O
we	O
developed	O
a	O
novel	O
high	O
-	O
throughput	O
screening	O
assay	O
based	O
on	O
peptides	O
,	O
derived	O
from	O
the	O
glycoproteins	O
of	O
the	O
aforementioned	O
viruses	O
,	O
which	O
contain	O
the	O
cathepsin	B-ENZY
L	I-ENZY
cleavage	O
site	O
.	O

The	O
experiments	O
showed	O
that	O
myosin	B-ENZY
light	I-ENZY
chain	I-ENZY
kinase	I-ENZY
(	O
MLCK	B-ENZY
)	O
and	O
myosin	O
1	O
are	O
crucial	O
for	O
the	O
initiation	O
of	O
the	O
internalisation	O
.	O

Human	O
,	O
camel	O
,	O
and	O
horse	O
receptors	O
were	O
potent	O
and	O
nearly	O
equally	O
effective	O
MERS	O
virus	O
receptors	O
,	O
while	O
goat	O
and	O
bat	B-ENZY
receptors	O
were	O
considerably	O
less	O
effective	O
.	O

There	O
appeared	O
to	O
be	O
no	O
seasonal	O
influence	O
on	O
the	O
frequency	O
of	O
Giardia	O
spp	B-ENZY
.	O

A	O
mono	O
-	O
infection	O
with	O
Giardia	O
spp	B-ENZY
.	O

and	O
Eimeria	O
spp	B-ENZY
.	O
could	O
be	O
detected	O
in	O
646	O
/	O
1564	O
samples	O
(	O
41	O
.	O
3	O
%)	O
and	O
208	O
/	O
1564	O
samples	O
(	O
13	O
.	O
3	O
%),	O
respectively	O
,	O
with	O
a	O
mean	O
age	O
of	O
11	O
.	O
3	O
and	O
55	O
.	O
0	O
days	O
,	O
respectively	O
.	O

The	O
results	O
indicate	O
that	O
in	O
Southern	O
Germany	O
in	O
addition	O
to	O
Eimeria	O
spp	B-ENZY
.,	O
Giardia	O
spp	B-ENZY
.	O
seems	O
to	O
play	O
a	O
contributing	O
role	O
in	O
diarrhoea	O
in	O
older	O
calves	O
,	O
whereas	O
Cryptosporidium	O
spp	B-ENZY
.	O

Investigations	O
revealed	O
neutrophilic	O
leucocytosis	O
(	O
30	O
,	O
000	O
/	O
cubic	O
millimeter	O
;	O
86	O
%)	O
with	O
high	O
serum	O
lipase	B-ENZY
(	O
770	O
Unit	O
/	O
Liter	O
)	O
and	O
alanine	B-ENZY
transaminase	I-ENZY
(	O
379	O
Unit	O
/	O
Liter	O
)	O
and	O
low	O
serum	O
potassium	O
(	O
3	O
.	O
0	O
millimol	O
/	O
Liter	O
).	O

However	O
,	O
the	O
interaction	O
between	O
the	O
components	O
in	O
STING	O
-	O
TRAF3	O
-	O
TBK1	B-ENZY
complex	O
is	O
disrupted	O
by	O
PLpro	O
-	O
TM	O
.	O

Furthermore	O
,	O
SARS	O
PLpro	O
-	O
TM	O
reduces	O
the	O
levels	O
of	O
ubiquitinated	O
forms	O
of	O
RIG	O
-	O
I	O
,	O
STING	O
,	O
TRAF3	O
,	O
TBK1	B-ENZY
,	O
and	O
IRF3	O
in	O
the	O
STING	O
-	O
TRAF3	O
-	O
TBK1	B-ENZY
complex	O
.	O

The	O
primary	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
role	O
of	O
E	O
.	O
coli	O
,	O
Enterococcus	O
spp	B-ENZY
.,	O
C	O
.	O
perfringens	O
and	O
C	O
.	O
difficile	O
in	O
the	O
pathogenesis	O
of	O
neonatal	O
porcine	O
diarrhea	O
with	O
no	O
established	O
casual	O
agents	O
.	O

ABSTRACT	O
:	O
A	O
series	O
of	O
4	O
-(	O
naphthalen	O
-	O
1	O
-	O
yl	O
)-	O
1	O
,	O
2	O
,	O
5	O
-	O
thiadiazol	O
-	O
3	O
-	O
hydroxyl	O
derivatives	O
(	O
Ia	O
-	O
Im	O
and	O
IIa	O
-	O
IIe	O
)	O
designed	O
as	O
novel	O
HIV	O
-	O
1	O
non	O
-	O
nucleoside	O
reverse	B-ENZY
transcriptase	I-ENZY
inhibitors	O
(	O
NNRTIs	O
)	O
was	O
synthesized	O
via	O
an	O
expeditious	O
route	O
and	O
evaluated	O
for	O
their	O
anti	O
-	O
HIV	O
activities	O
in	O
MT	O
-	O
4	O
cell	O
cultures	O
.	O

Although	O
many	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
like	O
coronaviruses	O
(	O
SARS	O
-	O
like	O
CoVs	O
)	O
have	O
been	O
discovered	O
in	O
bats	O
worldwide	O
,	O
there	O
are	O
significant	O
different	O
genic	O
structures	O
,	O
particularly	O
in	O
the	O
S1	O
domain	O
,	O
which	O
are	O
responsible	O
for	O
host	O
tropism	O
determination	O
,	O
between	O
bat	B-ENZY
SARS	O
-	O
like	O
CoVs	O
and	O
human	O
SARS	O
CoVs	O
,	O
indicating	O
that	O
most	O
reported	O
bat	B-ENZY
SARS	O
-	O
like	O
CoVs	O
are	O
not	O
the	O
progenitors	O
of	O
human	O
SARS	O
CoV	O
.	O
We	O
have	O
identified	O
diverse	O
alphacoronaviruses	O
and	O
a	O
close	O
relative	O
(	O
LYRa11	O
)	O
to	O
SARS	O
CoV	O
in	O
bats	O
collected	O
in	O
Yunnan	O
,	O
China	O
.	O

Further	O
analysis	O
showed	O
that	O
alpha	O
-	O
and	O
betacoronaviruses	O
have	O
different	O
circulation	O
and	O
transmission	O
dynamics	O
in	O
bat	B-ENZY
populations	O
.	O

Male	O
C57BL	O
/	O
6	O
mice	O
were	O
exposed	O
to	O
low	O
-	O
tidal	O
-	O
volume	O
(	O
6	O
mL	O
/	O
kg	O
)	O
or	O
high	O
-	O
tidal	O
-	O
volume	O
(	O
30	O
mL	O
/	O
kg	O
)	O
mechanical	O
ventilation	O
using	O
room	O
air	O
with	O
or	O
without	O
2	O
g	O
/	O
g	O
NF	O
-	O
B	O
inhibitor	O
SN50	O
or	O
6	O
g	O
/	O
g	O
NRF	O
short	O
interfering	O
RNA	O
or	O
100	O
g	O
/	O
g	O
neutrophil	B-ENZY
elastase	I-ENZY
inhibitor	O
administration	O
.	O

Neutrophil	B-ENZY
elastase	I-ENZY
inhibitor	O
ameliorated	O
high	O
-	O
tidal	O
-	O
volume	O
ventilation	O
-	O
induced	O
lung	O
injury	O
,	O
neutrophil	O
influx	O
,	O
production	O
of	O
MIP	O
-	O
2	O
and	O
malondialdehyde	O
,	O
activation	O
of	O
NF	O
-	O
B	O
and	O
NRF	O
,	O
apoptotic	O
epithelial	O
cell	O
death	O
,	O
and	O
disruption	O
of	O
bronchial	O
microstructure	O
in	O
mice	O
.	O

Understanding	O
the	O
protective	O
effects	O
of	O
neutrophil	B-ENZY
elastase	I-ENZY
inhibitor	O
associated	O
with	O
the	O
reduction	O
of	O
MIP	O
-	O
2	O
allow	O
clarification	O
of	O
the	O
pathophysiological	O
mechanisms	O
regulating	O
severe	O
lung	O
inflammation	O
and	O
development	O
of	O
possible	O
therapeutic	O
strategies	O
involved	O
in	O
acute	O
lung	O
injury	O
.	O

On	O
an	O
evolutionary	O
scale	O
,	O
this	O
host	O
-	O
virus	O
interaction	O
might	O
have	O
resulted	O
in	O
the	O
large	O
diversity	O
of	O
zoonotic	O
viruses	O
in	O
bats	O
,	O
possibly	O
through	O
bat	B-ENZY
viruses	O
adapting	O
to	O
be	O
more	O
tolerant	O
of	O
the	O
fever	O
response	O
and	O
less	O
virulent	O
to	O
their	O
natural	O
hosts	O
.	O

Here	O
we	O
show	O
that	O
rhesus	O
macaques	O
infected	O
with	O
Sin	O
Nombre	O
virus	O
(	O
SNV	O
),	O
the	O
primary	O
etiological	O
agent	O
of	O
HPS	B-ENZY
in	O
North	O
America	O
,	O
propagated	O
in	O
deer	O
mice	O
develop	O
HPS	B-ENZY
,	O
which	O
is	O
characterized	O
by	O
thrombocytopenia	O
,	O
leukocytosis	O
,	O
and	O
rapid	O
onset	O
of	O
respiratory	O
distress	O
caused	O
by	O
severe	O
interstitial	O
pneumonia	O
.	O

We	O
anticipate	O
this	O
model	O
will	O
advance	O
our	O
understanding	O
of	O
HPS	B-ENZY
pathogenesis	O
and	O
will	O
greatly	O
facilitate	O
research	O
toward	O
the	O
development	O
of	O
effective	O
therapeutics	O
and	O
vaccines	O
against	O
hantaviral	O
diseases	O
.	O

Reduced	O
edema	O
correlated	O
with	O
lung	O
epithelia	O
integrity	O
and	O
proper	O
localization	O
of	O
Na	O
+/	O
K	O
+	O
ATPase	B-ENZY
,	O
which	O
participates	O
in	O
edema	O
resolution	O
.	O

Our	O
study	O
focused	O
on	O
the	O
role	O
of	O
protease	O
activity	O
on	O
infection	O
by	O
investigating	O
the	O
spike	O
protein	O
of	O
a	O
PEDV	O
isolate	O
(	O
wtPEDV	O
)	O
using	O
a	O
reverse	O
genetics	O
system	O
based	O
on	O
the	O
trypsin	B-ENZY
-	O
independent	O
cell	O
culture	O
-	O
adapted	O
strain	O
DR13	O
(	O
caPEDV	O
).	O

The	O
reservoir	O
is	O
probably	O
the	O
dromedary	O
camel	O
and	O
the	O
bat	B-ENZY
is	O
the	O
vector	O
.	O

TITLE	O
:	O
Porcine	O
epidemic	O
diarrhea	O
virus	O
nucleocapsid	O
protein	O
antagonizes	O
beta	O
interferon	O
production	O
by	O
sequestering	O
the	O
interaction	O
between	O
IRF3	O
and	O
TBK1	B-ENZY
.	O

TITLE	O
:	O
Papain	B-ENZY
-	O
like	O
protease	O
(	O
PLpro	O
)	O
inhibitory	O
effects	O
of	O
cinnamic	O
amides	O
from	O
Tribulus	O
terrestris	O
fruits	O
.	O

These	O
data	O
suggest	O
the	O
therapeutic	O
potential	O
of	O
GAPDH	B-ENZY
for	O
sepsis	O
-	O
related	O
ALI	O
/	O
ARDS	O
.	O

The	O
virus	O
,	O
tentatively	O
named	O
fruit	O
bat	B-ENZY
alphaherpesvirus	O
1	O
(	O
FBAHV1	O
),	O
has	O
a	O
double	O
-	O
stranded	O
DNA	O
genome	O
of	O
149	O
,	O
459	O
bp	O
.	O

We	O
suggest	O
the	O
possibility	O
that	O
viral	O
acquisition	O
of	O
the	O
host	O
AKAP7	O
PDE	O
domain	O
might	O
have	O
occurred	O
during	O
evolution	O
,	O
allowing	O
diverse	O
RNA	O
viruses	O
to	O
antagonize	O
the	O
RNase	B-ENZY
L	O
pathway	O
.	O

In	O
our	O
previous	O
work	O
,	O
we	O
showed	O
that	O
a	O
panel	O
of	O
murine	O
monoclonal	O
antibodies	O
(	O
mAbs	O
)	O
that	O
target	O
the	O
S2	O
subunit	O
of	O
the	O
S	O
protein	O
are	O
capable	O
of	O
neutralizing	O
SARS	O
-	O
CoV	O
infection	O
in	O
vitro	O
(	O
Lip	B-ENZY
KM	O
et	O
al	O
,	O
J	O
Virol	O
.	O

The	O
bat	B-ENZY
virus	O
roots	O
the	O
phylogenetic	O
tree	O
of	O
MERS	O
-	O
CoV	O
,	O
providing	O
evidence	O
for	O
an	O
evolution	O
of	O
MERS	O
-	O
CoV	O
in	O
camels	O
that	O
preceded	O
that	O
in	O
humans	O
.	O

Differences	O
between	O
dairy	O
and	O
beef	O
cows	O
in	O
the	O
number	O
of	O
cases	O
of	O
diarrhea	O
and	O
rates	O
of	O
infection	O
by	O
Salmonella	O
spp	B-ENZY
.	O

Efforts	O
at	O
predictive	O
structure	O
-	O
based	O
inhibitor	O
development	O
for	O
bat	B-ENZY
coronavirus	O
M	O
(	O
pro	O
)	O
s	O
to	O
increase	O
the	O
preparedness	O
against	O
zoonotic	O
transmission	O
to	O
man	O
are	O
described	O
as	O
well	O
.	O

The	O
ester	O
derivative	O
RDS1759	O
selectively	O
inhibited	O
RNase	B-ENZY
H	I-ENZY
activity	O
and	O
viral	O
replication	O
in	O
the	O
low	O
micromolar	O
range	O
,	O
making	O
contacts	O
with	O
residues	O
Q475	O
,	O
N474	O
,	O
and	O
Y501	O
.	O

Overall	O
,	O
we	O
provide	O
the	O
first	O
demonstration	O
that	O
RNase	B-ENZY
H	I-ENZY
inhibition	O
by	O
DKAs	O
is	O
due	O
not	O
only	O
to	O
their	O
chelating	O
properties	O
but	O
also	O
to	O
specific	O
interactions	O
with	O
highly	O
conserved	O
amino	O
acid	O
residues	O
in	O
the	O
RNase	B-ENZY
H	I-ENZY
domain	O
,	O
leading	O
to	O
effective	O
targeting	O
of	O
HIV	O
retrotranscription	O
in	O
cells	O
and	O
hence	O
offering	O
important	O
insights	O
for	O
the	O
rational	O
design	O
of	O
RNase	B-ENZY
H	I-ENZY
inhibitors	O
.	O

First	O
,	O
whereas	O
MERS	O
-	O
CoV	O
prefers	O
human	O
DPP4	O
over	O
bat	B-ENZY
DPP4	O
as	O
its	O
receptor	O
,	O
HKU4	O
shows	O
the	O
opposite	O
trend	O
.	O

Arterial	O
blood	O
gas	B-ENZY
analyses	O
were	O
performed	O
just	O
before	O
and	O
every	O
30	O
min	O
after	O
OA	O
challenge	O
.	O

Syntenin	O
redistributed	O
from	O
the	O
nucleus	O
to	O
the	O
cell	O
cytoplasm	O
during	O
infection	O
with	O
viruses	O
containing	O
the	O
E	O
protein	O
PBM	O
,	O
activating	O
p38	O
MAPK	B-ENZY
and	O
leading	O
to	O
the	O
overexpression	O
of	O
inflammatory	O
cytokines	O
.	O

Interestingly	O
,	O
administration	O
of	O
a	O
p38	O
MAPK	B-ENZY
inhibitor	O
led	O
to	O
an	O
increase	O
in	O
mice	O
survival	O
after	O
infection	O
with	O
SARS	O
-	O
CoV	O
,	O
confirming	O
the	O
relevance	O
of	O
this	O
pathway	O
in	O
SARS	O
-	O
CoV	O
virulence	O
.	O

ABSTRACT	O
:	O
The	O
papain	B-ENZY
-	O
like	O
protease	O
(	O
PLpro	O
)	O
domain	O
from	O
the	O
deadly	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
)	O
was	O
overexpressed	O
and	O
purified	O
.	O

Finally	O
,	O
the	O
PEDV	O
and	O
TGEV	O
infection	O
affected	O
the	O
MAPK	B-ENZY
pathway	O
,	O
and	O
inhibition	O
of	O
MAPK	B-ENZY
pathway	O
regulated	O
the	O
changes	O
of	O
tight	O
junctions	O
and	O
microfilaments	O
of	O
cells	O
.	O

Our	O
computational	O
data	O
are	O
in	O
line	O
with	O
available	O
experimental	O
results	O
,	O
such	O
as	O
X	O
-	O
ray	O
geometries	O
,	O
measured	O
pKa	B-ENZY
values	O
,	O
mutagenesis	O
experiments	O
,	O
and	O
the	O
measured	O
differences	O
between	O
the	O
kinetic	O
parameters	O
of	O
substrates	O
and	O
inhibitors	O
.	O

Our	O
findings	O
support	O
a	O
bat	B-ENZY
origin	O
for	O
MERS	O
-	O
CoV	O
and	O
indicate	O
the	O
need	O
for	O
surveillance	O
of	O
HKU4	O
-	O
related	O
viruses	O
in	O
bats	O
.	O

RESULTS	O
:	O
Significant	O
improvement	O
was	O
observed	O
in	O
HR	O
,	O
MAP	O
,	O
PaO2	O
/	O
FiO2	O
,	O
total	O
bilirubin	O
(	O
TBIL	O
)	O
and	O
alanine	B-ENZY
aminotransferase	I-ENZY
(	O
ALT	O
)	O
levels	O
after	O
treatment	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

However	O
,	O
the	O
stretch	O
-	O
induced	O
[	O
Ca	O
(	O
2	O
+)]	O
i	O
elevation	O
was	O
not	O
inhibited	O
by	O
ATP	O
diphosphohydrolase	O
apyrase	B-ENZY
or	O
a	O
purinergic	O
receptor	O
antagonist	O
suramin	O
.	O

Mitogen	B-ENZY
-	I-ENZY
activated	I-ENZY
protein	I-ENZY
kinase	I-ENZY
(	O
MAPK	B-ENZY
)	O
pathways	O
are	O
involved	O
in	O
cytokine	O
production	O
,	O
but	O
the	O
mechanisms	O
that	O
regulate	O
these	O
pathways	O
remain	O
poorly	O
characterized	O
.	O

Spred	O
-	O
2	O
controls	O
the	O
development	O
of	O
LPS	O
-	O
induced	O
lung	O
inflammation	O
by	O
negatively	O
regulating	O
the	O
ERK	B-ENZY
-	O
MAPK	B-ENZY
pathway	O
.	O

TITLE	O
:	O
Characterization	O
of	O
uncultivable	O
bat	B-ENZY
influenza	O
virus	O
using	O
a	O
replicative	O
synthetic	O
virus	O
.	O

The	O
aim	O
was	O
to	O
compare	O
the	O
results	O
of	O
IFAT	O
,	O
ELISA	O
and	O
PCR	O
and	O
to	O
investigate	O
the	O
possible	O
associations	O
between	O
seropositivity	O
to	O
Leishmania	O
spp	B-ENZY
and	O
signalment	O
,	O
living	O
conditions	O
,	O
season	O
of	O
sampling	O
,	O
health	O
status	O
of	O
the	O
cats	O
,	O
and	O
seropositivity	O
to	O
other	O
infectious	O
agents	O
.	O

Inhaled	O
nitric	O
oxide	O
as	O
the	O
first	O
vasodilator	O
to	O
produce	O
selective	O
pulmonary	O
vasodilation	O
has	O
beneficial	O
effects	O
on	O
gas	B-ENZY
exchange	O
and	O
ventilation	O
,	O
improving	O
outcome	O
in	O
children	O
with	O
severe	O
hypoxia	O
.	O

MERS	O
-	O
CoV	O
replication	O
depends	O
in	O
part	O
on	O
a	O
virus	O
-	O
encoded	O
papain	B-ENZY
-	O
like	O
protease	O
(	O
PL	O
(	O
pro	O
))	O
that	O
cleaves	O
the	O
viral	O
replicase	O
polyproteins	O
at	O
three	O
sites	O
releasing	O
non	O
-	O
structural	O
protein	O
1	O
(	O
nsp1	O
),	O
nsp2	O
,	O
and	O
nsp3	O
.	O

We	O
present	O
a	O
case	O
of	O
ACS	B-ENZY
managed	O
with	O
percutaneous	O
catheter	O
decompression	O
.	O

The	O
clinical	O
indications	O
for	O
,	O
and	O
the	O
use	O
of	O
,	O
ECMO	O
therapy	O
in	O
the	O
management	O
of	O
refractory	O
hypoxemia	O
is	O
briefly	O
reviewed	O
,	O
followed	O
by	O
a	O
description	O
of	O
how	O
ECMO	O
works	O
to	O
provide	O
gas	B-ENZY
exchange	O
and	O
tissue	O
perfusion	O
.	O

Gas	B-ENZY
distribution	O
in	O
LH	O
patients	O
was	O
analyzed	O
by	O
electric	O
impedance	O
tomography	O
.	O

For	O
many	O
emerging	O
bat	B-ENZY
viruses	O
,	O
spillover	O
also	O
requires	O
viral	O
shedding	O
from	O
bats	O
,	O
and	O
survival	O
of	O
the	O
virus	O
in	O
the	O
environment	O
.	O

The	O
increase	O
in	O
PGD	O
resulted	O
in	O
poorer	O
gas	B-ENZY
exchange	O
in	O
the	O
recipients	O
of	O
donor	O
lungs	O
from	O
heavy	O
alcohol	O
users	O
,	O
and	O
these	O
recipients	O
subsequently	O
required	O
mechanical	O
ventilation	O
for	O
a	O
longer	O
time	O
following	O
transplant	O
.	O

In	O
this	O
study	O
,	O
we	O
generated	O
a	O
novel	O
approximately	O
10	O
-	O
kb	O
molecular	O
data	O
set	O
of	O
19	O
nuclear	O
exon	O
and	O
intron	O
gene	O
fragments	O
for	O
40	O
bat	B-ENZY
species	O
to	O
elucidate	O
the	O
phylogenetic	O
relationships	O
within	O
the	O
families	O
Rhinolophidae	O
and	O
Hipposideridae	O
.	O

Trends	O
for	O
AST	B-ENZY
and	O
Plt	O
differed	O
significantly	O
between	O
the	O
recovery	O
and	O
progression	O
groups	O
in	O
the	O
first	O
48	O
hours	O
.	O

Since	O
indoleamine	O
-	O
2	O
,	O
3	O
-	O
dioxygenase	O
(	O
IDO	B-ENZY
)	O
is	O
the	O
key	O
and	O
rate	O
-	O
limiting	O
enzyme	O
of	O
tryptophan	O
catabolism	O
,	O
the	O
aim	O
of	O
this	O
work	O
was	O
to	O
explore	O
whether	O
specific	O
inhibition	O
of	O
IDO	B-ENZY
by	O
Levo	O
-	O
1	O
-	O
methyl	O
tryptophan	O
(	O
MT	O
)	O
could	O
affect	O
MHV	O
actions	O
.	O

Furthermore	O
,	O
histological	O
liver	O
examination	O
indicated	O
that	O
MT	O
induced	O
fibrosis	O
in	O
MHV	O
-	O
infected	O
animals	O
,	O
whereas	O
MT	O
itself	O
increased	O
uric	O
acid	O
levels	O
without	O
shortening	O
the	O
animal	O
life	O
Thus	O
,	O
under	O
our	O
experimental	O
conditions	O
,	O
results	O
indicated	O
an	O
exacerbated	O
response	O
to	O
MHV	O
infection	O
when	O
IDO	B-ENZY
was	O
blocked	O
by	O
MT	O
.	O

RdRp	O
sequences	O
allocated	O
all	O
Costa	O
Rican	O
bat	B-ENZY
CoVs	O
to	O
the	O
	O
-	O
CoV	O
group	O
.	O

In	O
this	O
study	O
,	O
we	O
analyzed	O
the	O
role	O
of	O
Na	O
(+),	O
K	O
(+)-	O
ATPase	B-ENZY
and	O
,	O
in	O
particular	O
,	O
of	O
its	O
ATP1A1	O
	O
subunit	O
during	O
coronavirus	O
(	O
CoV	O
)	O
infection	O
.	O

In	O
cell	O
culture	O
,	O
activation	O
of	O
Ebola	O
virus	O
,	O
as	O
well	O
as	O
SARS	O
-	O
and	O
MERS	O
-	O
coronavirus	O
can	O
be	O
accomplished	O
by	O
the	O
endosomal	O
cysteine	O
proteases	O
,	O
cathepsin	B-ENZY
L	I-ENZY
(	O
CTSL	O
)	O
and	O
cathepsin	B-ENZY
B	I-ENZY
(	O
CTSB	O
).	O

ABSTRACT	O
:	O
[	O
This	O
corrects	O
the	O
article	O
DOI	O
:	O
10	O
.	O
1371	O
/	O
journal	O
.	O
ppat	B-ENZY
.	O
1004502	O
.].	O

TITLE	O
:	O
Porcine	O
aminopeptidase	B-ENZY
N	I-ENZY
mediated	O
polarized	O
infection	O
by	O
porcine	O
epidemic	O
diarrhea	O
virus	O
in	O
target	O
cells	O
.	O

TITLE	O
:	O
Murine	O
coronavirus	O
ubiquitin	O
-	O
like	O
domain	O
is	O
important	O
for	O
papain	B-ENZY
-	O
like	O
protease	O
stability	O
and	O
viral	O
pathogenesis	O
.	O

TITLE	O
:	O
Analysis	O
of	O
cathepsin	O
and	O
furin	B-ENZY
proteolytic	O
enzymes	O
involved	O
in	O
viral	O
fusion	O
protein	O
activation	O
in	O
cells	O
of	O
the	O
bat	B-ENZY
reservoir	O
host	O
.	O

Further	O
analysis	O
of	O
furin	B-ENZY
-	O
like	O
proteases	O
from	O
fruit	O
bats	O
revealed	O
that	O
these	O
proteases	O
are	O
catalytically	O
active	O
and	O
resemble	O
other	O
mammalian	O
furins	O
in	O
their	O
response	O
to	O
a	O
potent	O
furin	B-ENZY
inhibitor	O
.	O

Infectious	O
recombinant	O
IBVs	O
are	O
generated	O
in	O
situ	O
following	O
the	O
transfection	O
of	O
vaccinia	O
virus	O
DNA	O
,	O
containing	O
the	O
modified	O
IBV	O
cDNA	O
,	O
into	O
cells	O
infected	O
with	O
a	O
recombinant	O
fowlpox	O
virus	O
expressing	O
T7	O
DNA	B-ENZY
-	I-ENZY
dependent	I-ENZY
RNA	I-ENZY
polymerase	I-ENZY
.	O

Compared	O
with	O
VicS	O
-	O
v	O
,	O
the	O
more	O
attenuated	O
VicS	O
-	O
del	O
strain	O
had	O
two	O
non	O
-	O
synonymous	O
changes	O
in	O
the	O
non	O
-	O
structural	O
protein	O
6	O
(	O
nsp6	O
),	O
a	O
transmembrane	O
(	O
TM	O
)	O
domain	O
that	O
may	O
participate	O
in	O
autocatalytic	O
release	O
of	O
the	O
3	O
-	O
chymotrypsin	B-ENZY
-	O
like	O
protease	O
,	O
a	O
polymorphic	O
difference	O
at	O
the	O
end	O
of	O
the	O
S2	O
gene	O
,	O
which	O
coincided	O
with	O
the	O
body	O
transcription	O
-	O
regulating	O
sequence	O
(	O
B	O
-	O
TRS	O
)	O
of	O
mRNA	O
3	O
and	O
a	O
truncated	O
open	O
reading	O
frame	O
for	O
a	O
peptide	O
encoded	O
by	O
gene	O
4	O
(	O
4b	O
).	O

ABSTRACT	O
:	O
The	O
HIV	O
-	O
1	O
Reverse	B-ENZY
Transcriptase	I-ENZY
(	O
RT	O
)	O
is	O
a	O
validated	O
and	O
deeply	O
explored	O
biological	O
target	O
for	O
the	O
treatment	O
of	O
AIDS	O
.	O

ABSTRACT	O
:	O
HIV	O
-	O
1	O
reverse	B-ENZY
transcriptase	I-ENZY
(	O
RT	O
)	O
is	O
still	O
an	O
extremely	O
attractive	O
pharmaceutical	O
target	O
for	O
the	O
identification	O
of	O
new	O
inhibitors	O
possibly	O
active	O
on	O
drug	O
resistant	O
strains	O
.	O

TITLE	O
:	O
SARS	O
hCoV	O
papain	B-ENZY
-	O
like	O
protease	O
is	O
a	O
unique	O
Lys48	O
linkage	O
-	O
specific	O
di	O
-	O
distributive	O
deubiquitinating	O
enzyme	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
compare	O
substrate	O
specificities	O
of	O
the	O
papain	B-ENZY
-	O
like	O
protease	O
(	O
PLpro	O
)	O
from	O
the	O
recently	O
emerged	O
Middle	O
East	O
respiratory	O
syndrome	O
(	O
MERS	O
)	O
hCoV	O
to	O
the	O
related	O
protease	O
from	O
SARS	O
,	O
SARS	O
PLpro	O
.	O

Severely	O
ill	O
patients	O
with	O
H7N9	O
had	O
significantly	O
longer	O
interval	O
from	O
onset	O
of	O
illness	O
to	O
neuraminidase	B-ENZY
inhibitor	O
treatment	O
and	O
to	O
death	O
.	O

Conclusion	O
FOB	O
-	O
BAL	B-ENZY
using	O
LMA	O
and	O
CPAP	O
appears	O
to	O
be	O
safe	O
and	O
effective	O
in	O
patients	O
who	O
develop	O
severe	O
acute	O
hypoxaemia	O
.	O

ABSTRACT	O
:	O
A	O
retrospective	O
cohort	O
study	O
was	O
preformed	O
aiming	O
to	O
verify	O
the	O
presence	O
of	O
transient	O
dysfunction	O
of	O
gas	B-ENZY
exchange	O
in	O
the	O
postoperative	O
period	O
of	O
cardiac	O
surgery	O
and	O
determine	O
if	O
this	O
disorder	O
is	O
linked	O
to	O
cardiorespiratory	O
events	O
.	O

CoV	O
RNA	O
was	O
detected	O
in	O
47	O
specimens	O
(	O
7	O
.	O
6	O
%),	O
from	O
13	O
different	O
bat	B-ENZY
species	O
,	O
using	O
broadly	O
reactive	O
consensus	O
PCR	O
primers	O
targeting	O
the	O
RNA	O
-	O
Dependent	O
RNA	O
Polymerase	O
gene	O
designed	O
to	O
detect	O
all	O
CoVs	O
.	O

These	O
data	O
suggest	O
that	O
bat	B-ENZY
CoV	O
lineages	O
are	O
not	O
strictly	O
concordant	O
with	O
their	O
hosts	O
.	O

At	O
baseline	O
,	O
48	O
patients	O
had	O
mild	O
to	O
severe	O
ARDS	O
according	O
to	O
Berlin	O
and	O
87	O
according	O
to	O
LIS	B-ENZY
(	O
Rs	O
=	O
0	O
.	O
54	O
,	O
P	O
<	O
0	O
.	O
001	O
).	O

When	O
the	O
LIS	B-ENZY
decreased	O
,	O
albumin	O
levels	O
increased	O
	O
1	O
g	O
/	O
L	O
(	O
AUROC	O
0	O
.	O
68	O
,	O
P	O
=	O
0	O
.	O
02	O
).	O

Reverse	B-ENZY
transcriptase	I-ENZY
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
on	O
formalin	O
fixed	O
paraffin	O
embedded	O
tissue	O
from	O
the	O
lung	O
,	O
spleen	O
,	O
and	O
kidney	O
was	O
negative	O
for	O
FRSCV	O
and	O
positive	O
for	O
ferret	O
enteric	O
coronavirus	O
(	O
FRECV	O
).	O

As	O
found	O
in	O
other	O
coronaviruses	O
,	O
the	O
majority	O
of	O
the	O
positive	O
-	O
stranded	O
RNA	O
MERS	O
-	O
CoV	O
genome	O
is	O
translated	O
into	O
two	O
polyproteins	O
,	O
one	O
created	O
by	O
a	O
ribosomal	O
frameshift	O
,	O
that	O
are	O
cleaved	O
at	O
three	O
sites	O
by	O
a	O
papain	B-ENZY
-	O
like	O
protease	O
and	O
at	O
11	O
sites	O
by	O
a	O
3C	O
-	O
like	O
protease	O
(	O
3	O
CL	O
(	O
pro	O
)).	O

ABSTRACT	O
:	O
This	O
study	O
was	O
conducted	O
to	O
evaluate	O
the	O
effects	O
of	O
open	O
endotracheal	O
suctioning	O
on	O
gas	B-ENZY
exchange	O
and	O
respiratory	O
mechanics	O
in	O
ARF	O
patients	O
under	O
the	O
modes	O
of	O
PCV	O
or	O
VCV	O
.	O

The	O
authors	O
compared	O
HFOV	O
with	O
LPSV	O
in	O
adult	O
patients	O
with	O
the	O
early	O
phase	O
of	O
ARDS	O
who	O
received	O
mechanical	O
ventilation	O
less	O
than	O
72	O
hours	O
and	O
had	O
moderate	O
to	O
severe	O
hypoxemia	O
(	O
PaO	B-ENZY
/	O
FiO2	O
ratio	O
less	O
than	O
or	O
equal	O
150	O
).	O

He	O
had	O
left	O
a	O
polytetrafluoroethylene	O
-	O
coated	O
pan	O
on	O
a	O
gas	B-ENZY
-	O
burning	O
stove	O
for	O
10	O
hours	O
while	O
unconscious	O
.	O

PEDV	O
-	O
SFCS	O
exhibited	O
trypsin	B-ENZY
-	O
independent	O
cell	O
-	O
cell	O
fusion	O
and	O
was	O
able	O
to	O
replicate	O
in	O
culture	O
cells	O
independently	O
of	O
trypsin	B-ENZY
,	O
though	O
to	O
low	O
titer	O
.	O

Serology	O
revealed	O
antibodies	O
against	O
canine	O
adenovirus	O
(	O
71	O
%),	O
canine	O
coronavirus	O
(	O
32	O
%),	O
canine	O
distemper	O
virus	O
(	O
17	O
%),	O
canine	O
parvovirus	O
(	O
96	O
%),	O
and	O
Leptospira	O
spp	B-ENZY
.	O

In	O
addition	O
,	O
cyclin	B-ENZY
-	I-ENZY
dependent	I-ENZY
kinase	I-ENZY
6	O
(	O
CDK6	O
)	O
was	O
identified	O
as	O
a	O
novel	O
antiviral	O
host	O
factor	O
in	O
SARS	O
-	O
CoV	O
replication	O
.	O

By	O
combining	O
this	O
high	O
temperature	O
isothermal	O
amplification	O
method	O
with	O
a	O
thermostable	O
invertase	B-ENZY
,	O
we	O
can	O
directly	O
transduce	O
Middle	O
-	O
East	O
respiratory	O
syndrome	O
coronavirus	O
and	O
Zaire	O
Ebolavirus	O
templates	O
into	O
glucose	O
signals	O
,	O
with	O
a	O
sensitivity	O
as	O
low	O
as	O
20	O
-	O
100	O
copies	O
/	O
l	O
,	O
equating	O
to	O
atto	O
-	O
molar	O
(	O
or	O
low	O
zepto	O
-	O
mole	O
).	O

METHODS	O
:	O
We	O
treated	O
human	O
lung	O
fibroblasts	O
(	O
HLF	O
)	O
with	O
PDGF	O
,	O
or	O
TGF1	O
,	O
or	O
combined	O
,	O
and	O
examined	O
the	O
activation	O
of	O
p38	O
MAPK	B-ENZY
,	O
p42	O
/	O
p44	O
MAPK	B-ENZY
and	O
SMAD3	O
.	O

We	O
conducted	O
a	O
phase	O
IIa	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
parallel	O
-	O
group	O
study	O
to	O
evaluate	O
the	O
safety	O
and	O
tolerability	O
of	O
dilmapimod	O
,	O
a	O
novel	O
p38	O
mitogen	B-ENZY
-	I-ENZY
activated	I-ENZY
protein	I-ENZY
kinase	I-ENZY
inhibitor	O
,	O
in	O
patients	O
at	O
risk	O
for	O
developing	O
acute	O
respiratory	O
distress	O
syndrome	O
admitted	O
with	O
an	O
Injury	O
Severity	O
Score	O
more	O
than	O
16	O
,	O
excluding	O
head	O
trauma	O
.	O

TITLE	O
:	O
Extracellular	B-ENZY
signal	I-ENZY
-	I-ENZY
regulated	I-ENZY
kinase	I-ENZY
(	O
ERK	B-ENZY
)	O
activation	O
is	O
required	O
for	O
porcine	O
epidemic	O
diarrhea	O
virus	O
replication	O
.	O

The	O
extracellular	B-ENZY
signal	I-ENZY
-	I-ENZY
regulated	I-ENZY
kinase	I-ENZY
(	O
ERK	B-ENZY
)	O
that	O
serves	O
as	O
a	O
critical	O
component	O
of	O
cellular	O
signal	O
transduction	O
pathways	O
to	O
modulate	O
a	O
variety	O
of	O
cellular	O
functions	O
has	O
been	O
shown	O
to	O
regulate	O
several	O
viral	O
infections	O
.	O

Inhibition	O
of	O
ERK	B-ENZY
activation	O
also	O
diminished	O
viral	O
protein	O
expression	O
and	O
genomic	O
and	O
subgenomic	O
RNA	O
transcription	O
.	O

The	O
main	O
reason	O
of	O
apneic	O
test	O
difficulties	O
was	O
severe	O
gas	B-ENZY
exchange	O
disturbances	O
secondary	O
to	O
ARDS	O
.	O

The	O
correlation	O
of	O
the	O
aeration	O
score	O
variation	O
(	O
ASV	O
)	O
and	O
the	O
arterial	O
blood	O
gas	B-ENZY
indexes	O
(	O
pH	O
,	O
PaO	B-ENZY
(	O
2	O
),	O
PaCO	O
(	O
2	O
),	O
PaO	B-ENZY
(	O
2	O
)/	O
FiO	O
(	O
2	O
))	O
were	O
recorded	O
also	O
.	O

Antineutrophil	O
cytoplasm	O
antibodies	O
were	O
proteinase	B-ENZY
3	I-ENZY
-	O
positive	O
in	O
65	O
.	O
5	O
%	O
of	O
the	O
patients	O
(	O
50	O
%	O
of	O
those	O
with	O
SGS	O
).	O
Despite	O
conventional	O
GPA	O
therapy	O
,	O
62	O
%	O
patients	O
experienced	O
	O
1	O
stenosis	O
relapse	O
(	O
s	O
)	O
(	O
81	O
%	O
of	O
SGS	O
patients	O
,	O
for	O
a	O
total	O
of	O
1	O
-	O
8	O
relapses	O
per	O
patient	O
).	O

ABSTRACT	O
:	O
Acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
is	O
a	O
syndrome	O
of	O
acute	O
lung	O
injury	O
that	O
is	O
characterized	O
by	O
noncardiogenic	O
pulmonary	O
edema	O
and	O
severe	O
hypoxemia	O
second	O
to	O
a	O
pathogenic	O
impairment	O
of	O
gas	B-ENZY
exchange	O
.	O

There	O
,	O
he	O
underwent	O
ECMO	O
V	O
-	O
V	O
therapy	O
lasting	O
22	O
days	O
,	O
which	O
resulted	O
in	O
the	O
improvement	O
of	O
his	O
arterial	O
blood	O
gas	B-ENZY
parameters	O
and	O
clinical	O
condition	O
.	O

TITLE	O
:	O
Real	O
-	O
time	O
reverse	B-ENZY
transcriptase	I-ENZY
polymerase	O
chain	O
reaction	O
assays	O
for	O
Middle	O
East	O
Respiratory	O
Syndrome	O
.	O

The	O
primers	O
and	O
probes	O
for	O
these	O
assays	O
were	O
evaluated	O
and	O
found	O
to	O
have	O
a	O
limit	O
of	O
detection	O
(	O
LOD	B-ENZY
)	O
of	O
0	O
.	O
005	O
plaque	O
-	O
forming	O
units	O
/	O
PCR	O
(	O
pfu	O
/	O
PCR	O
).	O

The	O
ancestral	O
origins	O
of	O
major	O
human	O
coronaviruses	O
(	O
HCoVs	O
)	O
likely	O
involve	O
bat	B-ENZY
hosts	O
.	O

Here	O
,	O
we	O
provide	O
conclusive	O
genetic	O
evidence	O
for	O
an	O
evolutionary	O
origin	O
of	O
the	O
common	O
cold	O
virus	O
HCoV	O
-	O
229E	O
in	O
hipposiderid	O
bats	O
by	O
analyzing	O
a	O
large	O
sample	O
of	O
African	O
bats	O
and	O
characterizing	O
several	O
bat	B-ENZY
viruses	O
on	O
a	O
full	O
-	O
genome	O
level	O
.	O

Finally	O
,	O
we	O
show	O
that	O
isoform	O
1	O
activates	O
the	O
SARS	O
-	O
CoV	O
spike	O
protein	O
for	O
cathepsin	B-ENZY
L	I-ENZY
-	O
independent	O
entry	O
into	O
target	O
cells	O
.	O

Here	O
,	O
we	O
show	O
that	O
age	O
-	O
dependent	O
increases	O
of	O
one	O
such	O
factor	O
in	O
the	O
lungs	O
,	O
a	O
phospholipase	B-ENZY
A2	I-ENZY
(	O
PLA2	O
)	O
group	O
IID	O
(	O
PLA2G2D	O
)	O
with	O
antiinflammatory	O
properties	O
,	O
contributed	O
to	O
worse	O
outcomes	O
in	O
mice	O
infected	O
with	O
severe	O
acute	O
respiratory	O
syndrome	O
-	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
).	O

We	O
analyzed	O
the	O
evolution	O
of	O
the	O
spike	O
(	O
S	O
)	O
gene	O
in	O
betacoronaviruses	O
(	O
betaCoVs	O
)	O
isolated	O
from	O
different	O
mammals	O
,	O
in	O
bat	B-ENZY
coronavirus	O
populations	O
,	O
as	O
well	O
as	O
in	O
MERS	O
-	O
CoV	O
strains	O
from	O
the	O
current	O
outbreak	O
.	O

Multivariate	O
analysis	O
associated	O
hospital	O
mortality	O
with	O
age	O
and	O
Pao	B-ENZY
The	O
overall	O
hospital	O
mortality	O
(	O
38	O
%)	O
was	O
similar	O
to	O
that	O
of	O
other	O
studies	O
and	O
according	O
to	O
the	O
presence	O
of	O
ARDS	O
(	O
Pao	B-ENZY
RESULTS	O
:	O
In	O
the	O
93	O
patients	O
comprising	O
the	O
study	O
,	O
hospital	O
mortality	O
was	O
38	O
%.	O

ABSTRACT	O
:	O
Prone	O
position	O
(	O
PP	O
)	O
has	O
been	O
used	O
since	O
the	O
1970s	O
to	O
treat	O
severe	O
hypoxemia	O
in	O
patients	O
with	O
ARDS	O
because	O
of	O
its	O
effectiveness	O
at	O
improving	O
gas	B-ENZY
exchange	O
.	O

Based	O
on	O
the	O
properties	O
of	O
active	O
-	O
site	O
mutants	O
,	O
we	O
conclude	O
that	O
the	O
RNA	O
-	O
synthesizing	O
activities	O
observed	O
in	O
de	O
novo	O
and	O
primer	O
-	O
dependent	O
polymerase	O
and	O
terminal	B-ENZY
transferase	I-ENZY
assays	O
cannot	O
be	O
attributed	O
to	O
recombinant	O
EAV	O
nsp9	O
-	O
RdRp	O
.	O

An	O
inverse	O
relationship	O
with	O
SCI	O
-	O
CG	O
scores	O
was	O
observed	O
for	O
patients	O
who	O
experienced	O
ACS	B-ENZY
more	O
than	O
48	O
months	O
after	O
the	O
loss	O
(	O
P	O
=	O
0	O
.	O
005	O
).	O

CONCLUSIONS	O
:	O
A	O
great	O
proportion	O
of	O
subjects	O
with	O
ACS	B-ENZY
report	O
the	O
loss	O
of	O
a	O
loved	O
one	O
.	O

ARDS	O
renal	O
recipients	O
with	O
ESKAPE	O
(	O
E	O
.	O
faecium	O
,	O
S	O
.	O
aureus	O
,	O
K	O
.	O
pneumoniae	O
,	O
A	O
.	O
baumannii	O
,	O
P	O
.	O
aeruginosa	O
,	O
and	O
Enterobacter	O
spp	B-ENZY
.)	O
pneumonia	O
are	O
probably	O
related	O
to	O
high	O
morbidity	O
and	O
mortality	O
.	O

ABSTRACT	O
:	O
Taxine	O
-	O
derived	O
alkaloids	O
,	O
taxane	O
-	O
derived	O
substances	O
,	O
and	O
glycosides	O
seem	O
to	O
be	O
responsible	O
for	O
the	O
toxicity	O
of	O
Taxus	O
spp	B-ENZY
.	O

Ventilation	O
in	O
the	O
prone	O
position	O
may	O
improve	O
lung	O
mechanics	O
and	O
gas	B-ENZY
exchange	O
and	O
could	O
improve	O
outcomes	O
.	O

Using	O
hemi	O
-	O
nested	O
reverse	B-ENZY
transcriptase	I-ENZY
(	O
RT	O
)-	O
PCR	O
amplification	O
of	O
fragments	O
within	O
the	O
highly	O
conserved	O
regions	O
of	O
the	O
respective	O
RNA	O
dependent	O
RNA	O
polymerase	O
(	O
RdRp	O
)	O
genes	O
,	O
we	O
detected	O
astrovirus	O
sequences	O
at	O
an	O
overall	O
detection	O
rate	O
of	O
25	O
.	O
8	O
%	O
of	O
the	O
analysed	O
animals	O
,	O
with	O
a	O
maximum	O
of	O
65	O
%	O
in	O
local	O
populations	O
.	O

Interestingly	O
,	O
the	O
sequence	O
similarities	O
in	O
samples	O
collected	O
from	O
the	O
same	O
bat	B-ENZY
species	O
in	O
different	O
geographical	O
areas	O
were	O
distinctly	O
larger	O
than	O
the	O
sequence	O
similarities	O
between	O
samples	O
from	O
different	O
species	O
sampled	O
at	O
the	O
same	O
location	O
.	O

MERS	O
-	O
CoV	O
ORF4b	O
inhibits	O
the	O
production	O
of	O
type	O
I	O
IFN	O
through	O
a	O
direct	O
interaction	O
with	O
IKK	O
/	O
TBK1	B-ENZY
in	O
the	O
cytoplasm	O
,	O
and	O
also	O
in	O
the	O
nucleus	O
with	O
unknown	O
mechanism	O
.	O

TITLE	O
:	O
Bat	B-ENZY
origin	O
of	O
human	O
coronaviruses	O
.	O

ABSTRACT	O
:	O
Glucose	B-ENZY
-	I-ENZY
6	I-ENZY
-	I-ENZY
phosphate	I-ENZY
dehydrogenase	I-ENZY
(	O
G6PD	B-ENZY
)-	O
deficient	O
cells	O
are	O
highly	O
susceptible	O
to	O
viral	O
infection	O
.	O

This	O
study	O
examined	O
the	O
mechanism	O
underlying	O
this	O
phenomenon	O
by	O
measuring	O
the	O
expression	O
of	O
antiviral	O
genes	O
-	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF	O
-	O
	O
)	O
and	O
GTPase	O
myxovirus	O
resistance	O
1	O
(	O
MX1	O
)-	O
in	O
G6PD	B-ENZY
-	O
knockdown	O
cells	O
upon	O
human	O
coronavirus	O
229E	O
(	O
HCoV	O
-	O
229E	O
)	O
and	O
enterovirus	O
71	O
(	O
EV71	O
)	O
infection	O
.	O

The	O
HSCARG	O
protein	O
,	O
a	O
nicotinamide	O
adenine	O
dinucleotide	O
phosphate	O
(	O
NADPH	O
)	O
sensor	O
and	O
negative	O
regulator	O
of	O
NF	O
-	O
B	O
,	O
was	O
upregulated	O
in	O
G6PD	B-ENZY
-	O
knockdown	O
cells	O
with	O
decreased	O
NADPH	O
/	O
NADP	O
	O
ratio	O
.	O

We	O
found	O
that	O
IL	O
-	O
17	O
level	O
was	O
elevated	O
in	O
bronchoalveolar	O
lavage	O
(	O
BAL	B-ENZY
)	O
fluid	O
of	O
ALI	O
mice	O
.	O

Upregulation	O
of	O
IL	O
-	O
17	O
resulted	O
in	O
increased	O
severity	O
of	O
ALI	O
as	O
evidenced	O
by	O
decreased	O
body	O
weight	O
and	O
survival	O
rate	O
,	O
elevated	O
level	O
of	O
total	O
protein	O
and	O
albumin	O
in	O
BAL	B-ENZY
fluid	O
,	O
as	O
well	O
as	O
more	O
apparent	O
histopathology	O
changes	O
of	O
lung	O
.	O

The	O
median	O
TAT	B-ENZY
of	O
more	O
than	O
a	O
half	O
of	O
the	O
laboratories	O
(	O
57	O
.	O
7	O
%)	O
was	O
less	O
than	O
6	O
hr	O
.	O

Our	O
goal	O
was	O
to	O
elucidate	O
the	O
prevalence	O
of	O
AHR	O
,	O
as	O
measured	O
by	O
a	O
methacholine	O
challenge	O
test	O
(	O
MCT	B-ENZY
),	O
in	O
children	O
with	O
SCD	O
who	O
did	O
not	O
have	O
concomitant	O
asthma	O
or	O
any	O
recent	O
history	O
of	O
acute	O
chest	O
syndrome	O
(	O
ACS	B-ENZY
).	O

TITLE	O
:	O
Isolation	O
and	O
Characterization	O
of	O
a	O
Novel	O
Bat	B-ENZY
Coronavirus	O
Closely	O
Related	O
to	O
the	O
Direct	O
Progenitor	O
of	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
Coronavirus	O
.	O

ABSTRACT	O
:	O
We	O
report	O
the	O
isolation	O
and	O
characterization	O
of	O
a	O
novel	O
bat	B-ENZY
coronavirus	O
which	O
is	O
much	O
closer	O
to	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
in	O
genomic	O
sequence	O
than	O
others	O
previously	O
reported	O
,	O
particularly	O
in	O
its	O
S	O
gene	O
.	O

PDE	O
activity	O
is	O
required	O
for	O
robust	O
replication	O
in	O
myeloid	O
cells	O
,	O
as	O
a	O
mutant	O
of	O
MHV	O
(	O
ns2	O
(	O
H126R	O
))	O
encoding	O
an	O
inactive	O
PDE	O
fails	O
to	O
antagonize	O
RNase	B-ENZY
L	O
activation	O
and	O
replicates	O
poorly	O
in	O
bone	O
marrow	O
-	O
derived	O
macrophages	O
(	O
BMM	O
),	O
while	O
ns2	O
(	O
H126R	O
)	O
replicates	O
to	O
high	O
titer	O
in	O
several	O
types	O
of	O
nonmyeloid	O
cells	O
,	O
as	O
well	O
as	O
in	O
IFN	O
receptor	O
-	O
deficient	O
(	O
Ifnar1	O
(-/-))	O
BMM	O
.	O

Finally	O
,	O
overexpression	O
of	O
RNase	B-ENZY
L	O
is	O
not	O
sufficient	O
to	O
compensate	O
for	O
inadequate	O
basal	O
OAS	O
levels	O
.	O

A	O
statistically	O
significant	O
difference	O
between	O
case	O
and	O
control	O
groups	O
was	O
found	O
only	O
for	O
Cystoisospora	O
suis	O
(	O
p	O
=	O
0	O
.	O
034	O
)	O
and	O
Eimeria	O
spp	B-ENZY
.	O

ABSTRACT	O
:	O
Prior	O
studies	O
have	O
demonstrated	O
that	O
the	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
A59	O
strain	O
ns2	O
protein	O
is	O
a	O
member	O
of	O
the	O
2H	O
phosphoesterase	O
family	O
and	O
exhibits	O
2	O
',	O
5	B-ENZY
'-	I-ENZY
phosphodiesterase	I-ENZY
(	O
PDE	O
)	O
activity	O
.	O

A	O
further	O
study	O
showed	O
that	O
the	O
CBP	O
degradation	O
by	O
nsp1	O
was	O
proteasome	B-ENZY
-	O
dependent	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
sensitivity	O
and	O
specificity	O
of	O
a	O
real	O
-	O
time	O
reverse	B-ENZY
transcriptase	I-ENZY
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
detecting	O
feline	O
coronavirus	O
(	O
FCoV	O
)	O
RNA	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMCs	O
)	O
and	O
serum	O
in	O
comparison	O
with	O
the	O
same	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
in	O
cell	O
-	O
free	O
body	O
cavity	O
effusion	O
.	O

The	O
compound	O
was	O
also	O
an	O
inhibitor	O
of	O
the	O
RNase	B-ENZY
H	I-ENZY
activity	O
of	O
wild	O
-	O
type	O
HIV	O
-	O
1	O
group	O
O	O
RT	O
,	O
although	O
we	O
observed	O
a	O
6	O
.	O
5	O
-	O
fold	O
increase	O
in	O
the	O
IC50	O
in	O
comparison	O
with	O
the	O
prototypic	O
HIV	O
-	O
1	O
group	O
M	O
subtype	O
B	O
enzyme	O
.	O

Our	O
results	O
show	O
that	O
RMNC6	O
acts	O
as	O
a	O
dual	O
inhibitor	O
with	O
allosteric	O
sites	O
in	O
the	O
DNA	O
polymerase	O
and	O
the	O
RNase	B-ENZY
H	I-ENZY
domains	O
of	O
HIV	O
-	O
1	O
RT	O
.	O

ABSTRACT	O
:	O
To	O
investigate	O
the	O
value	O
of	O
serum	O
cholinesterase	B-ENZY
(	O
S	O
-	O
ChE	O
)	O
levels	O
in	O
judgment	O
of	O
severity	O
and	O
prognosis	O
in	O
patients	O
with	O
severe	O
pneumonia	O
.	O

Respiratory	O
mechanics	O
and	O
gas	B-ENZY
-	O
exchange	O
were	O
measured	O
.	O

In	O
addition	O
,	O
the	O
production	O
of	O
pro	O
-	O
inflammatory	O
cytokines	O
and	O
the	O
activity	O
of	O
myeloperoxidase	B-ENZY
in	O
pulmonary	O
tissues	O
were	O
notably	O
repressed	O
.	O

The	O
present	O
study	O
has	O
identified	O
additional	O
numbers	O
of	O
genetically	O
diverse	O
bat	B-ENZY
-	O
borne	O
coronaviruses	O
with	O
a	O
wide	O
distribution	O
in	O
China	O
.	O

Both	O
NF	O
-	O
B	O
and	O
TBK1	B-ENZY
-	O
IRF3	O
signaling	O
cascades	O
are	O
activated	O
by	O
M	O
gene	O
products	O
.	O

Primaquine	O
should	O
be	O
avoided	O
or	O
given	O
with	O
caution	O
under	O
expert	O
supervision	O
in	O
patients	O
with	O
Glucose	B-ENZY
-	I-ENZY
6	I-ENZY
-	I-ENZY
phosphate	I-ENZY
dehydrogenase	I-ENZY
deficiency	O
(	O
G6PD	B-ENZY
),	O
in	O
whom	O
it	O
may	O
cause	O
severe	O
haemolysis	O
.	O

Particulate	O
substances	O
in	O
smoke	O
,	O
toxic	O
and	O
harmful	O
gas	B-ENZY
,	O
and	O
chemical	O
substances	O
act	O
together	O
would	O
rapidly	O
induce	O
the	O
occurrence	O
of	O
dramatic	O
pathophysiologic	O
reaction	O
in	O
the	O
respiratory	O
tract	O
,	O
resulting	O
in	O
acute	O
injury	O
to	O
the	O
respiratory	O
tract	O
,	O
thus	O
inducing	O
serious	O
injury	O
to	O
it	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
leading	O
to	O
death	O
of	O
the	O
victims	O
.	O

The	O
BAL	B-ENZY
neutrophil	O
content	O
was	O
also	O
higher	O
in	O
the	O
LPS	O
-	O
supine	O
group	O
compared	O
to	O
the	O
LPS	O
-	O
prone	O
and	O
control	O
groups	O
(	O
p	O
<	O
0	O
.	O
05	O
).	O

EGFR	O
is	O
also	O
the	O
upstream	O
activator	O
of	O
mitogen	B-ENZY
-	I-ENZY
activated	I-ENZY
protein	I-ENZY
kinase	I-ENZY
(	O
MAPK	B-ENZY
)	O
signaling	O
pathways	O
that	O
is	O
involved	O
in	O
F	O
-	O
actin	O
reorganization	O
.	O

Bat	B-ENZY
and	O
MERS	O
corona	O
-	O
viruses	O
are	O
structurally	O
related	O
.	O

We	O
found	O
that	O
MERS	O
-	O
CoV	O
shared	O
30	O
%	O
of	O
its	O
S	O
protein	O
antigenic	O
sites	O
with	O
HKU4	O
and	O
70	O
%	O
with	O
HKU5	O
bat	B-ENZY
-	O
CoV	O
.	O
Whereas	O
100	O
%	O
of	O
its	O
E	O
,	O
M	O
and	O
N	O
protein	O
'	O
s	O
antigenic	O
sites	O
are	O
found	O
to	O
be	O
conserved	O
with	O
those	O
in	O
HKU4	O
and	O
HKU5	O
.	O

Treatment	O
in	O
study	O
group	O
led	O
to	O
a	O
faster	O
and	O
better	O
recovery	O
of	O
respiratory	O
indexes	O
,	O
and	O
less	O
pronounced	O
changes	O
in	O
the	O
levels	O
of	O
blood	O
urea	O
nitrogen	O
and	O
alanine	B-ENZY
aminotransferase	I-ENZY
.	O

ABSTRACT	O
:	O
Glucose	B-ENZY
-	I-ENZY
6	I-ENZY
-	I-ENZY
phosphate	I-ENZY
dehydrogenase	I-ENZY
(	O
G6PD	B-ENZY
)	O
provides	O
the	O
reducing	O
agent	O
NADPH	O
to	O
meet	O
the	O
cellular	O
needs	O
for	O
reductive	O
biosynthesis	O
and	O
the	O
maintenance	O
of	O
redox	O
homeostasis	O
.	O

Almost	O
a	O
quarter	O
of	O
the	O
patients	O
were	O
healthcare	O
workers	O
(	O
23	O
.	O
5	O
%)	O
and	O
41	O
%	O
had	O
a	O
known	O
exposure	O
to	O
another	O
person	O
with	O
MERS	O
-	O
CoV	O
.	O
Survival	O
was	O
associated	O
with	O
male	O
gender	O
,	O
working	O
as	O
a	O
healthcare	O
worker	O
,	O
history	O
of	O
hypertension	O
,	O
vomiting	O
on	O
admission	O
,	O
elevated	O
respiratory	O
rate	O
,	O
abnormal	O
lung	O
exam	O
,	O
elevated	O
alanine	B-ENZY
transaminase	I-ENZY
(	O
ALT	O
),	O
clearance	O
of	O
MERS	O
-	O
CoV	O
on	O
repeat	O
PCR	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
testing	O
,	O
and	O
mycophenolate	O
mofetil	O
treatment	O
.	O

The	O
patients	O
in	O
early	O
group	O
were	O
not	O
treated	O
according	O
to	O
EGDT	O
guidance	O
,	O
so	O
only	O
age	O
,	O
the	O
case	O
history	O
of	O
chronic	O
disease	O
,	O
the	O
main	O
site	O
of	O
infection	O
,	O
organ	O
dysfunction	O
,	O
vital	O
signs	O
,	O
urine	O
output	O
,	O
the	O
amount	O
of	O
fluid	O
for	O
resuscitation	O
,	O
blood	O
routine	O
,	O
blood	O
gas	B-ENZY
analysis	O
,	O
time	O
for	O
starting	O
antibiotics	O
treatment	O
,	O
the	O
use	O
of	O
vasoactive	O
drugs	O
and	O
hormone	O
,	O
etc	O
.	O
were	O
recorded	O
.	O

RVA	O
isolation	O
was	O
achieved	O
for	O
nine	O
clinical	O
samples	O
following	O
one	O
or	O
two	O
passages	O
(	O
60	O
%)	O
and	O
was	O
properly	O
depended	O
on	O
HA	O
activity	O
and	O
trypsin	B-ENZY
treatment	O
of	O
inoculates	O
.	O

RESULTS	O
:	O
RVA	O
isolation	O
was	O
achieved	O
for	O
nine	O
clinical	O
samples	O
following	O
one	O
or	O
two	O
passages	O
(	O
60	O
%)	O
and	O
was	O
properly	O
depended	O
on	O
HA	O
activity	O
and	O
trypsin	B-ENZY
treatment	O
of	O
inoculates	O
.	O

The	O
decrease	O
in	O
the	O
activated	O
state	O
of	O
TRAF3	O
and	O
TRAF6	O
correlated	O
with	O
the	O
inactivation	O
of	O
TBK1	B-ENZY
in	O
response	O
to	O
IMQ	O
by	O
PLPro	O
.	O

Diverse	O
bat	B-ENZY
CoV	O
with	O
zoonotic	O
potential	O
could	O
be	O
introduced	O
by	O
migratory	O
bats	O
and	O
maintained	O
in	O
the	O
endemic	O
bat	B-ENZY
population	O
in	O
Taiwan	O
.	O

In	O
this	O
study	O
,	O
we	O
used	O
an	O
affinity	O
purification	O
/	O
mass	O
spectrometry	O
approach	O
to	O
demonstrate	O
that	O
a	O
bat	B-ENZY
MHC	O
class	O
I	O
molecule	O
,	O
Ptal	B-ENZY
-	O
N	O
*	O
01	O
:	O
01	O
,	O
binds	O
antigenic	O
peptides	O
and	O
associates	O
with	O
peptide	O
-	O
loading	O
complex	O
components	O
.	O

Intestinal	O
content	O
samples	O
were	O
collected	O
from	O
101	O
broiler	O
flocks	O
from	O
several	O
regions	O
of	O
Jordan	O
to	O
detect	O
the	O
presence	O
of	O
astrovirus	O
,	O
coronavirus	O
,	O
reovirus	O
,	O
and	O
rotavirus	O
,	O
by	O
using	O
reverse	B-ENZY
transcriptase	I-ENZY
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
).	O

Further	O
,	O
RIP3	O
depletion	O
reduced	O
the	O
necrotic	O
cells	O
in	O
the	O
lung	O
and	O
decreased	O
the	O
expression	O
of	O
MLKL	O
,	O
but	O
had	O
no	O
impact	O
on	O
cleaved	O
caspase	B-ENZY
-	I-ENZY
3	I-ENZY
in	O
LPS	O
-	O
induced	O
ARDS	O
.	O

Pulmonary	O
vascular	O
dysfunction	O
(	O
PVD	O
)	O
and	O
acute	O
cor	O
pulmonale	O
(	O
ACP	O
)	O
are	O
common	O
during	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
and	O
their	O
prevalence	O
may	O
be	O
even	O
more	O
important	O
during	O
ARDS	O
related	O
to	O
ACS	B-ENZY
(	O
ACS	B-ENZY
-	O
ARDS	O
).	O

In	O
addition	O
,	O
we	O
identified	O
a	O
novel	O
bat	B-ENZY
rotavirus	O
belonging	O
to	O
group	O
H	O
rotavirus	O
which	O
has	O
only	O
been	O
described	O
in	O
human	O
and	O
pigs	O
until	O
now	O
.	O

Therefore	O
,	O
our	O
results	O
suggest	O
the	O
need	O
for	O
continuing	O
surveillance	O
and	O
additional	O
virological	O
studies	O
in	O
domestic	O
bat	B-ENZY
.	O

Though	O
not	O
confirmed	O
yet	O
,	O
multiple	O
surveillance	O
and	O
phylogenetic	O
studies	O
suggest	O
a	O
bat	B-ENZY
origin	O
.	O

Additionally	O
,	O
this	O
epitope	O
was	O
cross	O
-	O
protective	O
between	O
human	O
and	O
bat	B-ENZY
CoVs	O
,	O
the	O
progenitors	O
for	O
many	O
human	O
CoVs	O
.	O

The	O
S	O
protein	O
has	O
a	O
multidomain	O
architecture	O
and	O
has	O
been	O
reported	O
to	O
bind	O
to	O
carbohydrate	O
(	O
sialic	O
acid	O
)	O
and	O
proteinaceous	O
(	O
aminopeptidase	B-ENZY
N	I-ENZY
)	O
cell	O
surface	O
molecules	O
.	O

The	O
range	O
of	O
threshold	O
cycle	O
(	O
Ct	O
)	O
values	O
observed	O
when	O
detecting	O
upE	O
in	O
sputum	O
samples	O
was	O
31	O
.	O
1	O
-	O
35	O
.	O
4	O
with	O
the	O
PK	O
-	O
DNase	B-ENZY
method	O
,	O
34	O
.	O
7	O
-	O
39	O
.	O
0	O
with	O
the	O
PBS	O
method	O
,	O
and	O
33	O
.	O
9	O
-	O
38	O
.	O
6	O
with	O
the	O
NALC	O
method	O
.	O

TITLE	O
:	O
Safe	O
and	O
Sensitive	O
Antiviral	O
Screening	O
Platform	O
Based	O
on	O
Recombinant	O
Human	O
Coronavirus	O
OC43	O
Expressing	O
the	O
Luciferase	B-ENZY
Reporter	O
Gene	O
.	O

STAT1	O
downregulation	O
was	O
blocked	O
by	O
a	O
proteasome	B-ENZY
inhibitor	O
but	O
not	O
by	O
an	O
autophagy	O
inhibitor	O
,	O
strongly	O
implicating	O
the	O
ubiquitin	O
-	O
proteasome	B-ENZY
targeting	O
degradation	O
system	O
.	O

Records	O
of	O
patients	O
with	O
severe	O
trauma	O
hospitalized	O
in	O
our	O
department	O
from	O
January	O
2010	O
to	O
December	O
2012	O
were	O
extracted	O
from	O
trauma	O
database	O
and	O
analyzed	O
,	O
including	O
gender	O
,	O
age	O
,	O
basic	O
situation	O
after	O
admission	O
[	O
including	O
systolic	O
pressure	O
,	O
diastolic	O
pressure	O
,	O
axillary	O
temperature	O
,	O
heart	O
rate	O
,	O
Injury	O
Severity	O
Score	O
(	O
ISS	O
),	O
Acute	O
Physiology	O
and	O
Chronic	O
Health	O
Evaluation	O
(	O
APACHE	O
)	O
	O
score	O
,	O
Glasgow	O
Coma	O
Score	O
,	O
and	O
urine	O
volume	O
on	O
the	O
first	O
day	O
],	O
the	O
first	O
time	O
determination	O
values	O
of	O
physiological	O
and	O
biochemical	O
indexes	O
after	O
admission	O
(	O
including	O
pH	O
value	O
,	O
base	O
excess	O
,	O
PaCO	O
(	O
2	O
),	O
PaO	B-ENZY
(	O
2	O
),	O
standard	O
bicarbonate	O
ion	O
,	O
leucocyte	O
count	O
,	O
neutrophile	O
granulocyte	O
,	O
hemoglobin	O
,	O
platelet	O
count	O
,	O
albumin	O
,	O
urea	O
nitrogen	O
,	O
lactic	O
acid	O
,	O
blood	O
glucose	O
,	O
and	O
blood	O
sodium	O
),	O
surgical	O
situation	O
,	O
length	O
of	O
ICU	O
stay	O
,	O
occurrence	O
of	O
major	O
complications	O
[	O
including	O
infection	O
,	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
),	O
multiple	O
organ	O
dysfunction	O
syndrome	O
(	O
MODS	O
)/	O
multiple	O
organ	O
failure	O
(	O
MOF	O
)],	O
and	O
death	O
.	O

Activation	O
of	O
caspase	B-ENZY
-	I-ENZY
3	I-ENZY
in	O
lung	O
tissue	O
after	O
DH	O
was	O
C5	O
-	O
dependent	O
whereas	O
local	O
inflammation	O
in	O
lung	O
tissue	O
was	O
C5	O
-	O
independent	O
.	O

Porcine	O
aminopeptidase	B-ENZY
N	I-ENZY
(	O
pAPN	O
)	O
has	O
been	O
reported	O
to	O
be	O
the	O
receptor	O
for	O
PEDV	O
,	O
although	O
robust	O
evidence	O
is	O
lacking	O
.	O

Early	O
diagnosis	O
and	O
intervention	O
has	O
the	O
potential	O
to	O
have	O
a	O
beneficial	O
effect	O
on	O
CAD	B-ENZY
prognosis	O
.	O

SM	B-ENZY
synthase	I-ENZY
(	O
SMS	B-ENZY
)	O
is	O
a	O
key	O
enzyme	O
in	O
the	O
synthesis	O
of	O
SM	O
,	O
however	O
,	O
the	O
effect	O
of	O
SMS	B-ENZY
on	O
the	O
inflammatory	O
pathway	O
involving	O
nuclear	O
factor	O
(	O
NF	O
)	O
B	O
induced	O
by	O
LPS	O
remains	O
to	O
be	O
elucidated	O
.	O

ELISAs	O
were	O
performed	O
for	O
the	O
detection	O
of	O
rota	O
-	O
and	O
coronavirus	O
,	O
E	O
.	O
coli	O
F5	O
and	O
Cryptosporidium	O
spp	B-ENZY
.	O

The	O
calcium	B-ENZY
/	I-ENZY
calmodulin	I-ENZY
-	I-ENZY
dependent	I-ENZY
protein	I-ENZY
kinase	I-ENZY
II	O
delta	O
(	O
CAMK2D	O
),	O
which	O
normally	O
influences	O
RCHY1	O
stability	O
by	O
phosphorylation	O
,	O
also	O
binds	O
to	O
SUD	O
.	O

Transient	O
transfection	O
of	O
pFcRn	O
promoter	O
luciferase	B-ENZY
report	O
plasmids	O
with	O
overexpression	O
of	O
NF	O
-	O
B	O
p65	O
transcription	O
factor	O
enhanced	O
the	O
activation	O
of	O
the	O
luciferase	B-ENZY
report	O
plasmids	O
.	O

We	O
identified	O
four	O
NF	O
-	O
B	O
transcription	O
factor	O
binding	O
sites	O
in	O
the	O
promoter	O
region	O
of	O
this	O
gene	O
using	O
luciferase	B-ENZY
reporter	O
system	O
,	O
chromatin	O
immunoprecipitation	O
,	O
electromobility	O
shift	O
assay	O
,	O
and	O
supershift	O
analysis	O
.	O

TITLE	O
:	O
Suppression	O
of	O
Virulent	O
Porcine	O
Epidemic	O
Diarrhea	O
Virus	O
Proliferation	O
by	O
the	O
PI3K	O
/	O
Akt	O
/	O
GSK	B-ENZY
-	O
3	O
/	O
	O
Pathway	O
.	O

TITLE	O
:	O
PaO	B-ENZY
ABSTRACT	O
:	O
During	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
ECMO	O
),	O
arterial	O
oxygen	O
partial	O
pressure	O
to	O
fractional	O
inspired	O
oxygen	O
(	O
PaO	B-ENZY
This	O
was	O
a	O
single	O
-	O
center	O
observational	O
study	O
of	O
adult	O
patients	O
(	O
n	O
=	O
81	O
)	O
undergoing	O
veno	O
-	O
venous	O
ECMO	O
support	O
for	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
.	O

The	O
risk	O
factors	O
of	O
elevated	O
amylase	O
or	O
lipase	B-ENZY
were	O
analyzed	O
by	O
Logistic	O
regression	O
analysis	O
.	O

The	O
risk	O
factors	O
of	O
elevated	O
amylase	O
or	O
lipase	B-ENZY
were	O
age	O
,	O
convulsions	O
,	O
consciousness	O
,	O
BE	O
,	O
PCT	O
,	O
calcium	O
,	O
mechanical	O
ventilation	O
,	O
severe	O
sepsis	O
and	O
MODS	O
(	O
OR	O
=	O
1	O
.	O
155	O
,	O
1	O
.	O
491	O
,	O
2	O
.	O
237	O
,	O
0	O
.	O
949	O
,	O
0	O
.	O
604	O
,	O
1	O
.	O
008	O
,	O
0	O
.	O
660	O
,	O
1	O
.	O
907	O
,	O
0	O
.	O
836	O
,	O
P	O
all	O
<	O
0	O
.	O
05	O
).	O

Chromatin	O
immunoprecipitation	O
,	O
dual	O
-	O
luciferase	B-ENZY
reporter	O
gene	O
assay	O
,	O
and	O
co	O
-	O
immunoprecipitation	O
experiments	O
illustrated	O
that	O
PEDV	O
-	O
N	O
could	O
induce	O
HMGB1	O
transcription	O
by	O
interacting	O
with	O
C	O
/	O
EBP	O
-	O
	O
,	O
which	O
could	O
bind	O
to	O
C	O
/	O
EBP	O
motif	O
in	O
HMGB1	O
promotor	O
region	O
.	O

The	O
phylogenetic	O
analysis	O
indicates	O
this	O
novel	O
strain	O
is	O
most	O
closely	O
related	O
to	O
lineage	O
D	O
Betacoronaviruses	O
detected	O
in	O
a	O
diverse	O
range	O
of	O
bat	B-ENZY
species	O
.	O

The	O
advancements	O
in	O
metagenomic	O
techniques	O
have	O
allowed	O
the	O
identification	O
of	O
SARS	O
-	O
like	O
coronaviruses	O
(	O
SL	O
-	O
CoVs	O
)	O
sequences	O
that	O
share	O
high	O
homology	O
to	O
the	O
human	O
SARS	O
-	O
CoV	O
epidemic	O
strains	O
from	O
wildlife	O
bats	O
,	O
presenting	O
concrete	O
evidence	O
that	O
bats	O
are	O
the	O
origin	O
and	O
natural	O
reservoir	O
of	O
SARS	O
-	O
CoV	O
.	O
The	O
application	O
of	O
reverse	O
genetics	O
further	O
enabled	O
that	O
characterization	O
of	O
these	O
bat	B-ENZY
CoVs	O
and	O
the	O
prediction	O
of	O
their	O
potential	O
to	O
cause	O
disease	O
in	O
humans	O
.	O

The	O
knowledge	O
gained	O
from	O
such	O
studies	O
is	O
valuable	O
in	O
the	O
surveillance	O
and	O
preparation	O
of	O
a	O
possible	O
future	O
outbreak	O
caused	O
by	O
a	O
spill	O
-	O
over	O
of	O
these	O
bat	B-ENZY
SL	O
-	O
CoVs	O
.	O

Several	O
strategies	O
based	O
on	O
membrane	O
gas	B-ENZY
exchangers	O
have	O
been	O
developed	O
.	O

Collected	O
data	O
was	O
subjected	O
to	O
descriptive	O
statistics	O
to	O
express	O
demographic	O
information	O
,	O
mean	O
knowledge	O
score	O
,	O
mean	O
attitude	O
score	O
and	O
practice	O
score	O
of	O
DHPs	B-ENZY
.	O

ABSTRACT	O
:	O
Human	O
coronavirus	O
229E	O
(	O
HCoV	O
-	O
229E	O
),	O
a	O
causative	O
agent	O
of	O
the	O
common	O
cold	O
,	O
enters	O
host	O
cells	O
via	O
two	O
distinct	O
pathways	O
:	O
one	O
is	O
mediated	O
by	O
cell	O
surface	O
proteases	O
,	O
particularly	O
transmembrane	O
protease	O
serine	O
2	O
(	O
TMPRSS2	O
),	O
and	O
the	O
other	O
by	O
endosomal	O
cathepsin	B-ENZY
L	I-ENZY
.	O
Thus	O
,	O
specific	O
inhibitors	O
of	O
these	O
proteases	O
block	O
virus	O
infection	O
.	O

These	O
results	O
indicated	O
that	O
Nur77	O
decreases	O
ET	O
-	O
1	O
expression	O
by	O
suppressing	O
NF	O
-	O
B	O
and	O
p38	O
MAPK	B-ENZY
in	O
LPS	O
-	O
stimulated	O
A549	O
cells	O
in	O
vitro	O
,	O
and	O
,	O
in	O
an	O
LPS	O
-	O
induced	O
ARDS	O
rat	O
model	O
,	O
CsnB	O
reduced	O
ET	O
-	O
1	O
expression	O
and	O
lung	O
injury	O
in	O
ARDS	O
rats	O
.	O

The	O
new	O
synthesized	O
compounds	O
are	O
active	O
towards	O
both	O
DNA	O
polymerase	O
and	O
ribonuclease	B-ENZY
H	I-ENZY
in	O
the	O
M	O
range	O
.	O

Besides	O
the	O
well	O
-	O
known	O
type	O
I	O
interferon	O
(	O
IFN	O
-	O
	O
/	O
	O
)	O
response	O
,	O
the	O
protein	B-ENZY
kinase	I-ENZY
R	O
(	O
PKR	O
)-	O
mediated	O
stress	O
response	O
is	O
being	O
recognized	O
as	O
an	O
important	O
innate	O
response	O
pathway	O
.	O

We	O
aimed	O
to	O
evaluate	O
the	O
effect	O
of	O
PEEP	O
on	O
ICP	O
and	O
CPP	O
in	O
a	O
large	O
population	O
of	O
patients	O
with	O
acute	O
brain	O
injury	O
and	O
varying	O
categories	O
of	O
acute	O
lung	O
injury	O
,	O
defined	O
by	O
PaO	B-ENZY
Retrospective	O
data	O
were	O
collected	O
from	O
341	O
patients	O
with	O
severe	O
acute	O
brain	O
injury	O
admitted	O
to	O
the	O
ICU	O
between	O
2008	O
and	O
2015	O
.	O

Levels	O
of	O
serum	O
amylase	O
and	O
lipase	B-ENZY
were	O
elevated	O
to	O
663	O
U	O
/	O
L	O
and	O
3	O
,	O
232	O
U	O
/	O
L	O
.	O
Contrast	O
-	O
enhanced	O
abdominal	O
CT	O
showed	O
pancreatic	O
swelling	O
,	O
peri	O
-	O
pancreatic	O
fat	O
infiltration	O
and	O
fluid	O
collection	O
.	O

Using	O
real	O
time	O
reverse	B-ENZY
transcriptase	I-ENZY
polymerase	O
chain	O
reaction	O
of	O
pediatric	O
patients	O
revealed	O
that	O
9	O
out	O
of	O
552	O
(	O
1	O
.	O
6	O
%)	O
was	O
positive	O
in	O
the	O
Kingdom	O
of	O
Saudi	O
Arabia	O
.	O

Clinically	O
,	O
patients	O
presented	O
with	O
severe	O
,	O
nonspecific	O
,	O
multisystem	O
disease	O
characterized	O
by	O
shortness	O
of	O
breath	O
,	O
abnormal	O
vital	O
signs	O
,	O
and	O
laboratory	O
derangements	O
including	O
hyponatremia	O
,	O
elevated	O
creatine	B-ENZY
kinase	I-ENZY
,	O
and	O
evidence	O
of	O
organ	O
dysfunction	O
.	O

Three	O
new	O
bat	B-ENZY
genera	O
and	O
species	O
were	O
newly	O
identified	O
as	O
host	O
of	O
coronaviruses	O
,	O
namely	O
Macroglossus	O
sp	O
.,	O
Megaerops	O
niphanae	O
and	O
Myotis	O
horsfieldii	O
.	O

Our	O
aim	O
was	O
to	O
investigate	O
the	O
relationships	O
between	O
ARDS	O
diagnosis	O
and	O
plasma	O
concentrations	O
of	O
tissue	O
factor	O
(	O
TF	O
),	O
tissue	B-ENZY
plasminogen	I-ENZY
activator	I-ENZY
(	O
t	O
-	O
PA	O
),	O
and	O
plasminogen	O
activator	O
inhibitor	O
-	O
1	O
(	O
PAI	O
-	O
1	O
)	O
in	O
mechanically	O
ventilated	O
patients	O
at	O
increased	O
risk	O
of	O
developing	O
ARDS	O
.	O

Of	O
the	O
2580	O
patients	O
who	O
underwent	O
a	O
bronchoalveolar	O
lavage	O
(	O
BAL	B-ENZY
)	O
procedure	O
at	O
Tosei	O
General	O
Hospital	O
between	O
May	O
2007	O
and	O
February	O
2015	O
,	O
we	O
retrospectively	O
analysed	O
the	O
data	O
of	O
68	O
DLI	O
patients	O
.	O

Soluble	O
TM	O
in	O
plasma	O
and	O
BAL	B-ENZY
fluid	O
(	O
BALF	O
),	O
and	O
other	O
biomarkers	O
were	O
included	O
in	O
our	O
analysis	O
.	O

At	O
the	O
time	O
of	O
diagnosis	O
,	O
39	O
patients	O
(	O
57	O
%)	O
had	O
respiratory	O
failure	O
(	O
partial	O
pressure	O
of	O
oxygen	O
/	O
inspiratory	O
oxygen	O
fraction	O
ratio	O
,	O
PaO	B-ENZY
Soluble	O
TM	O
in	O
BALF	O
is	O
an	O
independent	O
predictor	O
of	O
severe	O
DLI	O
.	O

The	O
MV	O
and	O
NIV	O
groups	O
did	O
not	O
differ	O
in	O
age	O
,	O
medical	O
history	O
,	O
etiology	O
of	O
CS	O
,	O
PaO	B-ENZY
Although	O
MV	O
is	O
generally	O
recommended	O
mode	O
of	O
ventilatory	O
support	O
in	O
CS	O
,	O
a	O
fair	O
number	O
of	O
patients	O
were	O
successfully	O
treated	O
with	O
NIV	O
.	O

ABSTRACT	O
:	O
Ubiquitin	O
-	O
like	O
domain	O
2	O
(	O
Ubl2	O
)	O
is	O
immediately	O
adjacent	O
to	O
the	O
N	O
-	O
terminus	O
of	O
the	O
papain	B-ENZY
-	O
like	O
protease	O
(	O
PLpro	O
)	O
domain	O
in	O
coronavirus	O
polyproteins	O
,	O
and	O
it	O
may	O
play	O
a	O
critical	O
role	O
in	O
protease	O
regulation	O
and	O
stability	O
as	O
well	O
as	O
in	O
viral	O
infection	O
.	O

All	O
polyphenols	O
were	O
more	O
potent	O
against	O
papain	B-ENZY
-	O
like	O
protease	O
(	O
PL	O

Over	O
two	O
thirds	O
were	O
either	O
""""	O
not	O
concerned	O
""""	O
or	O
""""	O
slightly	O
concerned	O
""""	O
about	O
contracting	O
MERS	O
-	O
CoV	O
;	O
believing	O
that	O
they	O
were	O
under	O
Allah	O
'	O
s	O
(	O
God	B-ENZY
'	O
s	O
)	O
protection	O
(	O
40	O
%)	O
was	O
the	O
most	O
cited	O
reason	O
.	O

Agreement	O
among	O
TTW	O
and	O
NS	O
,	O
TTW	O
and	O
NPS	O
,	O
and	O
TTW	O
and	O
BAL	B-ENZY
,	O
was	O
very	O
good	O
for	O
identification	O
of	O
P	O
.	O
multocida	O
,	O
M	O
.	O
haemolytica	O
,	O
and	O
M	O
.	O
bovis	O
.	O

ABSTRACT	O
:	O
Coronavirus	O
papain	B-ENZY
-	O
like	O
proteases	O
(	O
PLPs	O
)	O
can	O
act	O
as	O
proteases	O
that	O
process	O
virus	O
-	O
encoded	O
large	O
replicase	O
polyproteins	O
and	O
also	O
as	O
deubiquitinating	O
(	O
DUB	O
)	O
enzymes	O
.	O

Patients	O
with	O
Legionella	O
pneumonia	O
were	O
slightly	O
older	O
than	O
patients	O
with	O
acute	O
respiratory	O
failure	O
of	O
other	O
etiologies	O
(	O
51	O
[	O
48	O
-	O
56	O
]	O
vs	O
45	O
[	O
35	O
-	O
54	O
]),	O
but	O
with	O
no	O
significant	O
differences	O
in	O
acute	O
respiratory	O
failure	O
severity	O
between	O
groups	O
:	O
Pao	B-ENZY
In	O
Legionella	O
pneumonia	O
complicated	O
by	O
refractory	O
respiratory	O
failure	O
,	O
ECMO	O
support	O
allowed	O
patient	O
stabilization	O
under	O
lung	O
protective	O
ventilation	O
and	O
high	O
survival	O
rates	O
.	O

After	O
adjusting	O
for	O
severity	O
of	O
illness	O
,	O
risk	O
factors	O
for	O
mortality	O
were	O
:	O
hospital	O
acquired	O
pneumonia	O
(	O
HAP	O
)	O
(	O
aOR	B-ENZY
:	O
2	O
.	O
92	O
[	O
95	O
%	O
CI	O
1	O
.	O
15	O
,	O
7	O
.	O
40	O
];	O
P	O
=	O
0	O
.	O
024	O
)	O
and	O
bacteremia	O
(	O
aOR	B-ENZY
:	O
5	O
.	O
03	O
[	O
95	O
%	O
CI	O
1	O
.	O
77	O
,	O
14	O
.	O
35	O
];	O
P	O
=	O
0	O
.	O
003	O
).	O

TITLE	O
:	O
Group	O
A	O
Rotaviruses	O
in	O
Chinese	O
Bats	O
:	O
Genetic	O
Composition	O
,	O
Serology	O
,	O
and	O
Evidence	O
for	O
Bat	B-ENZY
-	O
to	O
-	O
Human	O
Transmission	O
and	O
Reassortment	O
.	O

ABSTRACT	O
:	O
To	O
help	O
reveal	O
the	O
diversity	O
and	O
evolution	O
of	O
bat	B-ENZY
coronaviruses	O
we	O
collected	O
1067	O
bats	O
from	O
21	O
species	O
in	O
China	O
.	O

ABSTRACT	O
:	O
This	O
is	O
the	O
first	O
country	O
-	O
wide	O
surveillance	O
of	O
bat	B-ENZY
-	O
borne	O
viruses	O
in	O
Kenya	O
spanning	O
from	O
2012	O
-	O
2015	O
covering	O
sites	O
perceived	O
to	O
have	O
medium	O
to	O
high	O
level	O
bat	B-ENZY
-	O
human	O
interaction	O
.	O

We	O
set	O
out	O
to	O
determine	O
if	O
dyspnea	O
in	O
patients	O
with	O
ENS	O
was	O
associated	O
with	O
hyperventilation	O
syndrome	O
(	O
HVS	B-ENZY
).	O

HVS	B-ENZY
was	O
defined	O
by	O
a	O
delayed	O
return	O
of	O
the	O
end	O
-	O
tidal	O
partial	O
pressure	O
of	O
carbon	O
dioxide	O
in	O
the	O
expired	O
gas	B-ENZY
to	O
baseline	O
during	O
HVPT	O
.	O

ABSTRACT	O
:	O
SARS	O
coronavirus	O
(	O
CoV	O
)	O
papain	B-ENZY
-	O
like	O
protease	O
(	O
PLpro	O
)	O
reportedly	O
induced	O
the	O
production	O
of	O
TGF	O
-	O
1	O
through	O
p38	O
MAPK	B-ENZY
/	O
STAT3	O
-	O
meidated	O
Egr	O
-	O
1	O
-	O
dependent	O
activation	O
(	O
Sci	O
.	O

Our	O
study	O
shows	O
that	O
potentially	O
novel	O
variants	O
of	O
paramyxoviruses	O
and	O
coronaviruses	O
commonly	O
circulate	O
in	O
bat	B-ENZY
and	O
rat	O
populations	O
in	O
Viet	O
Nam	O
.	O

Combined	O
with	O
sequence	O
variation	O
in	O
the	O
HKU5	O
-	O
CTD	O
receptor	O
binding	O
interface	O
,	O
we	O
propose	O
the	O
necessity	O
for	O
surveilling	O
the	O
mutation	O
in	O
BatCoV	O
HKU5	O
spike	O
protein	O
in	O
case	O
of	O
bat	B-ENZY
-	O
to	O
-	O
human	O
interspecies	O
transmission	O
.	O

TITLE	O
:	O
The	O
Rational	O
Design	O
of	O
Therapeutic	O
Peptides	O
for	O
Aminopeptidase	B-ENZY
N	I-ENZY
using	O
a	O
Substrate	O
-	O
Based	O
Approach	O
.	O

ECMO	O
and	O
non	O
-	O
ECMO	O
survivors	O
showed	O
similar	O
pulmonary	O
function	O
,	O
morphological	O
abnormalities	O
,	O
resting	O
arterial	O
blood	O
gas	B-ENZY
values	O
,	O
and	O
6	O
-	O
min	O
walking	O
distance	O
.	O

Bronchoalveolar	O
lavage	O
(	O
BAL	B-ENZY
)	O
with	O
normal	O
saline	O
and	O
surfactant	O
allows	O
the	O
removal	O
of	O
inhaled	O
material	O
,	O
the	O
recruitment	O
of	O
non	O
-	O
ventilating	O
areas	O
and	O
the	O
maintenance	O
of	O
the	O
surfactant	O
pool	O
size	O
.	O

Severity	O
criteria	O
often	O
depend	O
on	O
arterial	O
blood	O
gas	B-ENZY
results	O
.	O

TITLE	O
:	O
Uvaria	O
angolensis	O
as	O
a	O
promising	O
source	O
of	O
inhibitors	O
of	O
HIV	O
-	O
1	O
RT	O
-	O
associated	O
RNA	O
-	O
dependent	O
DNA	O
polymerase	O
and	O
RNase	B-ENZY
H	I-ENZY
functions	O
.	O

Zinc	O
phosphide	O
is	O
hydrolyzed	O
by	O
the	O
gastric	O
acid	O
and	O
is	O
transformed	O
into	O
phosphine	O
gas	B-ENZY
.	O

ABSTRACT	O
:	O
Our	O
previous	O
screening	O
of	O
50	O
240	O
structurally	O
diverse	O
compounds	O
led	O
to	O
the	O
identification	O
of	O
39	O
influenza	O
A	O
virus	O
infection	O
inhibitors	O
(	O
Kao	O
R	O
.	O
Y	O
.,	O
Yang	O
D	O
.,	O
Lau	O
L	O
.	O
S	O
.,	O
Tsui	O
W	O
.	O
H	O
.,	O
Hu	O
L	O
.	O
et	O
al	O
.	O
Nat	B-ENZY
Biotechnol	O
2010	O
;	O
28	O
:	O
600	O
-	O
605	O
).	O

ABSTRACT	O
:	O
Hantavirus	O
infection	O
is	O
an	O
acute	O
zoonosis	O
that	O
clinically	O
manifests	O
in	O
two	O
primary	O
forms	O
,	O
hemorrhagic	O
fever	O
with	O
renal	O
syndrome	O
(	O
HFRS	O
)	O
and	O
hantavirus	O
pulmonary	O
syndrome	O
(	O
HPS	B-ENZY
).	O

In	O
order	O
to	O
identify	O
potential	O
serological	O
markers	O
that	O
distinguish	O
HFRS	O
and	O
HPS	B-ENZY
,	O
serum	O
samples	O
collected	O
during	O
early	O
and	O
late	O
phases	O
of	O
the	O
disease	O
were	O
analyzed	O
for	O
48	O
analytes	O
using	O
multiplex	O
magnetic	O
bead	O
-	O
based	O
assays	O
.	O

These	O
profiles	O
suggest	O
a	O
strong	O
activation	O
of	O
an	O
innate	O
immune	O
and	O
inflammatory	O
responses	O
are	O
associated	O
with	O
HPS	B-ENZY
,	O
relative	O
to	O
HFRS	O
,	O
as	O
well	O
as	O
a	O
robust	O
activation	O
of	O
Th1	O
-	O
type	O
immune	O
responses	O
.	O

Further	O
studies	O
showed	O
that	O
both	O
MHV	O
and	O
SARS	O
-	O
CoV	O
N	O
proteins	O
directly	O
interacted	O
with	O
protein	O
activator	O
of	O
protein	B-ENZY
kinase	I-ENZY
R	O
(	O
PACT	O
),	O
a	O
cellular	O
dsRNA	O
-	O
binding	O
protein	O
that	O
can	O
bind	O
to	O
RIG	O
-	O
I	O
and	O
MDA5	O
to	O
activate	O
IFN	O
production	O
.	O

Half	O
the	O
patients	O
received	O
mechanical	O
ventilation	O
within	O
1	O
(	O
1	O
-	O
2	O
)	O
day	O
following	O
ICU	O
admission	O
(	O
the	O
ratio	O
of	O
arterial	O
oxygen	O
partial	O
pressure	O
to	O
fractional	O
inspired	O
oxygen	O
(	O
PaO	B-ENZY
Severe	O
VZV	O
-	O
CAP	O
is	O
responsible	O
for	O
an	O
acute	O
pulmonary	O
involvement	O
associated	O
with	O
a	O
significant	O
morbidity	O
and	O
mortality	O
.	O

Conversely	O
,	O
residue	O
R797	O
,	O
previously	O
reported	O
to	O
be	O
required	O
for	O
SARS	O
S	O
activation	O
by	O
trypsin	B-ENZY
,	O
was	O
dispensable	O
for	O
S	O
protein	O
cleavage	O
but	O
required	O
for	O
S	O
protein	O
activation	O
by	O
TMPRSS2	O
.	O

We	O
then	O
performed	O
combination	O
studies	O
of	O
Lupeol	O
and	O
the	O
active	O
site	O
RNase	B-ENZY
H	I-ENZY
inhibitor	O
RDS1759	O
,	O
and	O
blind	O
docking	O
calculations	O
,	O
demonstrating	O
that	O
Lupeol	O
binds	O
to	O
an	O
HIV	O
-	O
1	O
RT	O
allosteric	O
pocket	O
.	O

TITLE	O
:	O
A	O
New	O
Bat	B-ENZY
-	O
HKU2	O
-	O
like	O
Coronavirus	O
in	O
Swine	O
,	O
China	O
,	O
2017	O
.	O

We	O
queried	O
the	O
electronic	O
medical	O
records	O
with	O
the	O
diagnostic	O
codes	O
for	O
SCD	O
with	O
acute	O
chest	O
syndrome	O
(	O
ACS	B-ENZY
),	O
pulmonary	O
embolism	O
,	O
or	O
acute	O
respiratory	O
distress	O
syndrome	O
admitted	O
to	O
our	O
hospital	O
from	O
2008	O
to	O
2016	O
to	O
identify	O
patients	O
suspected	O
of	O
having	O
FES	O
.	O

Using	O
the	O
recombinant	O
S	O
proteins	O
as	O
probes	O
to	O
perform	O
S	O
protein	O
affinity	O
histochemistry	O
in	O
paraffin	O
-	O
embedded	O
tissues	O
,	O
although	O
no	O
tissue	O
or	O
enteric	O
binding	O
of	O
FECV	O
UU7	O
S	O
protein	O
was	O
detected	O
,	O
it	O
was	O
found	O
that	O
by	O
immunohistochemistry	O
that	O
the	O
tissue	O
distribution	O
of	O
FIPV	O
UU4	O
S	O
protein	O
-	O
bound	O
cells	O
correlated	O
with	O
that	O
of	O
FIPV	O
antigen	O
-	O
positive	O
cells	O
and	O
lesions	O
associated	O
with	O
FIP	O
and	O
that	O
the	O
affinity	O
binding	O
of	O
FIPV	O
UU4	O
S	O
protein	O
on	O
macrophages	O
was	O
not	O
affected	O
by	O
enzymatic	O
removal	O
of	O
host	O
cell	O
-	O
surface	O
sialic	O
acid	O
with	O
neuraminidase	B-ENZY
.	O

Adults	O
with	O
severe	O
injury	O
who	O
underwent	O
definitive	O
fixation	O
of	O
a	O
femoral	O
shaft	O
fracture	O
at	O
a	O
level	O
I	O
or	O
II	O
trauma	O
center	O
participating	O
in	O
ACS	B-ENZY
TQIP	O
(	O
2012	O
-	O
2015	O
)	O
were	O
included	O
.	O

This	O
study	O
was	O
conducted	O
to	O
develop	O
a	O
drug	O
delivery	O
system	O
using	O
lipid	O
-	O
core	O
nanocapsules	O
(	O
LNCs	O
)	O
to	O
improve	O
the	O
anti	O
-	O
inflammatory	O
effects	O
of	O
orally	O
administered	O
	O
-	O
bis	B-ENZY
.	O

	O
-	O
bis	B-ENZY
-	O
loaded	O
LNCs	O
(	O
	O
-	O
bis	B-ENZY
-	O
LNCs	O
)	O
were	O
prepared	O
by	O
interfacial	O
deposition	O
of	O
poly	O
(	O
	O
-	O
caprolactone	O
)	O
and	O
orally	O
administered	O
in	O
a	O
mouse	O
model	O
of	O
ARDS	O
triggered	O
by	O
an	O
intranasal	O
administration	O
of	O
lipopolysaccharide	O
(	O
LPS	O
).	O

Newly	O
Discovered	O
Nycteribiid	O
Bat	B-ENZY
Flies	O
Infesting	O
Previously	O
Unknown	O
Pteropodid	O
Bats	O
in	O
Uganda	O
.	O

However	O
,	O
little	O
is	O
known	O
about	O
the	O
role	O
of	O
bat	B-ENZY
ectoparasites	O
in	O
transmitting	O
and	O
maintaining	O
such	O
viruses	O
.	O

ABSTRACT	O
:	O
Several	O
infectious	O
disease	O
outbreaks	O
with	O
high	O
mortality	O
in	O
humans	O
have	O
been	O
attributed	O
to	O
viruses	O
that	O
are	O
thought	O
to	O
have	O
evolved	O
from	O
bat	B-ENZY
viruses	O
.	O

RT	O
-	O
PCR	O
and	O
sequencing	O
were	O
performed	O
for	O
specific	O
coronavirus	O
genes	O
to	O
identify	O
the	O
bat	B-ENZY
coronaviruses	O
in	O
different	O
bat	B-ENZY
samples	O
.	O

ABSTRACT	O
:	O
An	O
analysis	O
of	O
cardiac	O
injury	O
markers	O
in	O
patients	O
with	O
OSA	O
who	O
sustain	O
an	O
episode	O
of	O
acute	O
coronary	O
syndrome	O
(	O
ACS	B-ENZY
)	O
may	O
contribute	O
to	O
a	O
better	O
understanding	O
of	O
the	O
interactions	O
and	O
impact	O
of	O
OSA	O
in	O
subjects	O
with	O
ACS	B-ENZY
.	O

We	O
compared	O
peak	O
cardiac	O
troponin	O
I	O
(	O
cTnI	O
)	O
levels	O
in	O
patients	O
with	O
OSA	O
and	O
patients	O
without	O
OSA	O
who	O
were	O
admitted	O
for	O
ACS	B-ENZY
.	O

PPV	O
increased	O
PaO	B-ENZY
CONCLUSIONS	O
:	O
Our	O
findings	O
suggest	O
that	O
PPV	O
may	O
improve	O
oxygenation	O
and	O
partially	O
improve	O
hemodynamic	O
parameters	O
during	O
acute	O
exacerbations	O
of	O
ILD	O
.	O

There	O
are	O
additional	O
types	O
of	O
technology	O
frequently	O
used	O
in	O
the	O
general	O
stroke	O
population	O
that	O
can	O
address	O
similar	O
motor	O
deficits	O
that	O
occur	O
in	O
the	O
LIS	B-ENZY
population	O
.	O

Arterial	O
blood	O
samples	O
were	O
obtained	O
for	O
blood	O
gas	B-ENZY
analysis	O
before	O
electroacupuncture	O
(	O

In	O
the	O
following	O
days	O
,	O
we	O
observed	O
an	O
improvement	O
of	O
regional	O
ventilation	O
of	O
the	O
upper	O
and	O
middle	O
segments	O
of	O
the	O
left	O
lung	O
that	O
corresponded	O
well	O
with	O
laboratory	O
test	O
results	O
,	O
especially	O
arterial	O
blood	O
gas	B-ENZY
analysis	O
.	O

The	O
effects	O
of	O
nsp1	O
on	O
the	O
induction	O
of	O
typeinterferon	O
were	O
evaluated	O
by	O
dual	O
luciferase	B-ENZY
reporter	O
gene	O
assay	O
,	O
ELISA	O
and	O
VSV	O
bioassay	O
.	O

Using	O
these	O
techniques	O
,	O
we	O
discovered	O
many	O
novel	O
bat	B-ENZY
viruses	O
and	O
some	O
bat	B-ENZY
viruses	O
closely	O
-	O
related	O
to	O
known	O
human	O
/	O
animal	O
pathogens	O
,	O
including	O
coronavirus	O
,	O
norovirus	O
,	O
adenovirus	O
,	O
bocavirus	O
,	O
astrovirus	O
,	O
and	O
circovirus	O
.	O

To	O
investigate	O
the	O
detection	O
rates	O
of	O
bovine	O
coronavirus	O
(	O
BCoV	O
)	O
in	O
feces	O
of	O
healthy	O
and	O
diarrheic	O
calves	O
and	O
to	O
describe	O
the	O
usefulness	O
of	O
a	O
pancoronavirus	O
reverse	B-ENZY
transcriptase	I-ENZY
(	O
RT	B-ENZY
)	O
PCR	O
(	O
PanCoV	O
-	O
RT	B-ENZY
-	O
PCR	O
)	O
assay	O
to	O
identify	O
BCoV	O
in	O
samples	O
of	O
diarrheic	O
calves	O
.	O

The	O
serum	O
zinc	O
level	O
and	O
the	O
pulmonary	O
function	O
tests	O
and	O
liver	O
function	O
tests	O
including	O
total	O
lung	O
capacity	O
(	O
TLC	O
),	O
forced	O
vital	O
capacity	O
(	O
FVC	O
),	O
forced	O
expiratory	O
pressure	O
in	O
1	O
second	O
(	O
FEV1	O
),	O
alanine	B-ENZY
aminotransferase	I-ENZY
(	O
ALT	O
),	O
and	O
aspartate	B-ENZY
transaminase	I-ENZY
(	O
AST	B-ENZY
)	O
were	O
analyzed	O
.	O

In	O
light	O
of	O
the	O
pathogenic	O
mechanism	O
of	O
feline	O
coronavirus	O
that	O
relies	O
on	O
endosomal	O
acidification	O
for	O
cytoplasmic	O
entry	O
,	O
a	O
novel	O
vacuolar	O
ATPase	B-ENZY
blocker	O
,	O
diphyllin	O
,	O
and	O
its	O
nanoformulation	O
are	O
herein	O
investigated	O
for	O
their	O
antiviral	O
activity	O
against	O
the	O
type	O
II	O
feline	O
infectious	O
peritonitis	O
virus	O
(	O
FIPV	O
).	O

In	O
the	O
combined	O
data	O
set	O
of	O
IBV	O
challenged	O
shell	O
gland	O
samples	O
,	O
the	O
comprehensive	O
ranking	O
showed	O
TATA	O
-	O
box	O
binding	O
protein	O
(	O
TBP	O
)	O
and	O
tyrosine	B-ENZY
3	I-ENZY
-	I-ENZY
monooxygenase	I-ENZY
/	O
tryptophan	B-ENZY
5	I-ENZY
-	I-ENZY
monooxygenase	I-ENZY
activation	O
protein	O
zeta	O
(	O
YWHAZ	O
)	O
as	O
the	O
two	O
most	O
stable	O
,	O
and	O
succinate	B-ENZY
dehydrogenase	I-ENZY
complex	O
flavoprotein	O
subunit	O
A	O
(	O
SDHA	O
)	O
and	O
albumin	O
(	O
ALB	O
)	O
as	O
the	O
two	O
least	O
stable	O
reference	O
genes	O
.	O

Severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
is	O
associated	O
with	O
high	O
morbidity	O
and	O
mortality	O
,	O
and	O
ECMO	O
has	O
been	O
proven	O
to	O
increase	O
the	O
survival	O
rates	O
in	O
these	O
patients	O
by	O
improving	O
the	O
gas	B-ENZY
exchange	O
and	O
thus	O
preventing	O
the	O
further	O
hypoxia	O
and	O
catecholamine	O
induced	O
multi	O
-	O
organ	O
damage	O
.	O

Herein	O
,	O
a	O
neuraminidase	B-ENZY
inhibitor	O
11b	O
absent	O
of	O
basic	O
moieties	O
was	O
discovered	O
in	O
the	O
process	O
of	O
searching	O
for	O
inhibitors	O
targeting	O
150	O
cavity	O
.	O

During	O
the	O
CPR	B-ENZY
which	O
lasted	O
for	O
an	O
hour	O
,	O
a	O
large	O
amount	O
of	O
body	O
fluid	O
was	O
splashed	O
.	O

The	O
nurse	O
was	O
presumed	O
to	O
have	O
touched	O
the	O
mask	O
to	O
adjust	O
its	O
position	O
during	O
the	O
CPR	B-ENZY
.	O

Other	O
studies	O
have	O
shown	O
that	O
MTD	B-ENZY
-	O
induced	O
increases	O
in	O
miR	O
-	O
223	O
expression	O
are	O
mainly	O
contributed	O
by	O
Ly6G	O
+	O
neutrophils	O
from	O
the	O
haematopoietic	O
system	O
.	O

We	O
have	O
previously	O
demonstrated	O
an	O
ameliorated	O
syndrome	O
and	O
improved	O
survival	O
in	O
mice	O
with	O
early	O
administration	O
of	O
valproic	O
acid	O
(	O
VPA	O
),	O
a	O
broad	O
-	O
spectrum	O
histone	B-ENZY
deacetylase	I-ENZY
inhibitor	O
,	O
while	O
studies	O
in	O
humans	O
have	O
shown	O
no	O
benefit	O
when	O
anti	O
-	O
inflammatories	O
are	O
administered	O
late	O
.	O

The	O
medians	O
of	O
PaO	B-ENZY
Since	O
the	O
duration	O
of	O
MV	O
before	O
ECMO	O
institution	O
was	O
strongly	O
correlated	O
to	O
the	O
outcome	O
of	O
adult	O
respiratory	O
ECMO	O
,	O
medical	O
centers	O
are	O
suggested	O
to	O
find	O
a	O
suitable	O
prognosticating	O
tool	O
to	O
determine	O
the	O
starting	O
point	O
of	O
respiratory	O
ECMO	O
among	O
their	O
candidates	O
with	O
different	O
duration	O
of	O
MV	O
.	O

Among	O
them	O
,	O
c	O
-	O
Jun	O
N	O
-	O
terminal	O
kinases	O
(	O
JNK	B-ENZY
)	O
are	O
known	O
to	O
be	O
activated	O
by	O
various	O
environmental	O
stresses	O
including	O
virus	O
infections	O
.	O

Moreover	O
,	O
knockdown	O
and	O
overexpression	O
experiments	O
demonstrated	O
that	O
JNK	B-ENZY
served	O
as	O
a	O
pro	O
-	O
apoptotic	O
protein	O
during	O
IBV	O
infection	O
.	O

Interestingly	O
,	O
pro	O
-	O
apoptotic	O
activity	O
of	O
JNK	B-ENZY
was	O
not	O
mediated	O
via	O
c	O
-	O
Jun	O
,	O
but	O
involved	O
modulation	O
of	O
the	O
anti	O
-	O
apoptotic	O
protein	O
B	O
-	O
cell	O
lymphoma	O
2	O
(	O
Bcl2	O
).	O

This	O
study	O
identified	O
alpha	O
and	O
beta	O
-	O
CoVs	O
in	O
new	O
bat	B-ENZY
species	O
and	O
in	O
previously	O
unsurveyed	O
Italian	O
regions	O
.	O

RESULTS	O
:	O
Family	O
-	O
wide	O
PCR	O
screenings	O
were	O
used	O
to	O
test	O
302	O
bats	O
belonging	O
to	O
19	O
different	O
bat	B-ENZY
species	O
.	O

TITLE	O
:	O
Correction	O
to	O
:	O
Simultaneous	O
detection	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
,	O
Middle	O
East	O
respiratory	O
syndrome	O
,	O
and	O
related	O
bat	B-ENZY
coronaviruses	O
by	O
real	O
-	O
time	O
reverse	O
transcription	O
PCR	O
.	O

First	O
,	O
we	O
evaluated	O
the	O
inhibitory	O
effects	O
of	O
compounds	O
2	O
and	O
3	O
on	O
PRRSV	O
3CLSP	B-ENZY
activity	O
.	O

RESULTS	O
:	O
There	O
was	O
no	O
significant	O
difference	O
in	O
gender	O
,	O
age	O
,	O
onset	O
to	O
diagnosis	O
time	O
,	O
APACHE	O
II	O
score	O
,	O
PaO	B-ENZY

When	O
a	O
critical	O
event	O
occurred	O
,	O
the	O
PaO	B-ENZY
The	O
transport	O
of	O
critically	O
ill	O
patients	O
is	O
associated	O
with	O
potential	O
risks	O
.	O

However	O
,	O
the	O
pathogenic	O
mechanisms	O
underlying	O
influenza	O
virus	O
-	O
GAS	B-ENZY
superinfection	O
are	O
not	O
yet	O
fully	O
understood	O
.	O

Markers	O
of	O
muscle	O
proteolysis	O
were	O
not	O
different	O
(	O
P	O
>	O
0	O
.	O
05	O
)	O
between	O
treatments	O
within	O
dpi	O
;	O
however	O
,	O
at	O
dpi	O
5	O
,	O
20S	O
proteasome	B-ENZY
activity	O
was	O
increased	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
in	O
longissimus	O
dorsi	O
of	O
PEDV	O
pigs	O
compared	O
with	O
Control	O
pigs	O
.	O

He	O
presented	O
with	O
severe	O
diarrhoea	O
86	O
days	O
post	O
BMT	B-ENZY
and	O
was	O
diagnosed	O
with	O
graft	O
-	O
versus	O
-	O
host	O
disease	O
(	O
GVHD	O
)	O
based	O
on	O
skin	O
and	O
rectal	O
biopsies	O
.	O

This	O
is	O
an	O
ancillary	O
study	O
of	O
the	O
ISAACC	O
study	O
,	O
which	O
is	O
a	O
multicentre	O
,	O
prospective	O
,	O
open	O
-	O
label	O
,	O
parallel	O
,	O
randomized	O
,	O
and	O
controlled	O
trial	O
(	O
NCT01335087	O
)	O
in	O
patients	O
with	O
hospital	O
admission	O
for	O
ACS	B-ENZY
.	O

One	O
of	O
the	O
limitations	O
in	O
using	O
traditional	O
culture	O
systems	O
from	O
non	O
-	O
reservoir	O
species	O
is	O
that	O
cell	O
types	O
and	O
culture	O
conditions	O
may	O
not	O
be	O
compatible	O
for	O
isolation	O
of	O
bat	B-ENZY
-	O
borne	O
viruses	O
.	O

P	O
.	O
lylei	O
bats	O
were	O
captured	O
monthly	O
during	O
January	O
-	O
December	O
2012	O
for	O
detection	O
of	O
CoV	O
at	O
three	O
areas	O
in	O
Chonburi	O
province	O
;	O
two	O
human	O
dwellings	O
,	O
S1	O
and	O
S2	O
,	O
where	O
few	O
fruit	O
trees	O
were	O
located	O
with	O
an	O
open	O
pig	O
farm	O
,	O
0	O
.	O
6	O
km	O
and	O
5	O
.	O
5	O
km	O
away	O
from	O
the	O
bat	B-ENZY
roost	O
,	O
S3	O
.	O

Whether	O
viral	O
reactivation	O
during	O
parturition	O
period	O
or	O
stress	O
is	O
responsible	O
in	O
maintaining	O
transmission	O
in	O
the	O
bat	B-ENZY
colony	O
needs	O
to	O
be	O
explored	O
.	O

Ten	O
alphacoronaviruses	O
in	O
eleven	O
bat	B-ENZY
species	O
belonging	O
to	O
the	O
Miniopteridae	O
,	O
Vespertilionidae	O
and	O
Rhinolophidae	O
families	O
and	O
,	O
a	O
SARS	O
-	O
CoV	O
-	O
related	O
Betacoronavirus	O
in	O
Rhinolophus	O
ferrumequinum	O
were	O
identified	O
.	O

That	O
said	O
,	O
the	O
identified	O
coronaviruses	O
were	O
consistently	O
associated	O
with	O
a	O
particular	O
bat	B-ENZY
species	O
or	O
genus	O
,	O
and	O
these	O
relationships	O
were	O
maintained	O
no	O
matter	O
the	O
geographic	O
location	O
.	O

PEDV	O
infection	O
of	O
two	O
APN	O
-	O
knockout	O
Vero	O
cells	O
had	O
the	O
same	O
efficiency	O
as	O
the	O
Vero	O
cells	O
with	O
or	O
without	O
neuraminidase	B-ENZY
treatment	O
.	O

Among	O
the	O
isolated	O
metabolites	O
,	O
three	O
phloroglucinol	O
derivatives	O
and	O
quercitrin	O
were	O
effective	O
on	O
both	O
RT	O
-	O
associated	O
RDDP	O
and	O
RNase	B-ENZY
H	I-ENZY
activities	O
in	O
biochemical	O
assays	O
.	O

ABSTRACT	O
:	O
A	O
25	O
-	O
year	O
-	O
old	O
female	O
with	O
sickle	O
cell	O
anemia	O
presented	O
with	O
respiratory	O
failure	O
due	O
to	O
acute	O
chest	O
syndrome	O
(	O
ACS	B-ENZY
).	O

Using	O
chimeric	O
mouse	O
hepatitis	O
virus	O
(	O
MHV	O
)	O
expressing	O
TMEV	O
L	O
*,	O
we	O
showed	O
that	O
L	O
*	O
efficiently	O
inhibits	O
RNase	B-ENZY
L	O
in	O
vivo	O
.	O

Thus	O
,	O
the	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
fecal	O
S100A12	O
concentrations	O
in	O
a	O
cohort	O
of	O
puppies	O
with	O
intestinal	O
parasites	O
(	O
Cystoisospora	O
spp	B-ENZY
.,	O
Toxocara	O
canis	O
,	O
Giardia	O
sp	O
.)	O
and	O
viral	O
agents	O
that	O
are	O
frequently	O
encountered	O
and	O
known	O
to	O
cause	O
gastrointestinal	O
signs	O
in	O
dogs	O
(	O
coronavirus	O
,	O
parvovirus	O
)	O
as	O
a	O
comparative	O
model	O
.	O

Univariate	O
analysis	O
only	O
showed	O
increased	O
fecal	O
S100A12	O
concentrations	O
in	O
dogs	O
shedding	O
Cystoisospora	O
spp	B-ENZY
.	O

ABSTRACT	O
:	O
Infections	O
with	O
bat	B-ENZY
-	O
origin	O
coronaviruses	O
have	O
caused	O
severe	O
illness	O
in	O
humans	O
by	O
'	O
host	O
jump	O
'.	O

In	O
addition	O
,	O
Bayesian	O
analysis	O
was	O
conducted	O
to	O
address	O
the	O
origin	O
of	O
PEAV	O
,	O
and	O
the	O
divergence	O
time	O
between	O
PEAV	O
and	O
bat	B-ENZY
-	O
HKU2	O
was	O
estimated	O
at	O
1926	O
,	O
which	O
indicates	O
that	O
PEAV	O
is	O
not	O
newly	O
emerged	O
and	O
may	O
have	O
circulated	O
in	O
swine	O
herds	O
for	O
several	O
decades	O
since	O
the	O
interspecies	O
transmission	O
of	O
this	O
coronavirus	O
from	O
bat	B-ENZY
to	O
swine	O
.	O

Patients	O
included	O
were	O
<	O
18	O
years	O
old	O
with	O
HMP	O
or	O
RSV	O
detected	O
from	O
nasopharyngeal	O
specimens	O
by	O
commercial	O
reverse	B-ENZY
transcriptase	I-ENZY
polymerase	O
chain	O
reaction	O
assay	O
admitted	O
to	O
a	O
study	O
site	O
.	O

However	O
,	O
the	O
Deltastream	O
systems	O
were	O
exchanged	O
more	O
frequently	O
due	O
to	O
elective	O
technical	O
complications	O
(	O
e	O
.	O
g	O
.	O
worsened	O
gas	B-ENZY
transfer	O
,	O
development	O
of	O
coagulation	O
disorder	O
,	O
increased	O
bleedings	O
complications	O
)	O
compared	O
to	O
the	O
other	O
exchanged	O
systems	O
(	O
p	O
=	O
0	O
.	O
013	O
).	O

Optimization	O
of	O
gas	B-ENZY
exchange	O
while	O
limiting	O
damage	O
to	O
the	O
lungs	O
is	O
key	O
.	O

Aminopeptidase	B-ENZY
N	I-ENZY
(	O
APN	O
)	O
is	O
a	O
known	O
receptor	O
of	O
TGEV	O
.	O

More	O
importantly	O
,	O
by	O
exploring	O
potential	O
interactions	O
between	O
GRP78	O
and	O
spikes	O
of	O
other	O
coronaviruses	O
,	O
we	O
discovered	O
that	O
the	O
highly	O
conserved	O
human	O
GRP78	O
could	O
interact	O
with	O
the	O
spike	O
protein	O
of	O
bat	B-ENZY
coronavirus	O
HKU9	O
(	O
bCoV	O
-	O
HKU9	O
)	O
and	O
facilitate	O
its	O
attachment	O
to	O
the	O
host	O
cell	O
surface	O
.	O

Furthermore	O
,	O
PDCoV	O
infection	O
necessitated	O
the	O
activation	O
of	O
the	O
initiator	O
caspase	B-ENZY
-	I-ENZY
9	I-ENZY
responsible	O
for	O
the	O
intrinsic	O
mitochondrial	O
apoptosis	O
pathway	O
.	O

Reintroduced	O
wood	O
bison	O
in	O
southwestern	O
Yukon	O
may	O
be	O
of	O
high	O
value	O
for	O
wood	O
bison	O
recovery	O
because	O
it	O
is	O
a	O
large	O
and	O
geographically	O
isolated	O
population	O
with	O
no	O
bacteriologic	O
,	O
histopathologic	O
,	O
or	O
serologic	O
evidence	O
of	O
exposure	O
to	O
Brucella	O
spp	B-ENZY
.	O

ABSTRACT	O
:	O
Acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
is	O
a	O
life	O
threatening	O
condition	O
characterized	O
by	O
severe	O
hypoxemia	O
due	O
to	O
pulmonary	O
gas	B-ENZY
exchange	O
failure	O
and	O
was	O
first	O
recognized	O
in	O
1960s	O
.	O

TITLE	O
:	O
Heme	B-ENZY
Oxygenase	I-ENZY
-	O
1	O
Reduces	O
Sepsis	O
-	O
Induced	O
Endoplasmic	O
Reticulum	O
Stress	O
and	O
Acute	O
Lung	O
Injury	O
.	O

Heme	B-ENZY
oxygenase	I-ENZY
-	O
1	O
(	O
HO	O
-	O
1	O
),	O
an	O
ER	O
-	O
anchored	O
protein	O
,	O
exerts	O
antioxidant	O
and	O
protective	O
functions	O
under	O
ALI	O
.	O

The	O
need	O
for	O
advanced	O
CPR	B-ENZY
with	O
epinephrine	O
administration	O
on	O
the	O
scene	O
predicts	O
poor	O
neurological	O
outcome	O
(	O
severe	O
encephalopathy	O
or	O
death	O
)	O
in	O
drowned	O
children	O
.	O

Furthermore	O
,	O
a	O
virus	O
cell	O
entry	O
assay	O
and	O
a	O
cell	O
-	O
cell	O
fusion	O
assay	O
provided	O
no	O
evidence	O
that	O
the	O
S	O
protein	O
was	O
activated	O
by	O
exogenous	O
furin	B-ENZY
.	O

TITLE	O
:	O
The	O
Antiviral	O
Effects	O
of	O
Na	O
,	O
K	O
-	O
ATPase	B-ENZY
Inhibition	O
:	O
A	O
Minireview	O
.	O

Cardiac	O
glycosides	O
not	O
only	O
inhibit	O
the	O
pump	O
function	O
of	O
Na	O
,	O
K	O
-	O
ATPase	B-ENZY
but	O
also	O
activate	O
intracellular	O
signal	O
transduction	O
pathways	O
,	O
which	O
are	O
important	O
in	O
many	O
biological	O
processes	O
.	O

TITLE	O
:	O
Chlorine	O
gas	B-ENZY
inhalation	O
manifesting	O
with	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
successfully	O
treated	O
by	O
high	O
-	O
volume	O
hemofiltration	O
:	O
A	O
case	O
report	O
.	O

The	O
MERS	O
-	O
CoV	O
4a	O
accessory	O
protein	O
is	O
known	O
to	O
inhibit	O
SG	O
formation	O
in	O
cells	O
in	O
which	O
it	O
was	O
expressed	O
by	O
binding	O
to	O
double	O
-	O
stranded	O
RNAs	O
and	O
inhibiting	O
protein	B-ENZY
kinase	I-ENZY
R	O
(	O
PKR	O
)-	O
mediated	O
phosphorylation	O
of	O
the	O
	O
subunit	O
of	O
eukaryotic	O
initiation	O
factor	O
2	O
(	O
eIF2	O
).	O

Structural	O
comparisons	O
suggested	O
that	O
the	O
SARS	O
-	O
CoV	O
S	O
glycoprotein	O
retains	O
a	O
prefusion	O
architecture	O
after	O
trypsin	B-ENZY
cleavage	O
into	O
the	O
S1	O
and	O
S2	O
subunits	O
and	O
acidic	O
pH	O
treatment	O
.	O

Hypoxemia	O
was	O
defined	O
as	O
a	O
PaO	B-ENZY
Of	O
1604	O
patients	O
included	O
,	O
859	O
(	O
54	O
%,	O
95	O
%	O
CI	O
51	O
-	O
56	O
%)	O
were	O
hypoxemic	O
,	O
51	O
%	O
with	O
mild	O
(	O
n	O
=	O
440	O
),	O
40	O
%	O
with	O
moderate	O
(	O
n	O
=	O
345	O
),	O
and	O
9	O
%	O
(	O
n	O
=	O
74	O
)	O
with	O
severe	O
hypoxemia	O
.	O

In	O
summary	O
,	O
Rip3	O
-	O
mediated	O
oligomerization	O
of	O
SARS	O
3a	O
causes	O
necrotic	O
cell	O
death	O
,	O
lysosomal	O
damage	O
,	O
and	O
caspase	B-ENZY
-	I-ENZY
1	I-ENZY
activation	O
-	O
all	O
likely	O
contributing	O
to	O
the	O
clinical	O
manifestations	O
of	O
SARS	O
-	O
CoV	O
infection	O
.	O

Moreover	O
,	O
HRG	O
suppressed	O
tumor	O
necrosis	O
factor	O
	O
,	O
inducible	O
nitric	O
oxide	O
synthase	O
,	O
interleukin	O
6	O
,	O
and	O
neutrophil	B-ENZY
elastase	I-ENZY
mRNA	O
expression	O
and	O
myeloperoxidase	B-ENZY
activity	O
in	O
the	O
lung	O
.	O

We	O
studied	O
17	O
patients	O
with	O
moderate	O
-	O
to	O
-	O
severe	O
ARDS	O
[	O
PaO	B-ENZY
The	O
mean	O
""""	O
study	O
HFO	O
mPaw	O
""""	O
was	O
8	O
-	O
10	O
cmH	O
In	O
moderate	O
-	O
to	O
-	O
severe	O
ARDS	O
,	O
""""	O
short	O
-	O
term	O
""""	O
4	O
-	O
Hz	O
HFO	O
strategies	O
resulted	O
in	O
better	O
RV	O
function	O
versus	O
7	O
-	O
Hz	O
HFO	O
,	O
partly	O
attributable	O
to	O
improved	O
PaCO	O
This	O
study	O
was	O
registered	O
40	O
days	O
prior	O
to	O
the	O
enrollment	O
of	O
the	O
first	O
patient	O
at	O
ClinicalTrials	O
.	O
gov	O
,	O
ID	O
no	O
.	O
NCT02027129	O
,	O
Principal	O
Investigator	O
Spyros	O
D	O
.	O
Mentzelopoulos	O
,	O
date	O
of	O
registration	O
January	O
3	O
,	O
2014	O
.	O

Further	O
studies	O
revealed	O
that	O
TA	O
-	O
dampened	O
inflammatory	O
responses	O
by	O
downregulating	O
the	O
LPS	O
-	O
induced	O
toll	O
-	O
like	O
receptor	O
4	O
(	O
TLR4	O
)	O
expression	O
and	O
inhibiting	O
extracellular	O
-	O
signal	O
-	O
regulated	O
kinase	O
(	O
ERK	B-ENZY
)	O
1	O
/	O
2	O
and	O
p38	O
mitogen	B-ENZY
-	I-ENZY
activated	I-ENZY
protein	I-ENZY
kinase	I-ENZY
(	O
MAPK	B-ENZY
)	O
activation	O
.	O

This	O
PLP	O
-	O
mediated	O
anti	O
-	O
IFN	O
difference	O
was	O
seen	O
in	O
primate	O
,	O
human	O
as	O
well	O
as	O
bat	B-ENZY
cells	O
,	O
thus	O
independent	O
of	O
the	O
host	O
context	O
.	O

Taken	O
together	O
,	O
these	O
data	O
suggested	O
that	O
NF	O
-	O
B	O
activation	O
was	O
a	O
major	O
contributor	O
to	O
TGEV	O
infection	O
-	O
induced	O
inflammation	O
,	O
and	O
that	O
Nsp2	O
was	O
the	O
key	O
viral	O
protein	O
involved	O
in	O
the	O
regulation	O
of	O
inflammation	O
,	O
with	O
amino	O
acids	O
1	O
-	O
120	O
playing	O
a	O
critical	O
role	O
in	O
activating	O
NF	O
-	O
B	O
.	O
Abbreviations	O
:	O
TCID50	O
:	O
50	O
%	O
tissue	O
culture	O
infectious	O
dose	O
;	O
DMEM	O
:	O
Dulbecco	O
'	O
s	O
Modified	O
Eagle	O
Medium	O
;	O
eNOS	O
:	O
Endothelial	O
nitric	O
oxide	O
synthase	O
;	O
FBS	O
:	O
fetal	O
bovine	O
serum	O
;	O
IFA	O
:	O
Indirect	O
immunofluorescence	O
;	O
IB	O
:	O
inhibitor	O
of	O
nuclear	O
factor	O
kappa	O
-	O
B	O
;	O
IL	O
:	O
interleukin	O
;	O
IPEC	O
-	O
J2	O
:	O
intestinal	O
epithelial	O
cell	O
lines	O
J2	O
;	O
IKK	B-ENZY
:	O
IB	O
kinase	O
;	O
Luc	O
:	O
luciferase	B-ENZY
reporter	O
gene	O
;	O
mAbs	O
:	O
monoclonal	O
antibodies	O
;	O
MOI	O
:	O
multiple	O
of	O
infection	O
;	O
Nsp	O
:	O
nonstructural	O
protein	O
;	O
NF	O
-	O
B	O
:	O
nuclear	O
factor	O
-	O
kappa	O
;	O
ORFs	O
:	O
open	O
reading	O
frames	O
;	O
PBS	O
:	O
phosphate	O
-	O
buffered	O
saline	O
;	O
p65	O
p	O
-	O
p65	O
:	O
phosphorylated	O
;	O
RT	O
-	O
PCR	O
:	O
reverse	O
transcription	O
PC	O
;	O
SeV	O
:	O
Sendai	O
virus	O
;	O
ST	O
:	O
swine	O
testicular	O
;	O
TGEV	O
:	O
Transmissible	O
gastroenteritis	O
virus	O
;	O
TNF	O
-	O
	O
:	O
tumor	O
necrosis	O
factor	O
	O
;	O
UV	O
-	O
TGEV	O
:	O
Ultraviolet	O
light	O
-	O
inactivated	O
TGEV	O
;	O
ZnF	O
:	O
zinc	O
finger	O
.	O

Here	O
,	O
we	O
tested	O
the	O
prediction	O
that	O
little	O
brown	O
bats	O
(	O
Myotis	O
lucifugus	O
)	O
co	O
-	O
infected	O
with	O
the	O
M	O
.	O
lucifugus	O
coronavirus	O
(	O
Myl	O
-	O
CoV	O
)	O
and	O
with	O
Pseudogymnoascus	O
destructans	O
(	O
Pd	O
),	O
the	O
fungus	O
that	O
causes	O
bat	B-ENZY
white	O
-	O
nose	O
syndrome	O
(	O
WNS	O
),	O
exhibit	O
different	O
disease	O
severity	O
,	O
viral	O
shedding	O
and	O
molecular	O
responses	O
than	O
bats	O
infected	O
with	O
only	O
Myl	O
-	O
CoV	O
or	O
only	O
P	O
.	O
destructans	O
.	O

ABSTRACT	O
:	O
In	O
this	O
work	O
we	O
report	O
a	O
parallel	O
application	O
of	O
both	O
docking	O
-	O
and	O
shape	O
-	O
based	O
virtual	O
screening	O
(	O
VS	O
)	O
methods	O
,	O
followed	O
by	O
Molecular	O
Dynamics	O
simulations	O
(	O
MDs	O
),	O
for	O
discovering	O
new	O
compounds	O
able	O
to	O
inhibit	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
reverse	B-ENZY
transcriptase	I-ENZY
(	O
RT	O
)	O
RNA	O
-	O
dependent	O
DNA	O
polymerase	O
activity	O
.	O

The	O
use	O
of	O
halogenated	O
agents	O
,	O
such	O
as	O
sevoflurane	O
or	O
isoflurane	O
,	O
for	O
the	O
sedation	O
of	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
patients	O
can	O
improve	O
gas	B-ENZY
exchange	O
,	O
reduce	O
alveolar	O
edema	O
,	O
and	O
attenuate	O
inflammation	O
during	O
ARDS	O
.	O

Gas	B-ENZY
mass	O
spectrometry	O
was	O
performed	O
to	O
determine	O
the	O
concentration	O
of	O
halogenated	O
agents	O
dissolved	O
in	O
the	O
medium	O
.	O

Finally	O
,	O
he	O
was	O
diagnosed	O
with	O
multiple	O
acyl	B-ENZY
-	I-ENZY
CoA	I-ENZY
dehydrogenase	I-ENZY
deficiency	O
.	O

ABSTRACT	O
:	O
A	O
correction	O
to	O
this	O
article	O
has	O
been	O
published	O
and	O
is	O
linked	O
from	O
the	O
HTML	O
and	O
PDF	B-ENZY
versions	O
of	O
this	O
paper	O
.	O

Critical	O
residues	O
for	O
binding	O
to	O
MERS	O
-	O
CoV	O
spike	O
protein	O
were	O
mostly	O
conserved	O
in	O
bat	B-ENZY
DPP4	O
.	O

A	O
protein	O
corona	O
(	O
PC	O
)	O
on	O
TAT	B-ENZY
peptide	O
-	O
modified	O
PLDs	O
shields	O
the	O
active	O
moieties	O
and	O
effectively	O
reduces	O
clearance	O
of	O
the	O
TAT	B-ENZY
peptide	O
containing	O
nanoparticles	O
.	O

However	O
,	O
intratumoral	O
activity	O
was	O
influenced	O
by	O
the	O
number	O
of	O
TAT	B-ENZY
peptides	O
present	O
.	O

The	O
best	O
antitumor	O
efficacy	O
was	O
observed	O
with	O
a	O
TAT	B-ENZY
peptide	O
density	O
of	O
100	O
,	O
while	O
lower	O
amounts	O
showed	O
results	O
comparable	O
to	O
unmodified	O
PLDs	O
.	O

In	O
contrast	O
,	O
the	O
tracer	O
gas	B-ENZY
was	O
barely	O
detected	O
in	O
a	O
maternity	O
ward	O
to	O
the	O
south	O
of	O
room	O
8104	O
,	O
where	O
there	O
was	O
no	O
secondary	O
infected	O
patient	O
.	O

Several	O
factors	O
signal	O
poor	O
short	O
-	O
term	O
outcome	O
for	O
patients	O
who	O
present	O
to	O
the	O
ED	O
with	O
moderate	O
-	O
to	O
-	O
severe	O
BMT	B-ENZY
:	O
low	O
blood	O
pH	O
,	O
high	O
serum	O
lactate	O
level	O
,	O
presence	O
of	O
TBI	O
,	O
severe	O
hemorrhage	O
,	O
coagulopathy	O
,	O
organ	O
failure	O
(	O
respiratory	O
,	O
renal	O
,	O
and	O
MOF	O
),	O
and	O
ARDS	O
.	O

However	O
,	O
with	O
the	O
exception	O
of	O
neuraminidase	B-ENZY
inhibitors	O
for	O
influenza	O
infection	O
,	O
there	O
are	O
no	O
accepted	O
treatments	O
.	O

TITLE	O
:	O
Production	O
of	O
porcine	O
aminopeptidase	B-ENZY
N	I-ENZY
(	O
pAPN	O
)	O
site	O
-	O
specific	O
edited	O
pigs	O
.	O

Detailed	O
analyses	O
showed	O
that	O
the	O
S	O
-	O
layer	O
protein	O
inhibited	O
caspase	B-ENZY
-	I-ENZY
8	I-ENZY
and	O
caspase	B-ENZY
-	I-ENZY
3	I-ENZY
activity	O
.	O

TITLE	O
:	O
Structure	O
of	O
interferon	O
-	O
stimulated	O
gene	O
product	O
15	O
(	O
ISG15	O
)	O
from	O
the	O
bat	B-ENZY
species	O
Myotis	O
davidii	O
and	O
the	O
impact	O
of	O
interdomain	O
ISG15	O
interactions	O
on	O
viral	O
protein	O
engagement	O
.	O

TITLE	O
:	O
Potent	O
MERS	O
-	O
CoV	O
Fusion	O
Inhibitory	O
Peptides	O
Identified	O
from	O
HR2	O
Domain	O
in	O
Spike	O
Protein	O
of	O
Bat	B-ENZY
Coronavirus	O
HKU4	O
.	O

Recently	O
,	O
numerous	O
evolutionary	O
studies	O
have	O
suggested	O
that	O
MERS	O
-	O
CoV	O
originated	O
from	O
bat	B-ENZY
coronavirus	O
(	O
BatCoV	O
).	O

We	O
tested	O
human	O
and	O
camel	O
derived	O
Middle	O
East	O
Respiratory	O
Syndrome	O
coronaviruses	O
(	O
MERS	O
-	O
CoV	O
)	O
to	O
demonstrate	O
that	O
single	O
and	O
double	O
substitutions	O
in	O
the	O
cleavage	O
site	O
can	O
alter	O
the	O
activity	O
of	O
furin	B-ENZY
and	O
dramatically	O
change	O
cleavage	O
efficiency	O
.	O

Omega	O
-	O
3	O
PUFAs	O
administration	O
was	O
associated	O
with	O
a	O
significant	O
improvement	O
in	O
early	O
PaO	B-ENZY

The	O
new	O
S3	O
guideline	O
is	O
the	O
first	O
to	O
contain	O
recommendations	O
for	O
the	O
entire	O
process	O
of	O
treatment	O
in	O
these	O
groups	O
of	O
patients	O
(	O
indications	O
,	O
ventilation	O
modes	O
/	O
parameters	O
,	O
ac	O
-	O
companying	O
measures	O
,	O
treatments	O
for	O
refractory	O
impairment	O
of	O
gas	B-ENZY
exchange	O
,	O
weaning	O
,	O
and	O
follow	O
-	O
up	O
care	O
).	O

CONCLUSIONS	O
:	O
Recommendations	O
for	O
patients	O
undergoing	O
mechanical	O
ventilation	O
include	O
lung	O
-	O
protective	O
ventilation	O
,	O
early	O
sponta	O
-	O
neous	O
breathing	O
and	O
mobilization	O
,	O
weaning	O
protocols	O
,	O
and	O
,	O
for	O
those	O
with	O
severe	O
impairment	O
of	O
gas	B-ENZY
exchange	O
,	O
prone	O
positioning	O
.	O

An	O
arterial	O
blood	O
gas	B-ENZY
(	O
ABG	O
)	O
specifically	O
tests	O
blood	O
taken	O
from	O
an	O
artery	O
.	O

Specific	O
products	O
related	O
to	O
hypoxia	O
may	O
serve	O
as	O
early	O
biomarkers	O
for	O
ARDS	O
prediction	O
,	O
while	O
the	O
metabolites	O
with	O
significant	O
correlations	O
with	O
partial	O
pressure	O
of	O
arterial	O
oxygen	O
(	O
PaO	B-ENZY
RESULTS	O
:	O
A	O
total	O
of	O
222	O
metabolites	O
were	O
identified	O
in	O
our	O
study	O
,	O
of	O
which	O
128	O
were	O
significantly	O
altered	O
in	O
patients	O
with	O
ARDS	O
compared	O
with	O
healthy	O
controls	O
.	O

Since	O
bats	O
experimentally	O
infected	O
with	O
MERS	O
-	O
CoV	O
do	O
not	O
develop	O
signs	O
of	O
disease	O
,	O
we	O
tested	O
the	O
hypothesis	O
that	O
MERS	O
-	O
CoV	O
would	O
replicate	O
less	O
efficiently	O
in	O
bat	B-ENZY
cells	O
than	O
in	O
human	O
cells	O
because	O
of	O
its	O
inability	O
to	O
subvert	O
antiviral	O
responses	O
in	O
bat	B-ENZY
cells	O
.	O

We	O
identified	O
dampened	O
transcriptional	O
priming	O
,	O
a	O
novel	O
splice	O
variant	O
and	O
an	O
altered	O
leucine	O
-	O
rich	O
repeat	O
domain	O
of	O
bat	B-ENZY
NLRP3	O
as	O
the	O
cause	O
.	O

Participants	O
underwent	O
bronchoscopy	O
with	O
bronchoalveolar	O
lavage	O
(	O
BAL	B-ENZY
)	O
and	O
a	O
subset	O
underwent	O
pulmonary	O
function	O
testing	O
.	O

Past	O
viral	O
infection	O
was	O
associated	O
with	O
elevated	O
neutrophil	O
concentrations	O
and	O
bacterial	O
isolates	O
in	O
BAL	B-ENZY
fluid	O
,	O
including	O
recovery	O
of	O
classic	O
CF	O
bacterial	O
pathogens	O
.	O

The	O
human	O
SARS	O
-	O
CoVs	O
and	O
civet	O
SARSr	O
-	O
CoVs	O
were	O
collected	O
in	O
2003	O
/	O
2004	O
,	O
while	O
bat	B-ENZY
SARSr	O
-	O
CoVs	O
were	O
continuously	O
isolated	O
in	O
the	O
past	O
13	O
years	O
even	O
after	O
the	O
cessation	O
of	O
the	O
SARS	O
epidemic	O
.	O

Upon	O
successful	O
entry	O
and	O
infection	O
into	O
target	O
cells	O
,	O
the	O
luciferase	B-ENZY
reporter	O
gets	O
integrated	O
into	O
the	O
host	O
cell	O
genome	O
and	O
is	O
expressed	O
.	O

Using	O
a	O
simple	O
luciferase	B-ENZY
assay	O
,	O
transduced	O
cells	O
can	O
be	O
easily	O
quantified	O
.	O

In	O
this	O
study	O
,	O
we	O
screened	O
30	O
,	O
000	O
compounds	O
from	O
three	O
different	O
compound	O
libraries	O
against	O
one	O
of	O
the	O
essential	O
proteases	O
,	O
the	O
papain	B-ENZY
-	O
like	O
protease	O
(	O
PL	O

The	O
bat	B-ENZY
fauna	O
of	O
central	O
Asia	O
,	O
which	O
link	O
China	O
to	O
eastern	O
Europe	O
,	O
are	O
relatively	O
less	O
studied	O
than	O
other	O
regions	O
of	O
the	O
world	O
.	O

Two	O
peptides	O
(	O
16433	O
and	O
4934	O
)	O
in	O
the	O
nsp3	O
region	O
encoding	O
the	O
papain	B-ENZY
1	O
and	O
2	O
proteases	O
were	O
identified	O
for	O
final	O
testing	O
.	O

To	O
evade	O
further	O
complications	O
,	O
identifying	O
the	O
abdominal	O
compartment	O
syndrome	O
(	O
ACS	B-ENZY
)	O
and	O
Intra	O
-	O
abdominal	O
hypertension	O
(	O
IAH	O
),	O
in	O
critically	O
ill	O
individuals	O
and	O
hospitalised	O
in	O
the	O
intensive	O
care	O
unit	O
(	O
ICU	O
)	O
is	O
obligated	O
.	O

However	O
,	O
non	O
-	O
ST	O
elevation	O
myocardial	O
infarction	O
(	O
NSTEMI	O
)	O
had	O
not	O
yet	O
been	O
ruled	O
out	O
and	O
the	O
patient	O
was	O
started	O
on	O
started	O
on	O
a	O
heparin	O
infusion	O
per	O
the	O
ACS	B-ENZY
protocol	O
.	O

Phylogenetic	O
analysis	O
using	O
amino	O
acid	O
sequences	O
of	O
the	O
ORF	O
1ab	O
and	O
the	O
spike	O
gene	O
showed	O
that	O
the	O
bat	B-ENZY
coronavirus	O
strain	O
16BO133	O
was	O
grouped	O
with	O
the	O
Beta	O
-	O
CoV	O
lineage	O
B	O
and	O
was	O
closely	O
related	O
to	O
the	O
JTMC15	O
strain	O
isolated	O
from	O
Rhinolophus	O
ferrumequinum	O
in	O
China	O
.	O

To	O
test	O
applicability	O
of	O
in	O
vitro	O
results	O
to	O
real	O
life	O
,	O
virus	O
load	O
was	O
measured	O
in	O
two	O
households	O
in	O
a	O
double	O
crossover	O
study	O
of	O
four	O
Fuller	O
'	O
s	O
earth	O
-	O
based	O
cat	O
litters	O
by	O
testing	O
rectal	O
swabs	O
using	O
FCoV	O
reverse	B-ENZY
transcriptase	I-ENZY
quantitative	O
PCR	O
.	O

Pearson	O
test	O
was	O
used	O
to	O
analyze	O
the	O
correlation	O
between	O
neutral	O
red	O
phagocytosis	O
function	O
of	O
macrophages	O
and	O
alkaline	B-ENZY
phosphatase	I-ENZY
activity	O
and	O
other	O
indicators	O
.	O

Mean	O
airway	O
pressures	O
(	O
Paw	O
),	O
oxygenation	O
index	O
(	O
OI	O
),	O
arterial	O
oxygen	O
partial	O
pressure	O
(	O
PaO	B-ENZY

Plasma	O
fractionators	O
were	O
the	O
first	O
to	O
introduce	O
NAT	B-ENZY
testing	O
besides	O
pathogen	O
reduction	O
procedures	O
,	O
to	O
reduce	O
the	O
virus	O
transmission	O
risk	O
through	O
their	O
products	O
.	O

Years	O
later	O
the	O
diagnostics	O
industry	O
provided	O
commercial	O
HCV	O
and	O
HIV	O
-	O
1	O
and	O
later	O
HBV	O
NAT	B-ENZY
tests	O
on	O
automated	O
platforms	O
.	O

NAT	B-ENZY
tests	O
for	O
HIV	O
-	O
2	O
,	O
hepatitis	O
A	O
virus	O
,	O
and	O
Parvovirus	O
B19	O
followed	O
,	O
again	O
driven	O
by	O
transfusion	O
centres	O
with	O
their	O
in	O
-	O
house	O
tests	O
.	O

ABSTRACT	O
:	O
We	O
have	O
previously	O
reported	O
a	O
new	O
class	O
of	O
dendrimers	O
with	O
tryptophan	O
(	O
Trp	B-ENZY
)	O
residues	O
on	O
the	O
surface	O
that	O
show	O
dual	O
antiviral	O
activities	O
against	O
HIV	O
and	O
enterovirus	O
EV71	O
.	O

TITLE	O
:	O
Effect	O
of	O
adeno	O
-	O
associated	O
virus	O
(	O
AAV	O
)-	O
mediated	O
overexpression	O
of	O
PEPCK	B-ENZY
-	O
M	O
(	O
Pck2	O
)	O
on	O
Clenbuterol	O
-	O
induced	O
muscle	O
growth	O
.	O

In	O
the	O
CT	O
(	O
gut	O
-	O
associated	O
lymphoid	O
tissue	O
,	O
GALT	B-ENZY
)	O
the	O
precursors	O
of	O
FDC	O
and	O
IDC	O
are	O
MBL	O
-	O
producing	O
cells	O
and	O
CD83	O
-	O
positive	O
cells	O
,	O
respectively	O
.	O

Human	O
H7N9	O
influenza	O
viruses	O
are	O
resistant	O
to	O
amantadines	O
and	O
some	O
strains	O
are	O
also	O
resistant	O
to	O
neuraminidase	B-ENZY
inhibitors	O
greatly	O
limiting	O
the	O
options	O
for	O
treatment	O
.	O

A	O
prospective	O
observational	O
study	O
was	O
conducted	O
to	O
evaluate	O
serum	O
ACE	B-ENZY
levels	O
in	O
thoracic	O
trauma	O
patients	O
and	O
to	O
explore	O
its	O
prognostic	O
potential	O
with	O
regard	O
to	O
clinical	O
outcome	O
.	O

CONCLUSIONS	O
:	O
Our	O
study	O
demonstrates	O
that	O
serum	O
ACE	B-ENZY
levels	O
are	O
increased	O
in	O
thoracic	O
trauma	O
patients	O
with	O
higher	O
levels	O
,	O
indicating	O
the	O
severe	O
nature	O
of	O
trauma	O
in	O
concordance	O
with	O
increased	O
TTSS	O
scores	O
.	O

On	O
the	O
contrary	O
,	O
the	O
UPR	O
inhibitors	O
N	O
-	O
acetyl	O
cysteine	O
,	O
kifunensine	O
,	O
and	O
ATP	O
-	O
competitive	O
IRE1	O
kinase	O
-	O
inhibiting	O
RNase	B-ENZY
attenuator	O
;	O
produced	O
the	O
opposite	O
effects	O
.	O

Real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
revealed	O
that	O
all	O
17	O
fecal	O
samples	O
from	O
post	O
-	O
weaned	O
calves	O
with	O
diarrhea	O
and	O
one	O
out	O
of	O
15	O
from	O
diarrhea	O
-	O
recovered	O
calves	O
were	O
positive	O
for	O
BCoV	O
and	O
negative	O
for	O
Cryptosporidium	O
spp	B-ENZY
.,	O
Escherichia	O
coli	O
K99	O
,	O
Salmonella	O
spp	B-ENZY
.,	O
bovine	O
rotavirus	O
,	O
and	O
bovine	O
viral	O
diarrhea	O
virus	O
.	O

HLH	O
was	O
noted	O
in	O
7	O
(	O
32	O
%)	O
cases	O
at	O
a	O
median	O
(	O
IQR	O
)	O
hospital	O
stay	O
of	O
5	O
(	O
2	O
-	O
8	O
)	O
d	O
.	O
Children	O
with	O
HLH	O
had	O
significantly	O
higher	O
Pediatric	O
Index	O
of	O
Mortality	O
2	O
(	O
PIM	O
2	O
)	O
score	O
at	O
admission	O
and	O
higher	O
frequency	O
of	O
pain	O
abdomen	O
,	O
anemia	O
,	O
hypoalbuminemia	O
,	O
elevated	O
alanine	B-ENZY
aminotransferase	I-ENZY
(	O
ALT	O
)	O
and	O
ARDS	O
.	O

TITLE	O
:	O
Characterization	O
of	O
a	O
novel	O
bat	B-ENZY
-	O
HKU2	O
-	O
like	O
swine	O
enteric	O
alphacoronavirus	O
(	O
SeACoV	O
)	O
infection	O
in	O
cultured	O
cells	O
and	O
development	O
of	O
a	O
SeACoV	O
infectious	O
clone	O
.	O

TITLE	O
:	O
Peptide	O
presentation	O
by	O
bat	B-ENZY
MHC	O
class	O
I	O
provides	O
new	O
insight	O
into	O
the	O
antiviral	O
immunity	O
of	O
bats	O
.	O

To	O
further	O
understand	O
the	O
antiviral	O
immunity	O
of	O
bats	O
,	O
we	O
screened	O
and	O
identified	O
a	O
series	O
of	O
bat	B-ENZY
major	O
histocompatibility	O
complex	O
(	O
MHC	O
)	O
I	O
Ptal	B-ENZY
-	O
N	O
*	O
01	O
:	O
01	O
-	O
binding	O
peptides	O
derived	O
from	O
four	O
different	O
bat	B-ENZY
-	O
borne	O
viruses	O
,	O
i	O
.	O
e	O
.,	O
Hendra	O
virus	O
(	O
HeV	O
),	O
Ebola	O
virus	O
(	O
EBOV	O
),	O
Middle	O
East	O
respiratory	O
syndrome	O
coronavirus	O
(	O
MERS	O
-	O
CoV	O
),	O
and	O
H17N10	O
influenza	O
-	O
like	O
virus	O
.	O

Using	O
fecal	O
samples	O
collected	O
from	O
five	O
bat	B-ENZY
species	O
between	O
2014	O
and	O
2016	O
in	O
Finland	O
and	O
RT	O
-	O
PCR	O
,	O
RT	O
-	O
qPCR	O
,	O
and	O
NGS	O
,	O
we	O
identified	O
CoVs	O
in	O
10	O
of	O
79	O
(	O
13	O
%)	O
samples	O
,	O
including	O
two	O
novel	O
bat	B-ENZY
species	O
-	O
CoV	O
relationships	O
.	O

Histological	O
analysis	O
was	O
performed	O
,	O
and	O
results	O
showed	O
increase	O
serum	O
aminotransferase	O
(	O
ALT	O
and	O
AST	B-ENZY
)	O
levels	O
and	O
evident	O
liver	O
injury	O
on	O
days	O
3	O
and	O
7	O
,	O
especially	O
on	O
day	O
5	O
post	O
infection	O
.	O

Management	O
of	O
ACS	B-ENZY
is	O
complex	O
and	O
may	O
necessitate	O
mechanical	O
ventilation	O
and	O
veno	O
-	O
venous	O
extracorporeal	O
membrane	O
oxygenation	O
(	O
VV	O
-	O
ECMO	O
)	O
therapy	O
in	O
the	O
more	O
severe	O
cases	O
.	O

The	O
arterial	O
blood	O
gas	B-ENZY
showed	O
severe	O
oxygenation	O
impairment	O
and	O
he	O
was	O
intubated	O
for	O
mechanical	O
ventilation	O
.	O

(	O
1	O
.	O
7	O
%),	O
Campylobacter	O
spp	B-ENZY
.	O

(	O
5	O
.	O
4	O
%),	O
Campylobacter	O
spp	B-ENZY
.	O

In	O
the	O
current	O
study	O
,	O
the	O
effect	O
of	O
overexpression	O
,	O
silencing	O
,	O
antibody	O
inhibition	O
,	O
and	O
co	O
-	O
expression	O
with	O
porcine	O
aminopeptidase	B-ENZY
N	I-ENZY
(	O
pAPN	O
)	O
of	O
integrin	O
v3	O
on	O
PEDV	O
infection	O
was	O
investigated	O
and	O
analyzed	O
in	O
African	O
green	O
monkey	O
Vero	O
E6	O
cells	O
and	O
porcine	O
intestinal	O
epithelial	O
cells	O
(	O
IECs	O
)	O
using	O
the	O
classical	O
strain	O
CV777	O
and	O
variant	O
strain	O
HM2017	O
of	O
PEDV	O
.	O

TITLE	O
:	O
Prevalence	O
and	O
risk	O
factors	O
for	O
agents	O
causing	O
diarrhea	O
(	O
Coronavirus	O
,	O
Rotavirus	O
,	O
Cryptosporidium	O
spp	B-ENZY
.,	O
Eimeria	O
spp	B-ENZY
.,	O
and	O
nematodes	O
helminthes	O
)	O
according	O
to	O
age	O
in	O
dairy	O
calves	O
from	O
Brazil	O
.	O

On	O
the	O
3rd	O
day	O
,	O
GAS	B-ENZY
was	O
isolated	O
from	O
blood	O
culture	O
.	O

This	O
is	O
the	O
first	O
demonstration	O
of	O
IBV	O
-	O
induced	O
neural	O
symptoms	O
in	O
chickens	O
with	O
encephalitis	O
and	O
the	O
furin	B-ENZY
-	O
S2	O
'	O
site	O
as	O
a	O
determinant	O
of	O
neurotropism	O
.	O

TITLE	O
:	O
Murine	O
Coronavirus	O
Infection	O
Activates	O
the	O
Aryl	O
Hydrocarbon	O
Receptor	O
in	O
an	O
Indoleamine	B-ENZY
2	I-ENZY
,	I-ENZY
3	I-ENZY
-	I-ENZY
Dioxygenase	I-ENZY
-	O
Independent	O
Manner	O
,	O
Contributing	O
to	O
Cytokine	O
Modulation	O
and	O
Proviral	O
TCDD	O
-	O
Inducible	O
-	O
PARP	O
Expression	O
.	O

Furthermore	O
,	O
while	O
indoleamine	B-ENZY
2	I-ENZY
,	I-ENZY
3	I-ENZY
-	I-ENZY
dioxygenase	I-ENZY
(	O
IDO1	B-ENZY
)	O
drives	O
AhR	O
activation	O
in	O
other	O
settings	O
,	O
MHV	O
infection	O
induced	O
equal	O
expression	O
of	O
downstream	O
genes	O
in	O
wild	O
-	O
type	O
(	O
WT	O
)	O
and	O
IDO1	B-ENZY

Seven	O
patients	O
developed	O
severe	O
ARDS	O
and	O
one	O
patient	O
moderate	O
ARDS	O
according	O
to	O
the	O
Berlin	O
classification	O
with	O
a	O
PaO	B-ENZY
ECMO	O
is	O
a	O
viable	O
therapy	O
option	O
in	O
burn	O
patients	O
developing	O
severe	O
ARDS	O
and	O
can	O
contribute	O
to	O
survival	O
rates	O
similar	O
to	O
ECMO	O
therapy	O
in	O
non	O
-	O
burn	O
-	O
associated	O
severe	O
ARDS	O
.	O

Further	O
,	O
tests	O
for	O
anti	O
-	O
glomerular	O
basement	O
membrane	O
antibody	O
,	O
myeloperoxidase	B-ENZY
-	O
ANCA	O
,	O
and	O
proteinase	B-ENZY
3	I-ENZY
-	O
ANCA	O
revealed	O
negative	O
results	O
.	O

Children	O
under	O
two	O
years	O
of	O
age	O
and	O
children	O
with	O
malnutrition	O
may	O
have	O
a	O
risk	O
of	O
prolonged	O
Cryptosporidium	O
spp	B-ENZY
.	O

Cryptosporidium	O
spp	B-ENZY
.	O
may	O
cause	O
asymptomatic	O
infection	O
,	O
mild	O
diarrheal	O
disease	O
or	O
severe	O
diarrhea	O
with	O
high	O
volume	O
,	O
which	O
may	O
be	O
accompanied	O
by	O
nausea	O
,	O
vomiting	O
,	O
abdominal	O
pain	O
and	O
fever	O
,	O
following	O
a	O
1	O
-	O
7	O
day	O
incubation	O
period	O
.	O

Efforts	O
to	O
minimize	O
this	O
injury	O
are	O
typically	O
limited	O
by	O
the	O
need	O
to	O
preserve	O
adequate	O
gas	B-ENZY
exchange	O
.	O

Recently	O
,	O
sacubitril	O
/	O
valsartan	O
-	O
an	O
angiotensin	O
receptor	O
blocker	O
-	O
neprilysin	B-ENZY
inhibitor	O
-	O
has	O
been	O
added	O
in	O
clinical	O
practice	O
as	O
a	O
standard	O
therapy	O
for	O
heart	O
failure	O
.	O

It	O
is	O
hypothesized	O
that	O
MERS	O
-	O
CoV	O
originated	O
from	O
bat	B-ENZY
coronaviruses	O
and	O
that	O
dromedary	O
camels	O
are	O
its	O
natural	O
reservoir	O
.	O

Compared	O
with	O
controls	O
,	O
the	O
experimental	O
group	O
had	O
a	O
significantly	O
higher	O
proportion	O
of	O
antibiotics	O
discontinuation	O
or	O
de	O
-	O
escalation	O
in	O
the	O
ED	O
(	O
26	O
.	O
0	O
%	O
vs	O
16	O
.	O
1	O
%,	O
P	O
=	O
.	O
007	O
),	O
neuraminidase	B-ENZY
inhibitor	O
uses	O
(	O
8	O
.	O
9	O
%	O
vs	O
0	O
.	O
6	O
%,	O
P	O
<	O
.	O
001	O
),	O
and	O
shorter	O
duration	O
of	O
intravenous	O
antibiotics	O
(	O
10	O
.	O
0	O
vs	O
14	O
.	O
5	O
days	O
,	O
P	O
<	O
.	O
001	O
).	O

TITLE	O
:	O
Choking	O
agents	O
and	O
chlorine	O
gas	B-ENZY
-	O
History	O
,	O
pathophysiology	O
,	O
clinical	O
effects	O
and	O
treatment	O
.	O

Chlorine	O
gas	B-ENZY
can	O
cause	O
toxic	O
pneumonitis	O
,	O
lung	O
edema	O
and	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
).	O

In	O
this	O
work	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
5	O
,	O
6	O
-	O
dihydroxyindole	O
-	O
2	O
-	O
carboxylic	O
acid	O
(	O
DHICA	O
)	O
derivatives	O
on	O
both	O
HIV	O
-	O
1	O
Integrase	O
(	O
IN	O
)	O
and	O
Reverse	B-ENZY
Transcriptase	I-ENZY
associated	O
Ribonuclease	B-ENZY
H	I-ENZY
(	O
RNase	B-ENZY
H	I-ENZY
)	O
activities	O
.	O

The	O
basic	O
criterion	O
of	O
patient	O
inclusion	O
was	O
stable	O
respiration	O
impairment	O
leading	O
to	O
hypoxia	O
with	O
PaO	B-ENZY
Pancreatitis	O
-	O
associated	O
ARDS	O
was	O
diagnosed	O
in	O
36	O
cases	O
(	O
53	O
.	O
7	O
%).	O

Therefore	O
,	O
characterisation	O
of	O
viral	O
pathogens	O
in	O
bat	B-ENZY
communities	O
provides	O
important	O
basal	O
information	O
to	O
monitor	O
and	O
predict	O
the	O
emergence	O
of	O
diseases	O
relevant	O
to	O
conservation	O
and	O
public	O
health	O
.	O

In	O
addition	O
,	O
dual	O
-	O
luciferase	B-ENZY
reporter	O
assays	O
revealed	O
that	O
ubiquitin	O
-	O
specific	O
protease	O
47	O
(	O
USP47	O
),	O
a	O
deubiquitinase	O
-	O
encoding	O
gene	O
,	O
was	O
a	O
target	O
for	O
gga	O
-	O
miR	O
-	O
30d	O
.	O

The	O
laboratory	O
findings	O
revealed	O
acute	O
liver	O
failure	O
with	O
prothrombin	O
time	O
-	O
international	O
normalized	O
ratio	O
of	O
3	O
.	O
16	O
,	O
aspartate	B-ENZY
aminotransferase	I-ENZY
12	O
,	O
548	O
IU	O
/	O
L	O
,	O
alanine	B-ENZY
aminotransferase	I-ENZY
5	O
,	O
725	O
IU	O
/	O
L	O
,	O
and	O
blood	O
ammonia	O
102	O
g	O
/	O
dL	O
.	O
Head	O
magnetic	O
resonance	O
imaging	O
showed	O
hyperintense	O
signals	O
on	O
diffusion	O
-	O
weighed	O
images	O
of	O
globus	O
pallidus	O
.	O

The	O
phylogenetic	O
tree	O
showed	O
that	O
2019	O
-	O
nCoV	O
significantly	O
clustered	O
with	O
bat	B-ENZY
SARS	O
-	O
like	O
coronavirus	O
sequence	O
isolated	O
in	O
2015	O
,	O
whereas	O
structural	O
analysis	O
revealed	O
mutation	O
in	O
Spike	O
Glycoprotein	O
and	O
nucleocapsid	O
protein	O
.	O

Phylogenetic	O
analysis	O
revealed	O
that	O
2019	O
-	O
nCoV	O
fell	O
within	O
the	O
subgenus	O
Sarbecovirus	O
of	O
the	O
genus	O
Betacoronavirus	O
,	O
with	O
a	O
relatively	O
long	O
branch	O
length	O
to	O
its	O
closest	O
relatives	O
bat	B-ENZY
-	O
SL	O
-	O
CoVZC45	O
and	O
bat	B-ENZY
-	O
SL	O
-	O
CoVZXC21	O
,	O
and	O
was	O
genetically	O
distinct	O
from	O
SARS	O
-	O
CoV	O
.	O
Notably	O
,	O
homology	O
modelling	O
revealed	O
that	O
2019	O
-	O
nCoV	O
had	O
a	O
similar	O
receptor	O
-	O
binding	O
domain	O
structure	O
to	O
that	O
of	O
SARS	O
-	O
CoV	O
,	O
despite	O
amino	O
acid	O
variation	O
at	O
some	O
key	O
residues	O
.	O

Antiviral	O
drugs	O
commonly	O
used	O
in	O
clinical	O
practice	O
,	O
including	O
neuraminidase	B-ENZY
inhibitors	O
(	O
oseltamivir	O
,	O
paramivir	O
,	O
zanamivir	O
,	O
etc	O
.),	O
ganciclovir	O
,	O
acyclovir	O
and	O
ribavirin	O
,	O
are	O
invalid	O
for	O
2019	O
-	O
nCoV	O
and	O
not	O
recommended	O
.	O

PP	O
-	O
induced	O
changes	O
in	O
PaO	B-ENZY
Changes	O
in	O
PaO	B-ENZY

TGF	O
-	O
	O
-	O
stimulated	O
IPEC	O
-	O
J2	O
cells	O
highly	O
up	O
-	O
regulated	O
FcRn	O
expression	O
,	O
while	O
treatment	O
with	O
a	O
JNK	B-ENZY
-	O
specific	O
inhibitor	O
down	O
-	O
regulated	O
the	O
expression	O
.	O

Oseltamivir	O
is	O
the	O
most	O
widely	O
used	O
neuraminidase	B-ENZY
inhibitor	O
for	O
treatment	O
of	O
influenza	O
;	O
data	O
suggest	O
that	O
early	O
use	O
is	O
associated	O
with	O
reduced	O
mortality	O
in	O
critically	O
ill	O
patients	O
with	O
influenza	O
.	O

Furthermore	O
,	O
it	O
was	O
investigated	O
which	O
bat	B-ENZY
species	O
have	O
commercial	O
value	O
in	O
China	O
,	O
and	O
would	O
thus	O
likely	O
be	O
handled	O
for	O
trading	O
purposes	O
.	O

ACE2	O
plays	O
an	O
important	O
role	O
in	O
the	O
RAS	O
,	O
and	O
the	O
imbalance	O
between	O
ACE	B-ENZY
/	O
Ang	O
II	O
/	O
AT1R	O
pathway	O
and	O
ACE2	O
/	O
Ang	O
(	O
1	O
-	O
7	O
)/	O
Mas	O
receptor	O
pathway	O
in	O
the	O
RAS	O
system	O
will	O
lead	O
to	O
multi	O
-	O
system	O
inflammation	O
.	O

TITLE	O
:	O
Trypsin	B-ENZY
promotes	O
porcine	O
deltacoronavirus	O
mediating	O
cell	O
-	O
to	O
-	O
cell	O
fusion	O
in	O
a	O
cell	O
type	O
-	O
dependent	O
manner	O
.	O

We	O
also	O
demonstrated	O
that	O
trypsin	B-ENZY
promotes	O
PDCoV	O
replication	O
by	O
enhancing	O
cell	O
-	O
to	O
-	O
cell	O
membrane	O
fusion	O
.	O

TITLE	O
:	O
Swine	O
acute	O
diarrhea	O
syndrome	O
coronavirus	O
-	O
induced	O
apoptosis	O
is	O
caspase	O
-	O
and	O
cyclophilin	B-ENZY
D	O
-	O
dependent	O
.	O

The	O
mean	O
change	O
in	O
Pao	B-ENZY
Fixed	O
-	O
dose	O
iEPO	O
was	O
comparable	O
to	O
iNO	O
in	O
patients	O
with	O
moderate	O
-	O
to	O
-	O
severe	O
ARDS	O
for	O
oxygenation	O
and	O
ventilation	O
parameters	O
as	O
well	O
as	O
clinical	O
outcomes	O
.	O

The	O
widespread	O
existence	O
of	O
these	O
bat	B-ENZY
-	O
carried	O
or	O
-	O
released	O
viruses	O
might	O
have	O
an	O
easier	O
time	O
in	O
breaking	O
through	O
human	O
defenses	O
when	O
harsh	O
winter	O
makes	O
human	O
bodies	O
more	O
vulnerable	O
.	O

However	O
,	O
genome	O
and	O
ORF1a	O
homology	O
show	O
that	O
the	O
virus	O
is	O
not	O
the	O
same	O
coronavirus	O
as	O
the	O
coronavirus	O
derived	O
from	O
these	O
five	O
animals	O
,	O
whereas	O
the	O
virus	O
has	O
the	O
highest	O
homology	O
with	O
Bat	B-ENZY
coronavirus	O
isolate	O
RaTG13	O
.	O

The	O
binding	O
of	O
COVI	O
-	O
19	O
to	O
the	O
Toll	O
Like	O
Receptor	O
(	O
TLR	O
)	O
causes	O
the	O
release	O
of	O
pro	O
-	O
IL	O
-	O
1	O
which	O
is	O
cleaved	O
by	O
caspase	B-ENZY
-	I-ENZY
1	I-ENZY
,	O
followed	O
by	O
inflammasome	O
activation	O
and	O
production	O
of	O
active	O
mature	O
IL	O
-	O
1	O
which	O
is	O
a	O
mediator	O
of	O
lung	O
inflammation	O
,	O
fever	O
and	O
fibrosis	O
.	O

Compared	O
with	O
general	O
COVID	O
-	O
19	O
patients	O
(	O
45	O
.	O
2	O
%),	O
refractory	O
patients	O
had	O
an	O
older	O
age	O
,	O
male	O
sex	O
,	O
more	O
underlying	O
comorbidities	O
,	O
lower	O
incidence	O
of	O
fever	O
,	O
higher	O
levels	O
of	O
maximum	O
temperature	O
among	O
fever	O
cases	O
,	O
higher	O
incidence	O
of	O
breath	O
shortness	O
and	O
anorexia	O
,	O
severer	O
disease	O
assessment	O
on	O
admission	O
,	O
high	O
levels	O
of	O
neutrophil	O
,	O
aspartate	B-ENZY
aminotransferase	I-ENZY
(	O
AST	B-ENZY
),	O
lactate	O
dehydrogenase	O
(	O
LDH	O
)	O
and	O
C	O
-	O
reactive	O
protein	O
,	O
lower	O
levels	O
of	O
platelets	O
and	O
albumin	O
,	O
and	O
higher	O
incidence	O
of	O
bilateral	O
pneumonia	O
and	O
pleural	O
effusion	O
(	O
P	O
<	O
0	O
.	O
05	O
).	O

ABSTRACT	O
:	O
Extracorporeal	O
lung	O
support	O
is	O
increasingly	O
implemented	O
worldwide	O
in	O
clinical	O
practice	O
in	O
patients	O
with	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
and	O
is	O
required	O
when	O
mechanical	O
ventilation	O
is	O
unable	O
to	O
establish	O
sufficient	O
pulmonary	O
gas	B-ENZY
exchange	O
or	O
if	O
the	O
respirator	O
settings	O
are	O
persistent	O
elevated	O
with	O
an	O
increased	O
risk	O
for	O
ventilator	O
induced	O
lung	O
injury	O
(	O
VILI	O
).	O

Proteases	O
of	O
the	O
renin	B-ENZY
-	O
angiotensin	O
system	O
serve	O
as	O
receptors	O
needed	O
for	O
entry	O
into	O
target	O
cells	O
;	O
this	O
article	O
describes	O
the	O
current	O
knowledge	O
on	O
the	O
involvement	O
of	O
this	O
system	O
in	O
HCoV	O
pathogenesis	O
.	O

